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Summary of the project 
Background: Syncope is a common and challenging problem in the Emergency Department (ED), 
representing about 1-2% of patients visits. Early detection of the underlying cause is critical as it defines 
treatment and prognosis. Cardiac syncope is associated with the highest mortality of all syncope 
etiologies and requires specific interventions such as implantation of a pacemaker or defibrillator. ED 
clinicians struggle to rapidly identify the underlying cause and the threat of a possible serious cardiac 
origin which leads to numerous diagnostics and high hospitalisation rates. In an attempt to improve 
diagnosis and risk-stratification in syncope patients in the ED, several rules and scores were derived, 
mostly of mono-centric and rather small studies. Additionally, their external validity has never been 
assessed and their complexity represent a problem for a rapid and efficient implementation in the ED. 
Similarly, the diagnostic and prognostic value of some readily available cardiac biomarkers (such as 
cardiac troponins or B-type Natriuretic peptides) has been investigated in some pilot studies but the 
small number of patients assessed and the use of poorly sensitive assays resulted in varying results 
and did not allow for any definitive conclusions.  
Aim and Hypothesis: The aim of this thesis is to assess the accuracy of diagnostic and prognostic 
accuracy of scores and biomarkers in a large international cohort of syncope patients presenting to the 
ED. First, the accuracy of existing syncope-specific diagnostic and risk-stratification rules will be 
compared and their complexity put in perspective through a comparison with the CHADS2  score. 
Second, the diagnostic and prognostic performance of cardiac troponins, as assessed by three different 
assays, and BNP will be investigated. We hypothesize that complex syncope-specific scores might not 
reliably diagnose or risk-stratify syncope patients and that both assessed biomarkers, at least in certain 
subgroups of patients for which the determination of a precise etiology appears particularly difficult, 
could be of specific interest to improve the diagnosis and risk stratification of patients presenting with 
syncope to the ED.  
Patients and Methods: BASEL IX is an ongoing prospective international multicenter diagnostic cohort 
study coordinated by the University Hospital Basel. Patients >40y presenting to the ED with a syncope 
within the 12 last hours are enrolled and blood is drawn for the blinded analysis of the investigational 
biomarkers. All patients underwent clinical assessment that included standardized and detailed 
assessment of predefined details of the medical history and syncopal event. The adjudication of the 
final diagnosis is performed by two independent cardiologists based on all available information after 
diagnostic work-up of patients as well as the clinical follow-up at 12 months. Patients are followed up 
to 5 years. The diagnostic endpoint is the diagnostic accuracy for cardiac syncope, the prognostic 
endpoints are the accuracy to predict death or major cardiovascular events (MACE). 
Results: Syncope diagnostic and risk stratification rules showed a moderate accuracy in patients 
presenting with syncope to the ED (with Area Under The Receiver Operating Curve (AUC) between 
0.67 and 0.75 for diagnostic endpoints and between 0.57 and 0.79 for prognostic endpoints) and most 
of them were, not superior to a readily calculable CHADS2 score. Both assessed biomarkers performed 
with a moderate-to-good accuracy for the diagnosis and risk stratification of the overall cohort (AUC for 
diagnostic endpoints between 0.76 and 0.77, AUC for prognostic endpoints between 0.73 and 0.8 
depending on the chosen time-point). When assessed in patients for whom the diagnosis stayed 
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unclear despite initial ED evaluation, these biomarkers could provide guidance to the ED physician 
regarding his decision for hospitalization and further testing. 
Conclusion: Diagnosis and risk-stratification of patients with syncope is a challenging task and 
currently available structured clinical assessments scores do not sufficiently help with initial ED 
evaluation. Common and readily available cardiac biomarkers seem to represent a valuable tool, 
especially in patients for whom a first evaluation did not lead to a satisfactory diagnosis.  
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Introduction 
Syncope in the Emergency Department 
Syncope is defined as a “transient loss of consciousness due to cerebral hypoperfusion, 
characterized by a rapid onset, short duration and spontaneous complete recovery”[1]. It is a 
common and challenging problem in the Emergency Department (ED), representing about 1-
2% of patients visits[2–4],[5].  
The ability of ED clinicians to rapidly identify the underlying cause is often limited by scant 
patient recall, absence of witnesses, the paroxysmal nature of cardiac arrhythmias, and time 
pressure[6]. Moreover, as the opportunity to capture a spontaneous event during initial 
evaluation is very rare, the exact syncope etiology remains unclear in a relevant number of 
patients[7,8].  
Early detection and exact definition of the underlying cause is critical as it defines treatment 
and prognosis. For instance, reflex syncope requires lifestyle measures including education 
and reassurance as well as physical counterpressure manoeuvres, and has a very low risk of 
death[1]. In contrast, cardiac syncope requires specific cardiac interventions and has a high 
risk of death[1,9,10]. According to current European Guidelines[1] the evaluation of syncope 
in the ED should answer the following three questions :  
1. Is there a serious underlying cause that can be identified? 
2. If the cause is uncertain, what is the risk of a serious outcome? 
3. Should the patient be admitted to the hospital? 
These same guidelines[1] further recommend three main components for the initial evaluation 
of syncope in the ED: first a careful history taking, second a thorough physical examination 
and third an electrocardiogram (ECG). Depending on the results of these examinations, further 
investigations should be initiated.  
As the threat of a possible serious cardiac origin currently leads to consequent unnecessary 
admissions, diagnostic procedures and costs, ongoing research aims at improving pathways 
and organizational issues by focusing on these three initial components and subsequent 
diagnostic measures[1,6,8]. 
Cardiac syncope 
After reflex syncope, cardiac syncope represents the second most common cause of 
syncope[1]. A cardiac cause is found in about 5 to 30% of patients presenting to the ED with 
syncope. The spectrum of heart conditions likely to cause syncope is wide and can be 
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summarized as all cardiovascular pathologies leading to a temporary cardiac output 
impairment.  
Arrhythmias are the most common cause of cardiac syncope: they include pathologic 
bradycardia and pauses, as found in a sick sinus syndrome, high grade atrioventricular (AV) 
heart blocks (Mobitz II and complete AV blocks), tachycardia (ventricular as well as 
supraventricular) or drug-induced arrhythmias. The dysfunction of an implanted pacemaker 
can also lead to haemodynamic compromise and fainting.  
A variety of cardiac structural diseases (valvular, ischemic, congenital, neoplastic)[1,11] are 
known to cause syncope as well.  
Other cardiovascular pathologies, such as pulmonary embolism, acute aortic dissection or 
pulmonary hypertension, can lead to an increase in the afterload and consequently a decrease 
in the cardiac output, inducing syncope[1,9]. 
Syncope caused by one of these pathologies shows an increased one-year mortality 
compared to non-cardiac syncope (about 18-33% for cardiac syncope[9,10] versus 0-12% for 
the other etiologies[9,12]). Short-term morbidity is also not negligible in patients with an 
underlying cardiac etiology: Around 15% of syncope patients will experience a MACE within 
30 days of the initial event, with about half of these manifesting only during subsequent 
hospitalization or after discharge at home.[13,14] 
Both high mortality and morbidity emphasize the importance of recognizing the heart as the 
cause of the problem in order to initiate an effective mechanism-specific treatment (such as 
for example the implantation of a pacemaker or defibrillator, an electrophysiologic ablation 
therapy or a percutaneous coronary intervention) and improve the prognosis of the patient[1].  
Despite many efforts to improve the systematic evaluation of syncope patients, a high 
percentage remains undiagnosed after ED evaluation (17 to 33%[7,8]). This diagnostic 
uncertainty leads to unnecessary hospitalizations: depending on the country[15] 12 to 86% of 
ED syncope referrals are treated in an inpatient setting[1,3] but only 25% of these admissions 
are considered appropriate.[16] Moreover, patients with syncope are exposed to numerous 
diagnostic tests often irrelevant to the cause of syncope and at times associated with relevant 
risks and costs.[1] 
Therefore, research currently still focuses on designing and validating structured and 
standardized approaches using numerous components of the patient history, physical 
evaluation, electrocardiographic and laboratory data to provide guidance to ED physicians to 
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reduce unnecessary diagnostic procedures, superfluous admissions, misdiagnoses and 
costs.[1,6,8]  
Syncope-specific scores and structured ED evaluation 
In an attempt to identify patients at risk of cardiac syncope and adverse outcome, numerous 
syncope-specific diagnostic and risk-stratification scores have been developed. [5,17–22] 
These rules and scores incorporate important predictors for the diagnosis or outcome 
stemming from the past medical history, details of the syncopal event, physical examination, 
and basic diagnostic tests.  
Most of these scores focus on short-term serious outcomes, reflecting the largely unmet 
clinical need of reducing 30-day readmissions in syncope patients.[5,6,8,16,19,21,22] Less 
importance was attributed to long term outcome and fewer scores address adverse events 
occurring after 30 days.[18,20,22]  
The use of these tools in the ED is debated[1]. On the one hand, several of these scores were 
successfully validated in small cohorts[23–26] and they could represent cheap tools to reduce 
unnecessary admissions and help with diagnosis and risk stratification. On the other hand, 
their poor methodological quality, their complexity and the impractical parameters some of 
them take into account (as for instance some rarely conducted examinations[5]) cast doubt 
upon their usefulness in the ED, so that current guidelines do not recommend their 
implementation. [4,8]  
However, both American and European guidelines[1,4] recognize the need to focus on 
standardized tools to guide the evaluation by healthcare teams, both for the diagnosis and 
short- or long-term outcome in follow-up and score derivation stays on top of their research 
agenda.  
Biomarkers 
Blood biomarkers contributed greatly to the diagnostic and prognostic evaluation of other 
common presenting symptoms (including acute chest pain and acute dyspnea[27–29]). Given 
the near universal use of blood sampling at ED presentation, biomarkers linked to the 
pathophysiology of cardiac syncope (Figure a) could provide an incremental value in the 
detection of cardiac syncope but their utility in ED syncope evaluation remains unclear.[30] 
Previous pilot studies provided initial insights regarding a possible role of natriuretic peptides 
as quantitative markers of hemodynamic cardiac stress and high-sensitivity cardiac troponin 
(hs-cTn) as quantitative marker of cardiomyocyte injury.[31] 
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Cardiac troponins are regulatory proteins controlling the interaction between actin, myosin and 
calcium. Cardiac troponin I and T are released in the blood when the permeability of myocyte 
membranes increases, like during demand ischemia due to hypotension or supraventricular 
tachycardia, or myocardial strain due to pulmonary embolism.[32]  Troponin release is 
therefore consistent with numerous underlying mechanisms linked to cardiac syncope (Figure 
a). In three single-center studies plasma concentrations of hs-cTn at ED presentation overall 
displayed a moderate-to-high diagnostic accuracy for the detection of cardiac syncope and 
were associated with adverse outcomes.[33–35] 
BNP and N-terminal pro-BNP (NT-proBNP) derive from the same precursor, which is mainly 
secreted by cardiac myocytes in response to volume and pressure overload [36–38], 
summarizing and quantifying left ventricular and right ventricular dysfunction[28,36]. This 
biomarker has led to improvement in the diagnosis and risk-stratification of heart failure and 
has a prognostic predictive value in diverse cardiac and non-cardiac conditions[28,39] (as for 
example in myocardial infarction or pulmonary embolism). Elevated levels of BNP have been 
found in arrhythmias, as for instance in tachycardia or atrial fibrillation, as the result of the 
induced hemodynamic wall stress[38,40]. Arrhythmias being the most common cause of 
cardiac syncope[41], this peptide could thus represent a promising marker in their 
diagnosis.[42,43]  
As the measurement of these biomarkers is already well implemented in the everyday clinical 
practice[39], their use could increase the efficiency of the initial classification of the type of 
syncope and facilitate final diagnosis and risk estimation. However, previous studies 
assessing these biomarkers were rather small and some of them used clinically required 
biomarker measurements or assays whose sensitivity is nowadays obsolete. Accordingly, 
guidelines and clinicians remain skeptical about the role of biomarkers in the evaluation of 
syncope[4]. 
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Figure a - Main etiologies of cardiovascular syncope and their association with elevated plasma levels of BNP or 
cardiac troponin[32,38,44–49]  
The BASEL IX Syncope Study  
BASEL IX is a prospective ongoing international multicenter diagnostic cohort study 
coordinated by the University Hospital Basel enrolling unselected patients in fourteen hospitals 
in nine countries (Switzerland, Spain, Germany, Italy, Poland, New Zealand, Australia, the 
United States of America and Argentina) on four continents. Patients more than 40 years old 
presenting to the ED with a syncope within the 12 last hours are enrolled after providing 
informed consent. A blood draw is performed for the blinded analysis of the investigational 
biomarkers signals. Furthermore, a questionnaire is done using a clinical report form, and the 
patient’s medical history is recorded. Patients are contacted after 12 and 24 months to assess 
recurrence of syncope and occurrence of major adverse cardiac events (especially death, 
myocardial infarction, life-threatening arrhythmia, , ischemic and hemorrhagic stroke). The 
exact etiology of the index syncope is determined by two independent cardiologists blinded to 
investigational biomarker signals according to the newest ESC-Guidelines.[1] Cardiovascular 
causes of syncope are defined as supraventricular or ventricular arrhythmias, severe 
structural heart disease like hypertrophic cardiomyopathy or valvular diseases, pericardial 
tamponade or congenital myocardial or valvular anomalies, or other structural diseases as 
pulmonary embolus or acute aortic dissection,  leading to a transient loss of consciousness. 
Non-cardiac syncope includes reflex syncope or syncope due to orthostatic hypotension. 
The adjudication of the final diagnosis is performed based on all clinical information available 
after diagnostic work-up of patients as well as the clinical follow-up. In cases of disagreement, 
a third reviewer determined the final diagnosis. 
• BNP/NTproBNP
• Troponin
Hypertrophic
Cardio-
myopathy
• BNP/NTproB
NP
• Troponin
Arrhythmia
• BNP/NTproBNPValvular
disease
• BNP/NTproBNP
• Troponin
Pericardial
disease or
tamponade
• BNP/NTproBNP
• TroponinVascular problems
• BNP/NTproBNP
• Troponin
Acute
myocardial
infarction
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel
edoc.unibas.ch 
13 
Thesis aim and hypotheses  
The aim of this thesis is to assess various aspects of the diagnosis and risk-stratification of 
syncope patients presenting in the ED through the assessment of the accuracy of scores and 
biomarkers in a large, international cohort. First, the accuracy of existing syncope diagnostic 
and risk-stratification rules will be compared and their complexity put into perspective by 
comparing them with the easily-calculable CHADS2 score. Second, the diagnostic and 
prognostic accuracy of cardiac troponin, as assessed by three different assays, and BNP will 
be investigated. We hypothesize that the complex scores might not reliably diagnose or risk-
stratify syncope patients and that both assessed biomarkers, at least in certain subgroup of 
patients for which the determination of a precise etiology appears particularly difficult, could 
be of strong interest to improve the diagnosis and risk stratification of patients presenting with 
syncope to the ED. 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel
edoc.unibas.ch 
14 
I - Prospective Validation of Prognostic and Diagnostic Syncope Scores 
in the Emergency Department 
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Key questions 
• What is already known about this subject: The diagnosis and risk-
stratification of syncope patients in the ED is difficult. Several scores have 
been derived to fill this gap.  
• What does this study add? In a large cohort of syncope patients presenting 
to the ED, several syncope-specific scores performed poorly in the 
diagnosis of cardiac syncope. A simple CHADS2 score showed similar 
accuracy to predict death or major cardiovascular events than more 
complicated syncope-specific risk-stratification scores.  
• How might this impact on clinical practice? Complicated and time-
consuming syncope-specific risk scores could be replace with a simple 
CHADS2 -score. There is a need for better diagnostic and risk-stratification 
tools incorporating novel biochemical and electrocardiographic markers for 
syncope patients in the ED. 
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Abstract 
Background: Various scores have been derived for the assessment of syncope 
patients in the emergency department (ED) but stay inconsistently validated. We aim 
to compare their performance to the one of a common, easy-to-use CHADS2 score.  
Methods: We prospectively enrolled patients ≥ 40 years old presenting with syncope 
to the ED in a multicenter study. Early clinical judgment (ECJ) of the treating ED-
physician regarding the probability of cardiac syncope was quantified. Two 
independent physicians adjudicated the final diagnosis after 1-year follow-up. Major 
cardiovascular events (MACE) and death were recorded during 2 years of follow-up. 
Nine scores were compared by their area under the receiver-operator characteristics 
curve (AUC) for death, MACE or the diagnosis of cardiac syncope.  
Results: 1490 patients were available for score validation. The CHADS2-score 
presented a higher or equally high accuracy for death in the long- and short-term 
follow-up than other syncope-specific risk scores. This score also performed well for 
the prediction of MACE in the long- and short-term evaluation and stratified patients 
with accuracy comparative to OESIL, one of the best performing syncope-specific 
risk score. All scores performed poorly for diagnosing cardiac syncope when 
compared to the ECJ. 
Conclusions: The CHADS2-score performed comparably to more complicated 
syncope-specific risk scores in the prediction of death and MACE in ED syncope 
patients. While better tools incorporating biochemical and electrocardiographic 
markers are needed, this study suggests that the CHADS2-score is currently a good 
option to stratify risk in syncope patients in the ED.   
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Introduction 
Syncope is a transient loss of consciousness (T-LOC) associated with an inability to 
maintain postural tone due global cerebral hypoperfusion.[50] It is frequent and 
represents 1-2% of all Emergency Department (ED) visits.[2] The underlying 
etiologies range from benign conditions, such as vasovagal reactions, to life-
threatening cardiac diseases.[50–52] Early risk stratification during initial evaluation 
is important to guide decisions regarding treatment and disposition and prevent long-
term morbidity and mortality[50]. Syncope outcomes are mainly linked to the 
underlying etiology and the associated comorbidities. In the ED, the rapid 
identification of the underlying cause and associated risks are challenging, thus 
leading to a high hospitalization rate. However, only 25% of these hospitalizations 
have been considered appropriate[53] and, despite extensive cardiovascular 
investigations, 75% of patients in whom the cause of the syncope remains 
unexplained after initial clinical assessment will not receive a final diagnosis of 
causality[17]. 
In an attempt to improve the identification of patients at risk of adverse outcomes, 
numerous syncope-specific risk scores[5,18,23] have been derived. However, as 
highlighted in the recent ACC/AHA/HRS “Guideline for the Evaluation and 
Management of Patients With Syncope”,[54] these scores were derived in only a few 
centers, are based on inconsistent definitions of outcomes, time frames and 
predictors, and have been subject to limited external validation.10 Furthermore, these 
tools have not been implemented in most institutions, partly due to their perceived 
complexity. The CHADS2 score is widely known and used for prediction of 
thromboembolic episodes and initiation of treatment with anticoagulants in patients 
with atrial fibrillation[55]. In addition, it has recently been applied as a risk 
stratification tool for predicting mortality after an episode of syncope and was 
recommended in current guidelines[54,56]. However, a prospective validation in a 
multicenter study is lacking. Our study aims to validate syncope-specific risk 
scores[5,18,23] and compare their performance to the one of a common, easy-to-
use CHADS2 score in a large, multicenter cohort of prospectively enrolled patients 
presenting following a syncopal episode to the ED and provide a valid overview of 
the diagnostic and prognostic accuracy of these tools.  
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Methods 
Study design, setting and selection of participants 
BAsel Syncope EvaLuation Study (BASEL IX) is an ongoing prospective 
international diagnostic multicenter study enrolling patients in thirteen hospitals in 
eight countries (Switzerland, Spain, Germany, Italy, Poland, New Zealand, Australia 
and the United States of America). The study is designed to contribute to and 
improve the management of patients presenting with syncope (ClinicalTrials.gov 
registry, number NCT01548352). Patients aged more than 40 years presenting to 
the ED with syncope within the last twelve hours were recruited, after written 
informed consent was obtained.  
Patients with the final diagnosis of a non-syncopal loss of consciousness (e.g. 
epilepsy, fall, alcohol intoxication) were excluded of the analysis. As the majority of 
scores requested ECG data for their correct computation, patients who did not 
undergo electrocardiographic testing upon arrival to the ED were excluded as well. 
Patients in whom the final diagnosis remained unclear even after central adjudication 
were excluded for the validation of diagnostic scores (Supp. Figure I). 
The study was carried out according to the principles of the Declaration of Helsinki 
and approved by the local ethics committees. The authors designed the study, 
gathered, and analysed the data according to the STARD guidelines for studies of 
diagnostic accuracy, vouched for the data and analysis, wrote the paper, and 
decided to publish. 
Clinical assessment 
All patients underwent a clinical assessment that included standardized and detailed 
assessment of predefined details of medical history, including previous syncope 
events and circumstances of current syncope, vital signs, physical examination, 
routine laboratory tests, radiologic testing, and a 12-lead ECG.  Additionally, patients 
may have also undergone 24-hour ECG, external or implantable loop device, cardiac 
exercise test, Shellong test, tilt table testing, coronary angiography, continuous 
rhythm monitoring, pulse oximetry, echocardiography, results from device controls 
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(e.g. pacemaker) or electrophysiological examinations, and recording of findings of 
further investigations during recurrent hospitalization or ambulant treatment. 
Additional tests and treatment of patients were left to discretion of the attending 
physician. 
Clinical judgment by the ED physician regarding the presence of cardiac syncope 
was quantified using a visual analogue scale within 90 minutes after presentation 
and following initial patients’ assessment encompassing patient history and status as 
conducted by the ED physician, first standard laboratory values and the ECG.  
Follow-up and adjudicated final diagnosis 
Patients were contacted 6, 12 and 24 months after discharge by telephone or in 
written form. Information regarding recurrent syncope, hospitalization and cardiac 
events during follow up was furthermore obtained from the patient’s hospital notes, 
the family physician’s records and national mortality registries, where available. To 
determine the final diagnosis for the index syncope in each patient, two independent 
physicians reviewed all available medical records from the clinical data set and the 
study-specific data set. The clinical data set included data from the clinical 
assessment, while study-specific data included standardized forms uniformly 
collecting predefined details of patient history, the circumstances of syncope, and 
physical examination, as well as at least 12 months follow-up. In situations of 
disagreement between adjudicators, cases were reviewed and adjudicated in 
conjunction with a third physician. Further details regarding the adjudicated 
diagnosis are available in the supplemental material.  
Score selection and computation 
The scores listed in the recent AHA/ACC/HRS Guidelines,[54] for which our study 
contained appropriate data to allow their validation, were computed according to the 
original score definition (Supplemental table I). In total, seven syncope-specific 
scores mentioned in these guidelines were computed in all patients for this analysis: 
The score by Martin[20], the OESIL[18] score, the SFSR[19] score, the Boston 
Syncope[21], the STePS[22] score (for long- and short-term risk prediction) and the 
EGSYS[17] score. As these same guidelines mentioned the CHADS2 score as a 
long-term risk factor, this score and its extension, the CHA2DS2VASc score, were 
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analyzed as well. The computed scores were not available to the Emergency 
Physician at the time of admission.  
Table I summarizes the different scores, their individual components, the 
recommended cut-off values and their performance as reported in the original 
publications.  
Outcome measures 
As the definitions of clinical endpoints or serious outcomes and the time frame for 
predictions varied strongly between studies (Table I), we decided to validate all 
scores for clinically relevant endpoints. The co-primary prognostic endpoints were 
all-cause death and major adverse cardiovascular events (MACE, defined as a 
combined endpoint of all-cause death, life-threatening arrhythmia, 
pacemaker/implantable Cardioverter Defibrillator implantation, stroke, acute 
myocardial infarction (AMI) and pulmonary embolism) during 2 years of follow-
up[50,54] and the primary diagnostic endpoint was cardiac syncope. The co-
secondary prognostic endpoints were all-cause death and MACE at 30 days.  
Statistical analysis 
Continuous variables are presented as mean ± standard deviation (SD) when 
normally distributed and median with interquartile ranges (IQR) when non-normally 
distributed. Categorical variables are expressed as numbers and percentages. 
Mann-Whitney-U test was applied for comparison of continuous variables between 
cardiac and non-cardiac syncope. Categorical variables were compared by Pearson 
Chi-square test and Fisher’s exact test, respectively. 
Receiver-operating characteristic (ROC) curves were constructed to assess the 
sensitivity (SE) and specificity (SP) of each score regarding their prognostic and 
diagnostic accuracy for the predefined endpoints. SE and SP of the early clinical 
judgment of the ED physician for the diagnosis of cardiac syncope were assessed in 
a similar way. The comparison of areas under the independent ROC curves (AUC) 
was performed according to DeLong.  
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We assessed the performance of each score to predict cardiac syncope, death or 
MACE when either the recommended cut-off or any other possible cut-off was 
applied. 
Survival analysis was conducted using graphical representation of Kaplan-Meier 
curves. Difference in time-to-event stratification was tested by the use of the log-rank 
test. 
All hypothesis testing was two-tailed and p-values <0.05 were considered statistically 
significant. Statistical analyses were performed using IBM SPSS Statistics for 
Windows, version 22.0 (SPSS Inc, Chicago, IL) and the R statistical package 
(MathSoft, Seattle, WA, packages “foreign”, “haven”, “tableone”, “reshape2”, 
“ggplot2”, “gridExtra”, “survival”, “survminer”).   
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Results 
Characteristics of study subjects 
From May 2010 to August 2016, a total of 1753 patients were enrolled in the BASEL 
IX study (Supplemental Figure I).  
Patients with a non-syncopal loss of consciousness (n=214) or missing ECG’s 
(n=61) were excluded for both analyses, while patients in whom the final diagnosis 
remained unclear even after central adjudication (n=145) were excluded from 
analyses of diagnostic endpoints, leaving a total of 1490 and 1345 patients available 
for the analysis of diagnostic and prognostic endpoints, respectively. 
The characteristics of patients who suffered a cardiac syncope (n=216), a non-
cardiac syncope (n=1129) and a syncope of unknown etiology (n=145) are 
presented in Table II. Patients diagnosed with a cardiac syncope were significantly 
older, had more cardiovascular comorbidities and were taking more chronic 
medications.  
Prognostic accuracy of the scores 
During a median follow-up duration of 739 days (IQR 720-835) in survivors, 227 
patients (15.2%) died and 319 patients (21.4%) suffered from MACE.  
The prognostic accuracies of all analyzed scores for the prediction of death and 
MACE for the entire follow-up length are represented in Figure I. For the prediction of 
death, the CHADS2, CHA2DS2VASc, and STEPS long scores (all three AUC 0.71, 
95%CI 0.68-0.74) displayed the highest prognostic accuracy (p for comparison=ns).  
For the risk prediction of MACE, the OESIL, CHADS2, CHA2DS2VASc, Martin, 
Boston and STEPS long-term scores provided comparable prognostic accuracy 
(p=ns for comparison).  
The prognostic accuracies of the scores for death and MACE for a limited time span 
of 30 days following the initial syncope are presented in supplemental Figure II. The 
results were consistent with the long-term prognostic accuracy, with the CHADS2 and 
CHA2DS2VASc-Scores performing best for the short-term prediction of death (AUC 
0.79, 95%CI 0.72-0.87 and AUC 0.76, 95%CI 0.65-0.82 respectively, p=ns). The 
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Martin and the OESIL score again performed best for the prediction of MACE in the 
short term (AUC 0.72, 95%CI 0.68-0.75 and AUC 0.70, 95%CI 0.66-0.74 
respectively, p=ns).   
The percentage of patients ruled in and out and the sensitivity, specificity, negative 
predictive value and positive predictive value of the individual scores to predict death 
or MACE during the entire follow-up using the recommended cut-off levels of each 
individual score are presented in Supplemental Table IIA and IIB. The performance 
of the best performing scores at alternative cut-off points is presented in the 
supplemental Table IIIA and IIIB.  
Survival and survival free of MACE up to 2 years of follow-up according to the 
CHADS2 and OESIL score are shown in Figure II. Both scores allowed for an 
efficient and comparable risk stratification  
Diagnostic accuracy of the scores for cardiac syncope 
The diagnostic accuracy of all analyzed scores as well as the one of the Early 
Clinical Judgment of the ED physician for a syncope of cardiac etiology is 
represented in Figure I. Of all analyzed scores, the one by Martin and the OESIL 
score displayed the highest accuracy (AUC 0.75, 95%CI 0.72-0.78 and AUC 0.72, 
95%CI 0.68-0.75 respectively, p=ns). However, it performed poorly compared with 
the Early Clinical judgment of the ED physician (AUC 0.87, 95%CI 0.84-0.9, 
p=<0.001 for the comparison with the Martin score).  
Details regarding the performance of recommended or alternative cut-off points of 
each individual score to predict cardiac syncope are presented in Supplemental 
Table IIC and supplemental Table IIIC, respectively.  
When added to the early clinical judgment of the ED physician, the OESIL, Martin, 
CHA2DS2VASc and CHADS2 score did not lead to any improvement of the 
diagnostic accuracy of the Emergency Physician (Supplemental Table IV).  
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Discussion 
This large prospective, multicentre study using central diagnostic adjudication and 
long-term follow-up aimed to advance the rapid and accurate diagnosis and risk 
stratification of patients presenting with syncope to the ED by evaluating the 
prognostic and diagnostic utility of various clinical risk scores potentially 
implementable in the ED and compare their performance to the one of a common, 
easy-to-use CHADS2 score.  
We report four major findings. First, all validated syncope risk-stratification scores 
showed only moderate performance for the prediction of death and MACE on the 
long- and on the short-term. Second, the syncope-specific risk scores were less or 
equally accurate than a simpler CHADS2 score for the prediction of death and MACE 
over two years of follow-up and for a 30-days period following the index event. Third, 
all syncope-specific diagnostic scores performed poorly compared with the early 
clinical judgment of the ED physician. Fourth, none of the evaluated score added any 
diagnostic value to the early clinical judgment of the emergency physician.  
These findings corroborate and extend previous studies which tried to establish the 
most appropriate diagnostic and prognostic clinical use of various scores possibly 
implementable in the ED.[17–22,57] To the best of our knowledge, this is the first 
observational study using prospectively collected data to validate seven syncope-
specific scores in the same patient data set. We observed a strong overlap between 
several scores, most of them taking into account signs of the acute presentation, 
age, prior history of heart disease or electrocardiographic abnormalities. However, 
as highlighted in previous studies[58], the exact definition of the overlapping 
components was heterogeneous between scores, contributing to their variability in 
diagnostic and prognostic accuracy.  
Our study demonstrated that syncope-specific risk scores did not perform better than 
a simple CHADS2 or CHA2DS2VASc score. These scores has been validated in 
several cardiovascular diseases[59–63] and are widely used prediction tools for 
thromboembolic episodes and initiation of treatment with anticoagulants in patients 
with atrial fibrillation[55,64,65]. Our results discourage the unnecessary use of 
complicated and time-consuming syncope-specific scores for long- and short-term 
risk stratification, as comparable accuracy can be obtained through a simple, quick 
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and widespread score. However, the CHADS2 score is known to be a general 
indicator of morbidity and, as shown by Ruwald et al.[56], it stratifies a syncope 
population just as well as a general population not suffering any syncopal events. 
The performance of this score to predict adverse outcome better than or equally to 
syncope-specific scores highlights that syncope-related adverse prognostic factors 
are not reliably established.  
The diagnostic accuracy of all scores was poor and inferior to the early clinical 
judgment of the ED physician. Moreover, in conjunction with this judgment, none of 
the scores brought a clinically relevant improvement. This inferiority has been 
observed in previous studies[17] and reflects the difficulty of diagnostic models to 
capture the clinical synthesis made by a physician. Previous research tried to 
reproduce this complex process of physicians’ reflection using neural networks and 
could accurately predict short-term adverse outcome in patients presenting with 
syncope to the ED[66]. While the use of such sophisticated non-linear models is 
certainly promising, clinical validation of this approach is pending.  
We rated the different scores by analyzing and comparing their AUC for different 
endpoints (Figure I and Supplemental Figure II), leading to a cut-off-independent 
comparison of their accuracy. While the comparison of these AUCs reflects the 
relevance of the scores components, it only partly represents the real clinical value in 
the settings where the scores were developed and where they will be used. During 
score derivations, most of the authors accompanied their publication with a 
recommended cut-off [4,17–19,21,56], which is essential for the implementation of 
these scores into ED decision making. Our analysis reveals important differences in 
the sensitivity of the scores when the recommended cut-off was applied. For 
instance, the EGSYS and its recommended cut-off of ≥3 points led to a much lower 
sensitivity than other scores. A cut-off adaptation to ≥1 point would have significantly 
raised its sensitivity to detect cardiac syncope or stratify risk in our patient collective. 
Acknowledging that this score was derived in a study involving centers exclusively in 
Italy, the recommended cut-off does not seem to be generalizable to a more 
international setting. This again highlights the importance of validation studies to 
insure not only the relevance of the score components but also the suitability of the 
recommended cut-offs in other populations.  
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Furthermore, a single cut-off strategy was recommended for all the scores in the 
derivation studies. Recently, strategies using different cut-offs for rule-in and rule-out 
were proven useful for the diagnostic stratification of other cardiovascular diseases 
in clinical practice, mainly acute myocardial infarction[67–69]. Most of the validated 
syncope-specific scores already show very good safety, but classifying patients into 
“high-risk”, “low-risk” and “observe” cohorts could allow for clinical efficacy 
optimization and improvement of resource utilization.  
Some limitations merit considerations when interpreting our findings. First, despite 
using the most stringent methodology to adjudicate the etiology of the underlying 
syncope event, we still may have misclassified a small number of patients. Second, 
the underlying etiology of the syncopal events stayed unclear in 11% our patients. 
However, this percentage is much lower than reported by other studies[51] and 
highlight our strong methodology. Third, we did not validate three further syncope-
specific scores present in the literature due to the lack of systematic measurements 
of troponin and BNP in all of our patients. Fourth, we are aware that the validated 
scores have been originally derived to ease either diagnosis or risk-stratification and 
thus the definition of the endpoints and timeframes were heterogeneous. 
Nevertheless, to allow for comparison, we assessed all scores regarding their 
diagnostic and prognostic accuracy for death and MACE, which were endpoints we 
considered as clinically relevant. 
In conclusion, all currently available clinical scores perform only moderately in the 
prognosis and diagnosis of cardiac syncope. None of the scores bring a relevant 
improvement to the early judgment of the clinician. Syncope-specific risk-
stratification scores were less or equally accurate than a simpler CHADS2 score for 
the prediction of death and MACE in the short- and long-term follow-up. Our analysis 
underlines the need for improved tools for diagnosis and risk stratification, potentially 
including novel biochemical and electrocardiographic markers.  
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Figures 
 
Figure I: Accuracy of the analyzed scores for the prediction of death and MACE (for 
a median follow-up of 739 days) and for the diagnosis of cardiac syncope, as given 
by value of the Area Under the Curve.  
Whiskers represent the 95%-confidence intervals.  
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Figure II: Survival analysis using the OESIL- (A and B) or CHADS2-score (C and D) 
for time-to-death and time-to-first MACE until 720 days.  
p-values calculated according to the log-rank test.  
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Tables 
Table I: Summary of the scores and their performance according to the literature.  
Score Range Components Recommended 
cut-off 
Original 
endpoint 
Original 
accuracy 
Martin 0-4 Abnormal ECG, >45y of 
age, history of ventricular 
arrhythmias, history of 
CHF 
≥1a 1-y death or 
arrhythmia 
AUC=0.80 
NPV = 93%* 
OESIL 0-4 Abnormal ECG, >65y of 
age, no prodromi, 
cardiac history 
≥2 1-y death AUC=0.89 
NPV= 99% 
PPV=32% 
SE=97% 
SP =73% 
SFSR 0-1 Abnormal ECG, 
dyspnea, hematocrit, 
systolic BP<90mmHg, 
history of CHF 
≥1 7-d serious 
events 
NPV= 99% 
PPV=25% 
SE =96% 
SP =62% 
Boston 
Syncope 
Rule 
0-8 Symptoms of acute 
coronary syndrome, 
worrisome cardiac 
history, family history of 
SCD, valvular disease, 
signs of conduction 
disease, volume 
depletion, persistent 
abnormal vital signs, 
primary central nervous 
event 
≥1 30-d serious 
events 
NPV=100% 
PPV=44% 
SE = 97% 
SP=62% 
EGSYS -2-12 Abnormal ECG, cardiac 
history, palpitations, 
exertional, supine, 
precipitants, autonomic 
prodromi 
≥3 Cardiac 
etiology 
AUC=0.90 
NPV= 99% 
PPV=33% 
SE =95% 
SP = 61% 
                                                             a	As	mentioned	in	the	AHA/ACC	Guidelines[4]	
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STePS 
(short 
term) 
0-14a Abnormal ECG, trauma, 
no prodromi, male sex 
n.a. 10-d serious 
events 
n.a. 
STePS 
(long 
term)  
0-15† Age >65, neoplasms, 
cerebrovascular 
diseases, structural heart 
disease, ventricular 
arrhythmias 
n.a. 1-y serious 
events 
n.a. 
CHADS2  0-6 CHF, hypertension, 
Age>75, Diabetes, prior 
Stroke/TIA 
≥1 Cardiovascular 
death 
NPV = 93% 
PPV = 41% 
SE =82% 
SP = 67% 
CHA2DS2
VASc 
0-10 CHF, hypertension, 
Age>75, Diabetes, prior 
Stroke/TIA, Vascular 
disease, Age 65-74y, 
female sex 
n.a. n.a. n.a. 
 
Table I: Comparison of the analysed scores according to the data provided in the literature.  
AUC = Area Under the Curve, BP= Blood pressure, NPV = Negative predictive value, PPV = 
Positive Predictive Value, CHF = Congestive Heart Failure, ECG = Electrocardiogram, SE = 
Sensitivity, SP = Specificity, SCD = Sudden Cardiac Death,  TIA = Transient Ischemic 
Attack, n.a. = not applicable 
                                                             a	Derived	from	the	odds	ratios	of	the	original	publication	
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Table II Baseline characteristics 
 
All patients Not cardiac Cardiac Unknown p 
 
N= 1490 N= 892 N= 175 N= 128 
 
Age - years  [IQR] 71.0 [58.0, 80.0] 
68.0 [55.0, 
78.0] 
77.0 [66.0, 
84.0] 
79.0 [71.0, 
84.0] <0.001 
Women gender – no. (%) 593 (40) 458 (41) 78 (36) 57 (39) 0.468 
Characteristics of the 
syncope – no (%) 
     
    Nausea/Vomiting 430 (29) 362 (33) 44 (21) 24 (17) <0.001 
    Sweating 452 (31) 389 (35) 42 (20) 21 (15) <0.001 
    Pallor 398 (44) 323 (46) 47 (37) 28 (33) 0.013 
    Palpitations  101 (7) 77 (7) 18 (9) 6 (4) 0.293 
    Angina  91 (6) 63 (6) 20 (9) 8 (6) 0.118 
    Caused injury 214 (15) 150 (14) 33 (16) 31 (22) 0.027 
Position of the syncope – 
no (%) 
     
    While lying  36 (2) 27 (2) 6 (3) 3 (2) 0.901 
    While sitting  596 (40) 460 (41) 81 (38) 55 (38) 0.569 
    Orthostatic  181 (12) 152 (14) 16 (7) 13 (9) 0.020 
    While standing  656 (44) 473 (42) 111 (52) 72 (50) 0.016 
    Exertion 127 (9) 75 (7) 35 (16) 17 (12) <0.001 
Risk factors – no (%) 
     
    Hypertension 897 (60) 640 (57) 147 (69) 110 (76) <0.001 
    Hypercholesterolemia 626 (44) 449 (41) 106 (50) 71 (53) 0.003 
    Diabetes 228 (15) 155 (14) 44 (20) 29 (20) 0.011 
    Smoking 756 (51) 580 (52) 99 (47) 77 (55) 0.283 
History – no (%) 
     
    Previous stroke 124 (8) 87 (8) 18 (8) 19 (13) 0.091 
    Chronic heart failure 
(NYHA II – IV) 117 (8) 68 (6) 33 (16) 16 (11) <0.001 
    Arrhythmia 318 (22) 197 (18) 83 (39) 38 (27) <0.001 
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    Pacemaker  72 (5) 50 (4) 17 (8) 5 (4) 0.073 
    Coronary artery disease  325 (22) 207 (19) 73 (35) 45 (31) <0.001 
    Previous DVT or PE  103 (7) 71 (6) 14 (7) 18 (13) 0.020 
    Previous MI 192 (13) 125 (11) 43 (20) 24 (17) 0.001 
    Epilepsy 43 (3) 33 (3) 2 (1) 8 (6) 0.039 
Chronic medication – no 
(%) 
     
    ACEIs/ARBs 667 (45) 475 (42) 113 (52) 79 (54) 0.001 
    Alphablocker 117 (8) 83 (7) 19 (9) 15 (10) 0.386 
    Antiarrhythmics Class I 54 (4) 34 (3) 13 (6) 7 (5) 0.069 
    Aspirin 451 (30) 313 (28) 80 (37) 58 (40) 0.001 
    Beta-blockers 482 (32) 324 (29) 93 (43) 65 (45) <0.001 
    Calcium antagonists 253 (17) 176 (16) 42 (19) 35 (24) 0.021 
    Digitalis 26 (2) 13 (1) 11 (5) 2 (1) <0.001 
    Diuretics  456 (31) 303 (27) 98 (45) 55 (38) <0.001 
IQR = Interquartile Range, DVT=Deep venous thrombosis, PE= Pulmonary embolism, MI= 
Myocardial infarction, ACEI =Angiotensin converting enzyme inhibitors , ARB= Angiotensin 
receptor blockers, NYHA = New York Heart Association 
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Supplemental material 
Supplemental Methods:  
Adjudication of the final diagnosis 
The first step in the adjudication process was to decide whether there was syncope 
or not. If the criteria for a true syncope were not fulfilled, a distinction between the 
following non-syncopal disorders was made: pre-syncope; falls; stroke/TIA; epilepsy; 
metabolic disorders: e.g. hypoglycaemia, hypoxia, hyperventilation; intoxication: e.g. 
alcohol, benzodiazepines, opiates; functional (psychogenic pseudosyncope); others. 
The classification of syncope is based on pathophysiological considerations. The 
following predefined differential diagnoses were used: 
1) Cardiac syncope: We distinguished between: 
a. Arrhythmia as primary cause: Arrhythmias are the most common cause 
of syncope; Bradycardia: sinus node dysfunction, atrioventricular 
conduction system disease, implanted device malfunction or drug-
induced; Tachycardia: supraventricular or ventricular. 
b. Structural heart disease: structural heart diseases can cause syncope 
when circulatory demands outweigh the impaired ability of the heart to 
increase output. However, in some cases syncope may not solely be 
the result of restricted cardiac output, but be in part due to an 
inappropriate reflex. However, when a structural heart disease was the 
primary cause or contributed most to syncope, it was classified as 
cardiovascular syncope. 
c. Others: pulmonary embolism, acute aortic dissection, pulmonary 
hypertension or any other cause for a cardiovascular syncope. 
2) Reflex (neutrally-mediated) syncope: This syncope is characterized by 
cardiovascular reflexes which are normally useful in controlling circulation but 
become intermittently inappropriate in response to a trigger. The reflex results 
in vasodilation and/or bradycardia which lead to a fall in arterial blood pressure 
and consequently to cerebral hypoperfusion. Identifying a trigger is central 
when diagnosing a reflex syncope. Typically symptoms as lightheadedness, 
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nausea, sweating, weakness or visual disturbances precede reflex syncope. 
We distinguished between: 
a. Vasovagal: “common faint”, triggered by emotional distress/ pain or 
mediated by orthostatic stress. 
b. Situational: refers to reflex syncope associated with some specific 
circumstances, e.g. post-micturition, post-prandial, gastrointestinal 
stimulation, cough. 
c. Carotid sinus syncope: triggered by mechanical manipulation of the 
carotid sinus. It can be diagnosed by carotid sinus massage. 
d. Atypical forms: reflex syncope occurring with uncertain or apparently 
absent triggers. 
3) Syncope due to orthostatic hypotension: Orthostatic hypotension is defined as 
an abnormal decrease in systolic blood pressure after changing from supine to 
standing position. Key can be syncope immediately after standing up or a 
pathological Schellong test. We distinguished between: 
a. Primary autonomic failure: There is an autonomic failure which is 
clearly a primary part of Parkinson syndrome as idiopathic Parkinson 
disease or atypical Parkinson syndrome (multiple system atrophy, 
progressive supranuclear oculomotoric paresis, corticobasal 
degeneration or lewy body dementia). 
b. Secondary autonomic failure: autonomic failure may be due to 
circumstances such as diabetes, uraemia, amyloidosis or spinal cord 
injuries 
c. Drug-induced orthostatic hypotension: orthostatic hypotension is due to 
drugs which can lead to orthostatic hypotension such as diuretics, 
antidepressants, vasodilators, alcohol 
d. Volume depletion: orthostatic hypotension is caused by a hypovolemia 
due to haemorrhage, diarrhoea, vomiting or fever 
e. Others: sometimes the pathophysiology remains unclear. 
4) Others, non-cardiac syncope: Sometimes the underlying pathophysiological 
mechanism of syncope remains unclear, but a cardiac syncope is ruled-out. 
5) Syncope of unknown etiology (cardiac syncope possible): the etiology of 
syncope still remained unknown and a cardiac syncope was considered to be 
a possible cause.  
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Supplemental Figures:  
Supplemental figure I : Patient flow-chart.  
ED = Emergency Department.  
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Supplemental figure II: Accuracy of the analyzed scores for the prediction of death 
or MACE at 30 days, as given by value the Area Under the Curve. 
 
Whiskers represent the 95%-confidence intervals. 
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Supplemental Tables :  
Supplemental table I : Details of the score computation  
Score Variable Definition of the variable Computation with our data Computation 
oft he score  
CHADS2  Congestive heart 
failure 
Patients with clinical diagnostic of heart failure or 
LVEF<40% or NYHA Class II-IV 
If the patient had a clinical history of heart failure (NYHA II-IV) 
or an EF of <40% on the TTE 
+1 
Hypertension BPSys>140 or BPdiast>90 or 1 anti-hypertensive med.  If the patient had a history of hypertension or if he was under a 
chronic treatment of at least one alphablocker and/or one 
diuretic and/or one ACE-inhibitor and/or one AT-II blocker 
and/or one betablocker and/or one calcium antagonist.  
+1 
Age > 75yo  If age >75yo +1 
DM  Previous diagnosis or use of antidiabetic medications If the patient had a diagnosis of diabetes or was using 
antidiabetics, including insulin.  
+1 
History of Stroke 
or TIA 
 If the patient had a previous diagnosis of stroke or TIA +2 
CHA2DS2VASc Age >65yo  Age>65yo. +1 
Vascular disease History of myocardial infarction, peripheral artery 
disease or vascular plaques, including previous surgery 
for vessels or previous arterial and venous thrombosis.  
If the patient had a diagnosis of peripheral artery disease, a 
history of a previous myocardial infarction, deep vein 
thrombosis, a coronary artery bypass or a percutaneous 
coronary revascularisation.   
+1 
Sex Female If the patient was a woman +1 
OESIL score Cardiovascular 
disease 
1. Previous clinical or laboratory diagnosis of any form 
of structural heart disease, including ischemic heart 
disease, valvular dysfunction and primary myocardial 
disease, 
If the patient had a history of congestive heart failure (NYHA II-
IV), a known valvular disease, a previous history of stroke or 
TIA, myocardial infarction, bypass operation, percutaneous 
+1 
 41 
2. Previous diagnosis or clinical evidence of congestive 
heart failure, 
3. Previous diagnosis or clinical evidence of peripheral 
arterial disease, 
4. Previous diagnosis of stroke or transient ischemic 
attack. 
 
coronary revascularisation or a diagnosis of peripheral artery 
disease. 
No prodromi No prodromal symptoms such as light-headedness, 
nausea, diaphoresis, weakness, and visual 
disturbances  
If the patients had no prodromal symptoms such as light-
headedness, nausea, vomiting, diaphoresis, weakness, and 
visual disturbances.  
+1 
Abnormales EKG The tracings were considered abnormal in the following 
cases: 
1. Rhythm abnormalities (atrial fibrillation or flutter, 
supraventricular tachycardia, multi- focal atrial 
tachycardia, frequent or repetitive premature 
supraventricular or ventricular com- plexes, sustained 
or non-sustained ventricular tachycardia, paced 
rhythms), 
2. Atrioventricular or intraventricular conduction 
disorders (complete atrioventricular block, Mobitz I or 
Mobitz II atrioventricular block, bundle branch block or 
intraventricular conduction delay), 
3. Left or right ventricular hypertrophy, 
4. Left axis deviation, 
 5. Old myocardial infarction, 
6. ST segment and T wave abnormalities consistent 
with or possibly related to myocardial ischemia. 
Electrocardiographic recordings showing non- specific 
repolarization abnormalities were not considered as 
abnormal. 
The tracings were considered abnormal in the following cases: 
1. Rhythm abnormalities : Atrial fibrillation, atrial flutter, 
atrial ectopic rhythm, ventricular ectopic rhythm 
2. Atrioventricular block Mobitz I and II, complete 
atrioventricular block or higher atrioventricular blocks, 
right, left left-anterior hemi- and bundle branch block 
3. Left ventricular hypertrophy  
4. Left axis deviation 
5. Presence of significant Q-waves 
6. ST segments modification and T wave abnormalities 
possibly related to myocardial ischemia 
+1 
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Age >65yo  Age >65yo  
EGSYS score  Palpitation 
preceding 
syncope 
 If the patient reported palpitations preceding the event.  +4 
History of Heart 
disease or 
abnormal ECG in 
the ED 
ECG abnormality was considered as the presence of 
one or more of the following abnormalities: bradycardia 
(<40 beat/minute), ST changes (>1 mm elevation or 
depression), QT prolongation (440ms), ventricular 
tachycardia, atrioventricular block (second or third 
degree), sick sinus syndrome, ventricular and rapid 
paroxysmal supraventricular arrhythmias, sinus pauses, 
and pace malfunction. 
No precisions given regarding the “history of heart 
disease” component.  
The tracings were considered abnormal in the following cases: 
1. Bradycardia <40bpm 
2. Rhythm abnormalities : Atrial fibrillation, atrial flutter, 
atrial ectopic rhythm, ventricular ectopic rhythm and 
pacemaker rhythm 
3. Sicksinus syndrome 
4. Atrioventricular block Mobitz I and II, complete 
atrioventricular block or higher atrioventricular blocks 
5. ST segments modification and T wave abnormalities 
possibly related to myocardial ischemia 
6. QT prolongation (440ms) 
A history of heart disease was positive if the patient had a 
diagnosis of congestive heart failure (NYHA II-IV), of valve 
disease, a previous history of myocardial infarction, bypass 
surgery, percutaneous coronary intervention.  
+3 
Syncope during 
effort  
 If the patient reported syncope during effort.  +3 
Syncope while 
supine 
 If the patient reported syncope while supine. +2 
Precipitating or 
predisposing 
factor 
Predisposing or precipitating factors were considered 
as the presence of one or more of the following 
abnormalities: Warm-crowded place/prolonged 
orthostasis/fear–pain–emotion  
 
If the patient reported syncope while standing, sitting, while 
standing up or accompanied by weakness.  
 
-1 
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Autonomic 
prodromi 
Prodromal symptoms and signs were considered as the 
presence of one or more of the following abnormalities: 
nausea/vomiting 
If the patients had no prodromal symptoms such as light-
headedness, nausea, vomiting, diaphoresis, weakness, and 
visual disturbances. 
-1 
Martin Score  Age >45  Age >45yo 1 
History of 
congestive heart 
failure  
 If the patient had a known history of congestive heart failure 
(NYHA II-IV) 
1 
Arrhythmia Definition of arrhythmia: ventricular tachycardia (VT) of 
three or more beats; sinus pauses of 2 seconds or 
longer and those pauses that were symptomatic; 
symptomatic sinus bradycardia ("symptomatic" for the 
purposes of this study refers to the simultaneous 
occurrence of dizziness, lightheadedness, or  syncope 
and an arrhythmia on ECG monitoring); supra- 
ventricular tachycardia (SVT) with symptoms or 
associated with hypotension (systolic blood pressure 
less than 90 mm Hg); atrial fibrillation with slow 
ventricular response (RR interval longer than 3 
seconds); complete atrioventricular block; Mobitz II 
atrioventricular block; and evidence of pacemaker 
malfunction.  
Isolated, asymptomatic premature ventricular 
contractions (PVCs), couplets, asymptomatic premature 
atrial contractions, brief asymptomatic runs of SVT, 
chronic atrial fibrillation, and atrial flutter were not 
included in the definition of arrhythmias unless they 
were associated with symptoms (dizziness, 
lightheadedness, or syncope). 
If the patient had any known history of arrhythmia. 1 
Abnormal ECG:  
 
ECG reports and tracings (from ED ECG, Holter 
monitoring, or bedside ECG monitoring in the CCU) 
were reviewed for identification and verification of 
arrhythmias. Two definitions of clinically important 
arrhythmias were considered. It was not required that 
these arrhythmias were the cause of the syncope.  
ECG reports from the ED ECG, Holter monitoring and 
telemetry monitoring data were review.  
Abnormal parameters on the ECG were considered to be :  
1. Rhythm abnormalities : Atrial fibrillation, atrial flutter, 
atrial ectopic rhythm, ventricular ectopic rhythm 
1 
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Rhythm abnormalities were : atrial fibrillation or flutter, 
multifocal atrial tachycardia, junctional or paced 
rhythms; frequent or repetitive PVCs (including VT), 
conduction disorders (ie, left axis deviation, bundle 
branch block, intraventricular conduction delay), left or 
right ventricular hypertrophy (LVHor RVH), short 
PRinterval (less than 0.10sec), old myocardialinfarction, 
and atrioventricular block (ie, complete atrioventricular 
block, Mobitz II, or Mobitz I with other abnormalities 
present). 
Not abnormal: normal (including patients with only sinus 
bradycardia or sinus tachycardia); nonspecific ST- and 
T-wave abnormalities (NST) for patients with NST as 
the only abnormality 
 
2. Atrioventricular block Mobitz I and II, complete 
atrioventricular block or higher atrioventricular blocks, 
right, left left-anterior hemi- and bundle branch block 
or a PQ-time <0.10sec 
3. Left ventricular hypertrophy  
4. Left axis deviation 
5. Presence of significant Q-waves 
6. ST segments modification and T wave abnormalities 
possibly related to myocardial ischemia 
7. Presence of nonsustained ventricular tachycardia 
Abnormal parameters on the Holter analysis were considered 
to be:  
1. Rhythm abnormalities : Atrial fibrillation, atrial flutter, 
atrial ectopic rhythm, ventricular ectopic rhythm 
2. Atrioventricular block Mobitz I and II, complete 
atrioventricular block or higher atrioventricular blocks 
3. Incomplete and complete right, left blocks or 
combinations.  
4. Any pause >2.5 sec 
The telemetry monitoring data were considered abnormal if 
any pause of >2.5sec occurred.  
SFSR 
 
Abnormal ECG New abnormal ECG All ECGs upon arrival in the ED were compared with 
previously realized ECGs (anytime).  
A new pathology was considered when the ECG upon arrival 
but not the previous ECG displayed at least one of:  
1. Atrioventricular block Mobitz I and II, complete 
atrioventricular block or higher atrioventricular blocks, 
right, left left-anterior hemi- and bundle branch block 
2. Left ventricular hypertrophy  
3. Left axis deviation 
4. Presence of significant Q-waves 
5. ST segments modification and T wave abnormalities 
possibly related to myocardial ischemia 
6. Presence of nonsustained ventricular tachycardia 
7. QTc time >440 
8. Sick sinus syndrome 
Made the rule 
positive 
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Any rhythm abnormality (Atrial fibrillation, atrial flutter, atrial 
ectopic rhythm, ventricular ectopic rhythm), even already 
present on the previous ECG, was considered abnormal.  
Dyspnea  If the patient reported dyspnea before or after the event. Made the rule 
positive 
Hematocrit <30  If the haematocrit upon arrival was <30 Made the rule 
positive 
Systolic BP <90  If the systolic BP upon arrival was <90 Made the rule 
positive 
HF  If the patient had a clinical history of heart failure (NYHA II-IV) 
or an EF of <40% on the TTE 
Made the rule 
positive 
STEPS short 
term 
 
Abnormal ECG Electrocardiogram (ECG) was defined as abnormal in 
the presence of any of the following: 1) atrial fibrillation 
or tachycardia; 2) sinus pause >2 s; 3) sinus 
bradycardia with heart rate ranging between 35 and 45 
beats/min; 4) conduction disorders (i.e., bundle branch 
block, second-degree Mobitz I atrioventricular block); 5) 
ECG signs of previous 
myocardial infarction or ventricular hypertrophy; and 6) 
multiple premature ventricular beats. 
If any of:  
1. Rhythm abnormalities : Atrial fibrillation, atrial flutter 
or heart rate >100 bpm or <45bpm 
2. Atrioventricular block Mobitz I, complete 
atrioventricular block or higher atrioventricular blocks, 
right, left left-anterior hemi- and bundle branch block 
3. Left ventricular hypertrophy  
4. Left axis deviation 
5. Presence of significant Q-waves 
6. ST segments modification and T wave abnormalities 
possibly related to myocardial ischemia 
7. Presence of nonsustained ventricular tachycardia 
 
6.9 
Trauma  If the patient reported any injury 2.9 
No prodrome  If the patients had no prodromal symptoms such as light-
headedness, nausea, vomiting, diaphoresis, weakness, and 
visual disturbances. 
2.4 
Male Sex  Male sex 2.2 
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STEPS  Long 
term 
 
Age >65 yrs  Age >65yo 3.4 
Coexistence at 
presentation of 
neoplasms  
 If the patient displayed any diagnosis of leucemia, malignant 
lymphoma or malignant solid tumor.  
3.2 
Hx of 
Cerebrovascular 
diseases  
 If the patient had any history of stroke or TIA 2.5 
Structural heart 
disease 
 A history of heart disease was positive if the patient had a 
diagnosis of congestive heart failure (NYHA II-IV), of valve 
disease, a previous history of myocardial infarction, bypass 
surgery, percutaneous coronary intervention. 
2.3 
Ventricular 
arrhythmias 
 If the patient reported any diagnosis of arrhythmia 3.9 
Boston  Signs and 
symptoms of ACS 
Complaint of CP 
Ischemic ECG changes (ST elevation or deep ST 
depression) 
Other ECG changes : VT, VF, SVT, rapid AF or new 
ST/T wave change 
Complaint of SOB 
If the patient reported any complain of chest pain/dyspnea 
before or after the syncope, if the ECG upon arrival to the ED 
was showing Q-waves, ST elevation or deep ST depression, 
VT, VF or AF.  
Made the rule 
positive 
Worrisome 
cardiac history 
Hx of CAD, cardiomyopathy 
Hx of congestive HF or LV dysfunction 
Hx of Ventricular tachycardia or VF 
Hx of PM, ICD 
Prehosp use of antidysrhythmic meds but not BB or Ca-
blockers 
If the patient reported any history of arrhythmia, diagnosis of 
CHF (NYHA II-IV), showed a LV dysfunction in the TTE, had a 
Pacemaker, ICD or CRT, had a history of AMI, bypass, PCI, 
were taking antiarrhythmic class I medication or digitalis.  
Made the rule 
positive 
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FaHX SCD  If the patient reported any familial history of SCD Made the rule 
positive 
Valvular heart 
disease 
Heart murmur noted on examination or in history If the patient reported any diagnosis of valvular disease or if a 
systolic or diastolic murmur was noticed during physical 
examination.  
Made the rule 
positive 
Signs of 
conduction 
disease 
Multiple syncopal episodes within the last 6 mo 
Rapid heart beat by patient history 
Syncope during exercise 
QT interval >500 
2nd or 3rd degree AV block or intraventricular block 
If the patient reported syncope during exercise, any history of 
palpitations or more than 2 previous syncopal events.   
If the QTc interval was >500, if the ECG showed any of :  
1. Atrioventricular block Mobitz I, complete 
atrioventricular block or higher atrioventricular blocks, 
right, left left-anterior hemi- and bundle branch block 
2. QTc>500ms 
Made the rule 
positive 
Volume depletion GI bleeding by haemoccult or history 
Hct<30 
Dehydration not corrected in the ED by physician 
If the patient reported any GI bleeding during the last week, if 
there were signs of GI bleeding upon arrival to the ED or if 
haematocrit was lower than 30.  
Made the rule 
positive 
Persistent 
(>15min) 
abnormal vital 
signs in the ED  
Respiratory rate >24/min 
O2 saturation <90% 
SR <50bpm or >100bpm 
BP <90mmHg 
If respiratory rate >24/min 
O2 saturation <90% 
SR <50bpm or >100bpm 
BP <90mmHg 
Made the rule 
positive 
Primary CNS 
event 
SAH or stroke If a bleeding or acute ischemia was present on the cranial CT 
or if the patients received a discharge diagnosis of stroke or 
TIA.   
Made the rule 
positive 
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Supplemental table II: Effectiveness of the different scores for the risk stratification for death (B) and MACE (C) and for the 
diagnosis of cardiac syncope (C) when the recommended cut-off is used:  
Percentage of patients ruled in and out, sensitivity (SE), specificity (SP), negative predictive value (NPV) and positive predictive 
value (PPV). There is no recommended cut-off for the CHADSVasc and both STEPS scores.  
 
IIA) Effectiveness for the risk stratification for death 
 
Score Recommended 
cut-off 
% of patients 
ruled in 
% of patients 
ruled out 
SE SP NPV PPV 
CHADS ≥1 82,5 17,5 96,8 20,0 97,3 17,2 
OESIL ≥2 52,1 47,9 79,9 52,7 93,8 22,6 
EGSYS ≥3 14,2 85,8 18,3 86,5 86,0 18,9 
Boston ≥1 99,4 0,6 100,0 0,7 100,0 14,8 
SFSR ≥1 71,0 29,0 84,0 31,2 91,9 17,4 
Martin ≥1 95,8 4,2 100,0 4,9 100,0 15,3 
 
IIB) Effectiveness for the risk stratification for MACE 
 
Score Recommended 
cut-off 
% of patients 
ruled in 
% of patients 
ruled out 
SE SP NPV PPV 
CHADS ≥1 82,5 17,5 94,1 20,5 93,1 23,5 
OESIL ≥2 52,1 47,9 75,6 54,0 89,5 29,9 
EGSYS ≥3 14,2 85,8 18,9 87,0 80,5 27,4 
Boston ≥1 99,4 0,6 99,7 0,7 88,9 20,7 
SFSR ≥1 71,0 29,0 85,7 32,8 89,8 24,9 
Martin ≥1 95,8 4,2 99,7 5,2 98,4 21,4 
 
IIC) Effectiveness for the diagnosis of cardiac syncope 
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Score Recommended 
cut-off 
% of patients 
ruled in 
% of patients 
ruled out 
SE SP NPV PPV 
CHADS ≥1 81,0 19,0 93,1 21,3 94,1 18,4 
OESIL ≥2 49,4 50,6 74,5 55,4 91,9 24,2 
EGSYS ≥3 14,3 85,7 23,6 87,4 85,7 26,4 
Boston ≥1 99,3 0,7 100,0 0,8 100,0 16,2 
SFSR ≥1 70,0 30,0 89,4 33,7 94,3 20,5 
Martin ≥1 95,5 4,5 100,0 5,3 100,0 16,8 
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Supplemental table III: Details of the performance for CHADS2, OESIL, EGSYS and Martin when different cut-offs are assessed.  
 
A) Characteristics of the scores for the prediction of death 
CHAD
S 
        
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 82,5 17,5 96,8 20 97,3 17,2 14,2 0,5 
≥1 50,7 49,3 84 55 95,2 24,3 12,3 2,3 
≥2 19,2 80,8 34,7 83,5 88,1 26,6 5,1 9,6 
≥3 7,5 92,5 11,4 93,2 85,9 22,3 1,7 13 
≥4 1,7 98,3 1,8 98,3 85,3 15,4 0,3 14,4 
≥5 0,2 99,8 0,5 99,8 85,3 33,3 0,1 14,6 
≥6 0 100 0 100 85,3 #N/A 0 14,7 
         
OESIL         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 100 0 100 0 #N/A 14,7 14,7 0 
≥1 79 21 95,9 23,9 97,1 17,8 14,1 0,6 
≥2 52,1 47,9 79,9 52,7 93,8 22,6 11,7 3 
≥3 25,6 74,4 46,6 78 89,4 26,8 6,8 7,9 
≥4 5,6 94,4 13,7 95,8 86,6 36,1 2 12,7 
         
EGSY
S         
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Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥-2 100 0 100 0 #N/A 14,7 14,7 0 
≥-1 100 0 100 0 #N/A 14,7 14,7 0 
≥0 69,2 30,8 84 33,4 92,4 17,8 12,3 2,3 
≥1 69,1 30,9 84 33,4 92,4 17,9 12,3 2,3 
≥2 68,7 31,3 83,6 33,9 92,3 17,9 12,3 2,4 
≥3 14,2 85,8 18,3 86,5 86 18,9 2,7 12 
≥4 11,5 88,5 16 89,3 86,1 20,5 2,3 12,3 
≥5 10,3 89,7 13,7 90,3 85,9 19,6 2 12,7 
≥6 4,5 95,5 4,6 95,5 85,3 14,9 0,7 14 
≥8 0,4 99,6 0,9 99,7 85,4 33,3 0,1 14,6 
≥9 0,4 99,6 0,9 99,7 85,4 33,3 0,1 14,6 
≥10 0 100 0 100 85,3 #N/A 0 14,7 
         
Martin         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 95,8 4,2 100 4,9 100 15,3 14,7 0 
≥1 56,8 43,2 78,1 46,8 92,5 20,2 11,5 3,2 
≥2 22,8 77,2 42,5 80,6 89,1 27,4 6,2 8,5 
≥3 4,1 95,9 9,6 96,9 86,1 34,4 1,4 13,3 
≥4 0 100 0 100 85,3 #N/A 0 14,7 
 
B) Characteristics of the scores for the prediction of MACE 
CHAD
S 
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Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 82,5 17,5 96,8 20 97,3 17,2 14,2 0,5 
≥1 50,7 49,3 84 55 95,2 24,3 12,3 2,3 
≥2 19,2 80,8 34,7 83,5 88,1 26,6 5,1 9,6 
≥3 7,5 92,5 11,4 93,2 85,9 22,3 1,7 13 
≥4 1,7 98,3 1,8 98,3 85,3 15,4 0,3 14,4 
≥5 0,2 99,8 0,5 99,8 85,3 33,3 0,1 14,6 
≥6 0 100 0 100 85,3 #N/A 0 14,7 
         
OESIL         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 100 0 100 0 #N/A 20,6 20,6 0 
≥1 79 21 94,5 25 94,6 24,6 19,5 1,1 
≥2 52,1 47,9 75,6 54 89,5 29,9 15,6 5 
≥3 25,6 74,4 46,9 80 85,3 37,8 9,7 10,9 
≥4 5,6 94,4 11,7 96 80,7 43,4 2,4 18,2 
         
EGSY
S         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥-2 100 0 100 0 #N/A 14,7 14,7 0 
≥-1 100 0 100 0 #N/A 14,7 14,7 0 
≥0 69,2 30,8 84 33,4 92,4 17,8 12,3 2,3 
≥1 69,1 30,9 84 33,4 92,4 17,9 12,3 2,3 
≥2 68,7 31,3 83,6 33,9 92,3 17,9 12,3 2,4 
≥3 14,2 85,8 18,3 86,5 86 18,9 2,7 12 
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≥4 11,5 88,5 16 89,3 86,1 20,5 2,3 12,3 
≥5 10,3 89,7 13,7 90,3 85,9 19,6 2 12,7 
≥6 4,5 95,5 4,6 95,5 85,3 14,9 0,7 14 
≥8 0,4 99,6 0,9 99,7 85,4 33,3 0,1 14,6 
≥9 0,4 99,6 0,9 99,7 85,4 33,3 0,1 14,6 
≥10 0 100 0 100 85,3 #N/A 0 14,7 
         
Martin         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 100 0 100 0 #N/A 20,6 20,6 0 
≥1 95,8 4,2 99,7 5,2 98,4 21,4 20,5 0,1 
≥2 56,8 43,2 84,4 50,3 92,5 30,6 17,4 3,2 
≥3 22,8 77,2 43,6 82,7 85 39,5 9 11,6 
≥4 4,1 95,9 8,5 97 80,3 42,6 1,7 18,9 
 
C) Characteristics of the scores for the diagnosis of cardiac syncope 
CHAD
S 
        
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 100 0 100 0 #N/A 16,1 16,1 0 
≥1 81 19 93,1 21,3 94,1 18,4 14,9 1,1 
≥2 48 52 69,4 56,1 90,6 23,2 11,2 4,9 
≥3 17,7 82,3 27,3 84,1 85,8 24,8 4,4 11,7 
≥4 6,9 93,1 11,1 93,9 84,7 25,8 1,8 14,3 
≥5 1,6 98,4 3,2 98,7 84,2 31,8 0,5 15,5 
≥6 0,2 99,8 0,5 99,8 84 33,3 0,1 16          
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OESIL         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥0 100 0 100 0 #N/A 16,1 16,1 0 
≥1 77,2 22,8 93,1 25,8 95,1 19,3 14,9 1,1 
≥2 49,4 50,6 74,5 55,4 91,9 24,2 12 4,1 
≥3 23,8 76,2 53,7 81,9 90,2 36,2 8,6 7,4 
≥4 5,1 94,9 13 96,5 85,3 41,2 2,1 14          
EGSY
S 
        
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
≥-2 100 0 100 0 #N/A 16,1 16,1 0 
≥-1 100 0 100 0 #N/A 16,1 16,1 0 
≥0 67,7 32,3 90,3 36,6 95,2 21,4 14,5 1,6 
≥1 67,7 32,3 90,3 36,7 95,2 21,4 14,5 1,6 
≥2 67,3 32,7 89,8 37 95 21,4 14,4 1,6 
≥3 14,3 85,7 23,6 87,4 85,7 26,4 3,8 12,3 
≥4 11,4 88,6 21,8 90,5 85,8 30,5 3,5 12,6 
≥5 10,2 89,8 19,9 91,7 85,7 31,4 3,2 12,9 
≥6 4,6 95,4 6,9 95,8 84,3 24,2 1,1 14,9 
≥8 0,4 99,6 0,9 99,6 84 33,3 0,1 15,9 
≥9 0,4 99,6 0,9 99,6 84 33,3 0,1 15,9 
≥10 0 100 0 100 83,9 #N/A 0 16,1 
         
Martin         
Cutoff % ruled-
in 
% ruled-out SE SP NPV PPV % with events 
in rule-in 
% with 
events in 
rule-out 
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≥0 100 0 100 0 #N/A 16,1 16,1 0 
≥1 95,5 4,5 100 5,3 100 16,8 16,1 0 
≥2 55,3 44,7 89,4 51,2 96,2 25,9 14,3 1,7 
≥3 21,9 78,1 48,1 83,1 89,3 35,3 7,7 8,3 
≥4 3,9 96,1 8,3 97 84,7 34,6 1,3 14,7 
 
#N/A = not applicable 
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Supplemental Table IV: Comparison of the added value of different scores on top of 
the Clinical judgement of the ED physician for the prediction of cardiac syncope. 
 
Score AUC 
Clinical judgment 0.868 
(95%-CI  0.840-0.897) 
Clinical judgment +CHADS 0.871  
(95%-CI  0.845-0.898) 
(p=0.89) 
Clinical judgment + CHADSVasc 0.874  
(95%-CI  0.848-0.899) 
(p=0.79) 
Clinical judgment +OESIL 0.880  
(95%-CI  0.855-0.905) 
(p=0.54) 
Clinical judgment +Martin 0.880  
(95%-CI  0.855-0.905) 
(p=0.54) 
* p are given for the comparison with the clinical judgment alone. 
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II - B-Type natriuretic peptide for diagnosis and risk-stratification of 
syncope 
 
Jeanne du Fay Lavallaz, MD1,26 ; Patrick Badertscher, MD2,3a; Thomas Nestelberger, 
MD1,2; Tobias Zimmermann, MD1,2; Òscar Miró, MD2,4; Emilio Salgado, MD2,4; 
Michael Christ, MD5; Nicolas Geigy, MD6; Louise Cullen, MD, PhD2,7; Martin Than, 
MD2,8; F. Javier Martin-Sanchez, MD2,9; Salvatore Di Somma, MD, PhD2,10; W. Frank 
Peacock, MD2,11; Beata Morawiec, MD2,12; Joan Walter, MD1,2,3; Raphael 
Twerenbold, MD1,2,13; Christian Puelacher, MD1,2; Desiree Wussler, MD1,2; Jasper 
Boeddinghaus, MD1,2; Luca Koechlin, MD1,2,14; Ivo Strebel, PhDc1,2; Dagmar I. Keller, 
MD15; Jens Lohrmann, MD1; Eleni Michou, MD1; Michael Kühne, MD1; Tobias 
Reichlin, MD1,16 and Christian Mueller, MD1,2, for the BASEL IX Investigators7. 
 
 
Submitted to Circulation 
 
 
                                                             
6 Both authors have contributed equally and should be considered first author 
7 1Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University 
Hospital Basel, University of Basel; 2GREAT network; 3Division of Cardiology, University of 
Illinois at Chicago, United States of America; 4Hospital Clinic, Barcelona, Catalonia, Spain; 
5Department of Emergency Medicine, Kantonsspital Luzern, Switzerland; 6Department of 
Emergency Medicine, Hospital of Liestal, Switzerland; 7Royal Brisbane & Women's Hospital, 
Herston, Australia; 8Christchurch Hospital, Christchurch, New Zealand; 9Servicio de 
Urgencias, Hospital Clínico San Carlos, Madrid, Spain; 10Emergency Medicine, Department 
of Medical-Surgery Sciences and Translational Medicine, University Sapienza Rome, 
Sant’Andrea Hospital, Italy; 11Baylor College of Medicine, Department of Emergency 
Medicine, Houston, USA; 122nd Department of Cardiology, School of Medicine with the 
Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland; 13Department 
of General and Interventional Cardiology, University Heart Center Hamburg, University 
Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Heart Surgery, University 
Hospital Basel, Switzerland; 15Emergency Department, University Hospital Zurich, 
Switzerland; 16 Department of Cardiology, Inselspital, Bern, University Hospital, University of 
Bern, Switzerland 
 58 
Abstract  
Background: The clinical utility of B-type Natriuretic Peptide (BNP) for diagnosis 
and risk-stratification of syncope is incompletely understood.  
Objective : We aim at investigating BNP utility for the diagnosis of cardiac syncope 
and for the short/long-term prognostic of major cardiovascular events (MACE) or 
death. 
Methods: We evaluated the diagnostic and prognostic accuracy of BNP in patients 
presenting with syncope to the emergency department (ED) in a prospective 
diagnostic multicenter study. BNP was measured in a blinded fashion. Cardiac 
syncope, as adjudicated by two physicians based on all information available including 
1-year follow-up, was the diagnostic endpoint. MACE were defined as death, 
resuscitation, life-threatening arrhythmia, implantation of pacemaker/implantable 
cardioverter defibrillator, acute myocardial infarction, pulmonary embolism, 
stroke/transient ischemic attack, intracranial bleeding or valvular surgery. 
Results: Among 1561 patients available for diagnostic assessment, cardiac syncope 
was the adjudicated diagnosis in 239 patients (15.3%). BNP was significantly higher 
in cardiac syncope vs. other causes (p<0.01), and remained independent predictor of 
cardiac syncope in multivariable models. The diagnostic accuracy for cardiac 
syncope, as quantified by the Area Under the Curve (AUC), was 0.77 (95%CI 0.73-
0.80). A total of 463 MACE occurred during follow-up. The prognostic accuracy for 
MACE was moderate (AUC 0.70-0.77). BNP performed better than the OESIL, 
EGSYS, and ROSE syncope scores for both diagnostic and prognostic endpoints. 
When no obvious etiology is present on the ED, BNP could provide guidance for 
hospitalization. 
Conclusion: BNP provides useful diagnostic and prognostic information in ED 
patients with syncope.  
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Introduction 
Syncope is a transient loss of consciousness associated with an inability to maintain 
postural tone due to global cerebral hypoperfusion[1]. This symptom is commonly 
reported by patients presenting to the emergency department (ED).[2] Establishing the 
cause of syncope is often challenging, as well as time and resource consuming. The 
risk of death or other adverse events is substantially higher in patients with a cardiac 
cause of syncope in comparison to those with vasovagal or orthostatic 
etiologies.[1,51,52] Accordingly, the diagnosis of cardiac syncope and the risk-
stratification for short- and long-time major adverse cardiac events (MACE) are 
related.[51,52] 
In contrast to other common symptoms in the ED such as acute chest pain or acute 
dyspnea,[70–72] the possible clinical utility of cardiovascular biomarkers including B-
type natriuretic peptide (BNP) has not been thoroughly evaluated in large multicenter 
diagnostic studies adjudicating the final diagnosis. BNP is considered a quantitative 
marker of hemodynamic cardiac stress and released from the heart in response to 
increased intracardiac volume and pressure.[29,73] Its concentration reliably detects 
functionally relevant cardiac disease and predicts future cardiac events including 
arrhythmias and death in both presumably healthy individuals as well as patients with 
known cardiac disease.[74–78] 
Encouraged by promising data from pilot studies in patients with syncope[5,79–81] we 
aim at exploring the clinical utility of BNP in a large multicenter study, namely the 
diagnostic accuracy for an adjudicated diagnosis of cardiac syncope, and the 
prognostic accuracy for MACE and death at 5, 30, 180 and 720 days, In addition we 
evaluate  the diagnostic and prognostic accuracy of BNP with midregional pro-A-type 
natriuretic peptide (MR-proANP),[82]  and compare the diagnostic and prognostic 
accuracy of BNP with established syncope scores recommended in current 
guidelines[1,5,17,18]. We further characterize the clinical utility of BNP in a pre-defined 
subgroup of patients in whom no obvious syncope etiology was present following initial 
ED evaluation.  
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Methods 
Study design, setting and selection of participants 
BAsel Syncope EvaLuation Study (BASEL IX) is an ongoing prospective international 
diagnostic multicenter study enrolling patients from thirteen hospitals in eight countries 
(Switzerland, Spain, Germany, Italy, Poland, New Zealand, Australia and the United 
States of America). The study is designed to contribute to improving the management 
of patients presenting with syncope (ClinicalTrials.gov registry, number 
NCT01548352). Patients of age 40 years or older, and presenting to the ED with 
syncope within the last twelve hours, were recruited after written informed consent was 
obtained. Those with the final diagnosis of a non-syncopal loss of consciousness (e.g. 
epilepsy, fall, alcohol intoxication), or in whom BNP measurement was missing, were 
excluded. Patients in whom the final diagnosis remained unclear even after central 
adjudication were excluded from diagnostic analyses, but remained in the prognostic 
analyses. Patients with no obvious syncope etiology following initial ED evaluation 
(excluding patients presenting with as atrioventricular (AV) block II Type II Mobitz, AV-
Block III, heart rate < 40bpm, life-threatening arrhythmia at presentation, central 
pulmonary embolism, symptomatic orthostatic dysregulation and relevant aortic 
stenosis) were analyzed as a pre-defined subgroup to inform the need for 
hospitalization based on BNP concentrations and events in the follow-up.   
The study was carried out according to the principles of the Declaration of Helsinki and 
approved by the local ethics committees. The authors designed the study, gathered, 
and analysed the data according to the STARD guidelines for studies of diagnostic 
accuracy, vouch for the data and analysis, wrote the paper, and decided to submit for 
publication. 
Clinical assessment 
All patients underwent a clinical assessment that included standardized and detailed 
assessment of predefined details of medical history, including previous syncope events 
and circumstances of current syncope, vital signs, physical examination, routine 
laboratory tests, radiologic testing, and a 12-lead ECG.  Additionally, patients may 
have also undergone 24-hour ECG, external or implantable loop device, cardiac 
exercise test, Schellong test, tilt table testing, coronary angiography, continuous 
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rhythm monitoring, pulse oximetry, echocardiography, implanted cardiac device 
interrogation or electrophysiological examinations, and recording of findings of further 
investigations during recurrent hospitalization or ambulant treatment. Additional tests 
and treatment of patients were left to discretion of the clinically responsible physician.  
Follow-up and adjudicated final diagnosis 
Patients were contacted 6, 12 and 24 months after discharge by telephone or in written 
form. Information regarding recurrent syncope, hospitalization and cardiac events 
during follow up was furthermore obtained from the patient’s hospital notes, the family 
physician’s records and national mortality registries, where available. To determine the 
final diagnosis for the index syncope in each patient, two independent physicians, 
blinded to the BNP results, reviewed all available medical records from the clinical data 
set and the study-specific data set. The clinical data set included data from the clinical 
assessment, while study-specific data included standardized forms uniformly collecting 
predefined details of patient history, the circumstances of syncope, physical 
examination results, and at least 12 months follow-up. In situations of adjudicator 
disagreement about the diagnosis, cases were reviewed and adjudicated in 
conjunction with a third cardiologist. Predefined categories for the adjudication 
included cardiac syncope, reflex syncope, orthostatic syncope, other noncardiac 
syncope, and unknown cause of syncope. According to guidelines,[1] cardiac causes 
of syncope were defined as supraventricular or ventricular arrhythmia, severe 
structural heart disease (eg, hypertrophic cardiomyopathy or valvular disease), 
pericardial tamponade, congenital myocardial or valvular anomaly, aortic dissection, 
or acute pulmonary hypertension (eg, attributable to pulmonary embolism). It is 
important to highlight that the presence of cardiac disease (eg, coronary artery 
disease) alone was insufficient for the adjudication as cardiac syncope. The detailed 
reconstruction of the syncopal event with the study-specific data set and third-party 
anamnesis, as well as long-term follow-up regarding cardiovascular events and/or 
recurrent syncope, were critical pillars of the adjudication. Further details on the 
adjudication are given in the supplemental material.  
Blood sampling and laboratory methods 
Venous blood samples were drawn via a peripheral intravenous line upon ED arrival. 
EDTA plasma was then immediately processed and frozen at -80°C until it was 
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assayed. BNP measurements were performed by use of the Architect BNP assay[83]. 
The assay's LoB is 0.6 ng/l, LoD is 1.4 ng/l, and LoQ is 3.4 ng/l at 20% CV. There is 
no hook effect up to 100,000 ng/l. Total imprecision is < 10% for concentrations 4.5 
ng/l and higher. In this study, controls run on each assay plate provided inter-assay 
precision of 8.3% at 4.5 ng/l and 4.1% at 218 ng/l.  Measurement of MRproANP was 
performed using an validated sandwich immunoassays.[84] The laboratory team who 
measured BNP and/or MR-proANP were blinded to patient, clinical and diagnostic 
assessment, discharge and adjudicated diagnosis. 
Endpoints 
The primary diagnostic endpoint was the diagnostic accuracy of BNP concentrations 
for cardiac syncope. The co-primary prognostic endpoints were the accuracy of BNP 
concentrations to predict either death or overall MACE at 5 days, 30 days, 180 days 
and 720 days of follow-up.  
Secondary endpoints were the prognostic accuracies of BNP concentrations for 
ischemic and arrhythmic MACE at similar time points. Arrhythmic MACE were defined 
as a composite of death, reanimation, life-threatening arrhythmia, implantation of a 
pacemaker or implantable cardioverter defibrillator (ICD). Ischemic MACE were 
defined as a composite of death or acute myocardial infarction. Life-threatening 
arrhythmia was defined as ventricular fibrillation, sustained ventricular tachycardia 
[>120 beats/min], ventricular pause [>3s], ventricular standstill, or asystole, consistent 
with the definition given in previous syncope research[5]. Acute myocardial infarction 
was defined according to the Third Universal Definition[85]. Overall MACE included 
pulmonary embolism, stroke/transient ischemic attack (TIA), intracranial bleeding and 
valvular surgery in addition to arrhythmic and ischemic MACE.  pulmonary embolism, 
stroke/transient ischemic attack (TIA), intracranial bleeding and valvular surgery in 
addition to arrhythmic and ischemic MACE 
Direct comparison with syncope scores and a combination of clinical variables 
To further characterize the clinical utility of BNP, we performed a direct comparison 
of its diagnostic and prognostic accuracy with established syncope scores designed 
to inform the diagnosis of syncope in the ED[1,5,17,18]: This included the “Evaluation 
of Guidelines in Syncope Study” (EGSYS) diagnostic score, which was designed to 
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differentiate between cardiac and non-cardiac causes of syncope;[17] the OESIL risk 
score, which was designed to identify patients at higher risk of mortality within the 
first 12 months;[18] and the ROSE rule, which is a clinical decision rule to predict 1-
month serious outcome and all-cause death.[5] We validated these scores for their 
respective endpoints and compared their predictive accuracy to the one of a BNP 
concentration as a quantitative variable. (Supp. methods for details).  Moreover, we 
compared the diagnostic accuracy of BNP with a combination of several clinically 
relevant variables known as relevant confounders in the evaluation of syncope[51], 
as listed in the supplemental methods.  
Need for hospitalization in patients with no obvious syncope etiology upon ED 
evaluation 
In the pre-defined subgroup of patients with no obvious syncope etiology upon ED 
evaluation, BNP concentrations were analyzed depending on whether the patients 
had an adverse event (defined as death or MACE) within 30 days of the ED 
presentation in order to inform the possibility to avoid hospitalization without risking 
30-day readmission in these patients.  
Statistical analysis 
Continuous variables are presented as mean ± standard deviation (SD) or median with 
interquartile ranges (IQR). Categorical variables are expressed as numbers and 
percentages. Mann-Whitney-U test was applied for comparison of continuous 
variables and Pearson Chi-square test or Fisher’s exact test for comparison of 
categorical variables. Areas under the receiver operating characteristic (ROC) curve 
(AUC) were constructed to assess the diagnostic accuracy of BNP concentrations , for 
a combination of clinical variables or the EGSYS risk score[57] (Supp. methods). 
Comparisons of AUCs were performed according to DeLong[86]. Optimal cut-offs for 
given sensitivities/specificities for the diagnosis of cardiac syncope using BNP were 
derived. Confidence intervals for these measures were computed according to Agresti 
and Coull[87]. Univariable/Multivariable logistic regression was used to assess the 
predictive accuracy of log-transformed BNP concentrations to diagnose cardiac 
syncope (Supp. Methods). Confidence intervals for these measures were computed 
according to Agresti and Coull[87]. 
 64 
Time-dependent ROC[88] curves were computed using the “timeROC” package to 
assess the accuracy of BNP to predict death, MACE, ischemic and arrhythmic MACE 
during the whole follow-up length. A time-dependent ROC varies as a function of time 
and accommodates censored data.  
Cox proportional hazard (CPH) model was used to assess log-transformed BNP 
concentrations in the prediction of these outcomes when correcting for pre-defined 
important co-variates (Supp. Methods).  
Kaplan Meier curves were used to represent event-free survival. Comparison of KM 
curves was performed according to the log-rank test.  
All hypothesis testing was two-tailed, p-values <0.05 were considered statistically 
significant and a Bonferroni correction conducted when there was a concern for 
multiple testing.  
Statistical analyses were performed using the R statistical package (Vienna, Austria).   
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Results 
Characteristics of patients 
From May 2010 to March 2017, 1913 patients were enrolled (Figure A), of which 1575 
and 1430 patients were eligible for the analysis of prognostic and diagnostic endpoints, 
respectively.  
Mean age was 71 years, 41% of patients were women, and about half had a history of 
cardiovascular disease (Table A). Patients with a final adjudicated diagnosis of cardiac 
syncope (n=239, 15.3%) were significantly older, more often had a history of 
cardiovascular diseases and were more likely to be on long-term cardiovascular 
medications.  
Concentrations of BNP and syncope etiology 
BNP plasma concentrations were significantly higher in patients adjudicated to have 
cardiac syncope as compared to patients with reflex, orthostatic, or other non-cardiac 
syncope (Figure B, Bonferroni corrected p<0.001 for each comparison).  
Diagnostic accuracy of BNP for the diagnosis of cardiac syncope 
The diagnostic accuracy of BNP for cardiac syncope was moderate  (AUC 0.77, 95%-
CI 0.74-0.80; Figure C) in the whole patient collective. The BNP cut-off associated  with 
a specificity of ≥95% for rule-in of patients with cardiac syncope (344ng/L) allowed for 
a rule-in rate of ~9% of patients, while the cut-off for a sensitivity of ≥95% (15.4ng/L) 
for rule-out allowed a rule-out rate of ~21% of patients (Supplemental table A). Among 
cardiac syncope, patients with bradycardia-induced syncope had lower BNP 
concentrations in comparison to those with syncope due to ventricular tachycardia or 
valvular heart disease (suppl. Figure A.A). There was a non-significant trend for a 
higher accuracy of BNP to diagnose ventricular tachycardia or valvular disease (AUC 
0.8, 95%-CI 0.75-0.86) over bradycardia (AUC 0.75, 95%-CI 0.71-0.8, p=0.13).  
The diagnostic accuracy of BNP for cardiac syncope was higher than that of the 
EGSYS score (AUC 0.67, 95%CI 0.64-0.70, p<0.001) and than a combination of 
clinical variables (AUC 0.7, 95%-CI 0.67-0.74, p=0.004).  
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Prediction of cardiac syncope 
Logistic regression analysis confirmed BNP concentrations as predictors of cardiac 
syncope in both univariate and multivariable analyses (Supplemental table B). In 
multivariable analysis, only BNP concentrations and an abnormal ECG were significant 
predictors of a cardiac etiology.  
Direct comparison of BNP and MR-proANP for the diagnosis of cardiac syncope 
In the 688 patients eligible for the direct comparison of BNP and MR-proANP, both 
assays displayed similar diagnostic accuracy (AUC for BNP 0.77 (95%-CI 0.73-0.82) 
versus AUC for MR-proANP 0.80 (95%-CI 0.75-0.84), p = 0.16, Suppl. Figure B).  
Prognostic accuracy of BNP 
Follow-up was complete in 100% of patients at 5 days and  30 days, and in 84.3% of 
patients at 720 days. During follow-up 228 patients (14.4%) died, 459 (29.1%) suffered 
first a MACE, 282 (17.9%) suffered first from an ischemic MACE and 359 (22.8%) 
suffered first from an arrhythmic MACE.  
The prognostic accuracy of BNP up to 720 days was moderate to good for all four 
endpoints with AUCs ranging between 0.70 and 0.77 (Figure D). 
Prediction of death and MACE at 30 and 720 days 
Log-transformed BNP concentrations were significant predictors in the multivariable 
CPH model for all long-term prognostic endpoints (death, overall MACE, ischemic 
MACE and arrhythmic MACE at 720 days). Short-term, BNP concentrations were 
significant predictors for all MACE endpoints but not for death (Supplemental Table C). 
Direct comparison of BNP and MR-proANP for risk-stratification 
In the 762 patients eligible for the direct comparison of BNP and MR-proANP, both 
assays displayed similar prognostic accuracy for MACE (Suppl. Figure C).  
Direct comparison of BNP with established risk scores 
During the first month of follow-up, 183 patients (11.6%) suffered an adverse event as 
defined by the original derivation of the ROSE rule. The prevalence of each component 
of the rule is given in Supplemental table D.  The rule displayed an AUC of 0.62 (95%-
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CI 0.58-0.66) for the prediction of these adverse outcomes while BNP alone displayed 
an AUC of 0.75 (95%-CI 0.71-0.79, p<0.001)) for the same outcomes. Details on the 
sensitivity, specificity, NPV, PPV and incidence of criteria of the ROSE rule, and 
comparison with a BNP cut-off of 300pg/L alone, are given in Supplemental table E.  
The EGSYS score showed an AUC of 0.67 (95%-CI 0.64-0.70) while BNP alone 
displayed an AUC of 0.77 (95%-CI 0.73-0.80, p<0.001) to predict a diagnosis of cardiac 
syncope. During the first year of follow-up, 90 patients died. The OESIL score 
displayed an AUC of 0.72 (95%-CI 0.67-0.76) for the prediction of one-year death while 
BNP alone displayed an AUC of 0.77 (95%-CI 0.72-0.82, p=0.017) for this same 
outcome. BNP was significantly superior to all scores in the validation of their 
respective endpoints.  
Need for hospitalization in patients with no obvious syncope etiology upon ED 
evaluation 
Among patients with no obvious etiology for their syncope upon ED evaluation, 10 died 
within 30 days, 159 suffered from MACE, 41 suffered from ischemic MACE and 105 
from arrhythmic MACE.  
Patients experiencing an event in the follow-up had significantly high BNP 
concentrations (Figure E). The lowest 90%-sensitivity cut-off  to rule-out both death 
or MACE up to 30-day follow-up was 22ng/L (Supp. Table F) and allowed for a safe 
rule-out of 430 (30%) patients (Figure F). Among these patients, 122 patients (28%) 
had been hospitalized for a mean of 4.7 days.  
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Discussion 
This large prospective, multicentre study using central diagnostic adjudication and 
long-term follow-up aimed to advance the rapid and accurate diagnosis and risk 
stratification of patients presenting with syncope to the ED. We report seven major 
findings.  
First, BNP concentrations were significantly higher in patients adjudicated to have 
cardiac syncope as compared to other syncope etiologies. Second, BNP 
concentrations showed comparable and moderate accuracy for the diagnosis of 
cardiac syncope and BNP concentrations remained an independent predictor of a 
cardiac syncope after multivariable adjustments. Third, if applied as a triage tool on 
the whole syncope population, BNP concentrations allowed to rule-out and rule-in 
cardiac syncope with 95% sensitivity and 95% specificity in about 30% of patients. 
Fourth, in the subgroup that also had MR-proANP measurements available, the 
natriuretic pro-hormone fragment recently shown to have the highest diagnostic 
accuracy among several pro-hormones quantifying different pathophysiological 
processes[82], BNP and MR-proANP had comparable AUCs. Fifth, BNP performed 
well for the prediction of short- and long-term MACE. Sixth, as a single variable, BNP 
had higher diagnostic and prognostic accuracy as compared to OESIL, EGSYS, and 
ROSE syncope risk scores currently mentioned in clinical practice guidelines[1]. 
Seventh, in the subgroup of patients with no obvious syncope etiology upon ED 
evaluation, BNP could inform the decision for hospitalization by identifying patients 
with a very low risk of death and MACE within 30 days. For instance, a BNP cut-off of 
<22pg/L allowed to identify 30% of eligible patients with a mortality risk at 30-days of 
0%.  
Our findings extend and corroborate previous single-center studies on the clinical utility 
of BNP for diagnosis and risk-stratification of patients presenting to the ED following 
syncope[5,79,80,89]. To the best of our knowledge, this was the first multicenter study 
centrally adjudicating the cause of syncope by two independent physicians and 
incorporating long-term follow-up. The clinical value of the diagnostic utility of BNP for 
cardiac syncope observed in this study seems debatable. Although BNP 
concentrations remained predictive of cardiac syncope in multivariable models, and 
the AUC was higher than that of a commonly used syncope score, the performance of 
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BNP to diagnose cardiac syncope is only moderate. This suggests that the 
pathophysiological link between BNP as a quantitative marker for the presence and 
severity of cardiac disease and cardiac syncope is weaker than we had hypothesized. 
This may be explained by the high prevalence of bradycardia-induced syncope, which 
may often be related to degenerative processes not directly related to the 
hemodynamic severity of cardiac disease. In contrast, cardiac syncope due to 
conditions, such as severe aortic stenosis or ventricular tachycardia, seems more 
closely related to the hemodynamic severity of cardiac disease.[72,74,90–92].  
In conjunction with previous work our data suggest that BNP and MR-proANP provide 
comparable clinical utility in the early management of patients with 
syncope.[5,79,80,82,89] This is of major clinical importance as usually only one of 
these natriuretic peptides is made available to clinicians by the laboratory of the 
respective institution.  
The usefulness of BNP for risk-stratification has previously been established in a range 
of cardiovascular diseases[90] and in the context of syncope[5,80]. Our results showed 
that, even after correcting for the etiology of syncope, age and important baseline 
characteristics, BNP stayed a strong predictor of MACE including death in the long-
term follow-up. The better performance of this biomarker to predict arrhythmic MACE 
over ischemic MACE again reinforces previously suggested associations of BNP with 
arrhythmia[74,91,92].   
A pioneering study by Reed et al.[5] investigated the value of BNP for risk-stratification 
by integrating the biomarker as a dichotomized variable within a rule utilising additional 
clinical characteristics. This rule was derived and validated in the same study and 
performed with an AUC of 0.76 (95% CI: 0.70 to 0.83), a sensitivity of 87.2%, and a 
specificity of 65.5%. The poorer performance of the ROSE rule in this contemporary 
cohort may at least be in part explained by the current widespread use of 
gastroprotectant drugs and the related reductions in hemodynamically relevant acute 
gastrointestinal bleedings as a possible cause of syncope,[93] which weakened the 
importance of some of the prognostic components of the ROSE rule. In our study, BNP 
as a single quantitative variable was a more accurate prognosticator as compared to 
the multivariable ROSE score, as well as several other multivariable scores 
recommended in current clinical practice guidelines. Therefore, the simple use of this 
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biomarker alone as early risk-stratification tool in patients presenting to the ED seems 
to provide an appealing, rapid and easy triage tool, especially when this could lead to 
numerically fewer or shorter hospitalizations.   
Given the high rates of MACE associated with syncope and the well-documented value 
of BNP as a screening tool for cardiovascular disease in the community and in persons 
at increased risk,[77] our findings may justify the inclusion of BNP, a widely available 
and inexpensive biomarker, in the work-up of patients presenting with syncope to the 
ED.  
Some limitations of the present study merit consideration. First, only patients 
presenting to the ED were recruited. Therefore, it is unknown whether our findings can 
be extrapolated to patients presenting to primary care. Second, we cannot comment 
on the possible clinical utility of BNP in patients presenting >12 hours after their 
syncope or patients younger than 40 years of age, as these were excluded from the 
present study. Third, BNP concentrations were only obtained once and no serial 
measurements were available. Further studies are needed to evaluate the possible 
value of serial BNP sampling. Fourth, despite using the most stringent method of 
central adjudication of the final diagnosis by two independent physicians, we cannot 
exclude the possibility that a few patients might have been misclassified. This 
invariably may have led to a slight underestimation of the true diagnostic accuracy of 
BNP.  
In conclusion, BNP seems to be a promising biomarker, both for the diagnosis of 
cardiac syncope etiologies and for the risk-stratification for MACE, including death. 
Further studies are needed to determine which components of the patients’ history, 
comorbidities, ECG or elements of the physical examination could further increase the 
diagnostic and prognostic yield of this marker.  
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Figures 
 
Figure A - Patient flow. 
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- Functional (n=12)
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diagnostic analyses
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No MR-proANP measurement
available
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comparison with MR-proANP
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Figure B – Boxplots representing the BNP concentrations according to the syncope 
etiology. The boxplots represent the median with the interquartile range (IQR), 
whiskers represent ± 1.5 x the IQR.  P-values are calculated based on a Wilcoxon-
rang-sum test and corrected for multiple testing according to Bonferroni. 
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Figure C – Accuracy of BNP alone, the EGSYS score and a combination of clinically 
relevant variables for the diagnosis of cardiac syncope.  
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Figure D – Time-dependant ROC curves for the accuracy of BNP for the prognosis 
of death and several type of MACE. 
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Figure E – Boxplots representing the BNP concentrations according to whether or 
not patients experienced the event during the 30-day follow-up. The boxplots 
represent the median with the interquartile range (IQR), whiskers represent ± 1.5 x 
the IQR.  P-values are calculated based on a Wilcoxon-rang-sum test. 
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Figure F – Kaplan Meier representing event-free survival for death and MACE 
according to a BNP cut-off of 22pg/L. P-values are calculated with a log-rank test.  
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Tables 
 
Table A  Patients characteristics 
 All patients Cardiac Non cardiac Unknown P value 
Number of patients 1575 239 1191 145  
Age-years (median 
[IQR]) 
71.0 [57.0, 80.0] 77.0 [66.5, 83.0] 68.0 [55.0, 78.0] 78.0 [69.0, 84.0] <0.001 
Female - no. (%) 643 (41) 84 (35) 499 (42) 60 (41) 0.151 
Characteristics of the syncope - no. (%) 
Nausea or vomiting 463 (30) 48 (21) 393 (33) 22 (15) <0.001 
Sweating 482 (31) 51 (22) 409 (35) 22 (15) <0.001 
Pallor 427 (45) 49 (36) 351 (48) 27 (32) 0.002 
Palpitations 108 (7) 24 (10) 77 (7) 7 (5) 0.077 
Angina 93 (6) 25 (11) 61 (5) 7 (5) 0.006 
Caused injury 232 (15) 39 (17) 160 (14) 33 (23) 0.010 
Position of the syncope - no. (%) 
While lying 41 (3) 6 (3) 32 (3) 3 (2) 0.907 
While sitting 627 (40) 85 (36) 487 (41) 55 (38) 0.265 
Orthostatic 187 (12) 18 (8) 158 (13) 11 (8) 0.010 
While standing 698 (45) 127 (53) 497 (42) 74 (52) 0.002 
Exertion 137 (9) 43 (18) 77 (7) 17 (12) <0.001 
Risk factors - no. (%) 
Hypertension 936 (60) 165 (70) 662 (56) 109 (76) <0.001 
Hypercholesterolemi
a 
643 (42) 116 (50) 456 (39) 71 (52) <0.001 
Diabetes 219 (14) 47 (20) 145 (12) 27 (19) 0.002 
Smoking 797 (51) 114 (49) 606 (51) 77 (55) 0.511 
History - no. (%) 
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Table A  Patients characteristics 
 All patients Cardiac Non cardiac Unknown P value 
Previous stroke 125 (8) 18 (8) 87 (7) 20 (14) 0.023 
Chronic heart failure  
 (NYHA II-IV) 
120 (8) 38 (16) 66 (6) 16 (11) <0.001 
Arrhythmia 329 (21) 90 (38) 201 (17) 38 (27) <0.001 
Pacemaker 72 (5) 21 (9) 49 (4) 2 (1) 0.001 
ICD or CRT 41 (3) 17 (7) 21 (2) 3 (2) <0.001 
Coronary artery 
disease 
338 (22) 87 (38) 210 (18) 41 (29) <0.001 
Previous DVT or PE 111 (7) 15 (6) 80 (7) 16 (11) 0.140 
Previous MI 201 (13) 53 (22) 125 (10) 23 (16) <0.001 
Chronic medication - no. (%) 
ACEIs/ARBs 706 (45) 128 (54) 498 (42) 80 (55) <0.001 
Alphablocker 118 (7) 19 (8) 85 (7) 14 (10) 0.530 
Antiarrhythmics 
Class I 
57 (4) 16 (7) 33 (3) 8 (6) 0.005 
Aspirin 458 (29) 90 (38) 314 (26) 54 (37) <0.001 
Beta-blockers 501 (32) 104 (44) 336 (28) 61 (42) <0.001 
Calcium antagonists 262 (17) 46 (19) 180 (15) 36 (25) 0.006 
Digitalis 27 (2) 12 (5) 13 (1) 2 (1) <0.001 
Diuretics 471 (30) 107 (45) 311 (26) 53 (37) <0.001 
IQR = Interquartile Range, DVT=Deep venous thrombosis, PE= Pulmonary embolism, MI= 
Myocardial infarction, ACEI =Angiotensin converting enzyme inhibitors , ARB= Angiotensin 
receptor blockers, NYHA = New York Heart Association. 
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Supplemental material 
Supplemental methods 
Clinical assessment and follow-up 
All patients underwent a clinical assessment that included standardized and detailed 
assessment of predefined details of medical history, including previous syncope 
events and circumstances of current syncope, vital signs, physical examination, 
routine laboratory tests, radiologic testing, and a 12-lead ECG.  Additionally, patients 
may have also undergone 24-hour ECG, external or implantable loop device, cardiac 
exercise test, Shellong test, tilt table testing, coronary angiography, continuous 
rhythm monitoring, pulse oximetry, echocardiography, results from device controls 
(e.g. pacemaker) or electrophysiological examinations, and recording of findings of 
further investigations during recurrent hospitalization or ambulant treatment. 
During the follow-up, information regarding recurrent syncope, hospitalization and 
cardiac events during follow up was furthermore obtained from the patient’s hospital 
notes, the family physician’s records and national mortality registries, where 
available. 
Adjudication of the final syncope diagnosis 
The first step in the adjudication process was to decide whether there was syncope 
or not. The clinical data set included data from the clinical assessment, while study-
specific data included standardized forms uniformly collecting predefined details of 
patient history, the circumstances of syncope, and physical examination, as well as 
at least 12 months follow-up. If the criteria for a true syncope were not fulfilled, a 
distinction between the following non-syncopal disorders was made: pre-syncope; 
falls; stroke/TIA; epilepsy; metabolic disorders: e.g. hypoglycaemia, hypoxia, 
hyperventilation; intoxication: e.g. alcohol, benzodiazepines, opiates; functional 
(psychogenic pseudosyncope); others. 
The classification of syncope is based on pathophysiological considerations. The 
following predefined differential diagnoses were used: 
6) Cardiac syncope: We distinguished between: 
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a. Arrhythmia as primary cause: Arrhythmias are the most common cause 
of syncope; Bradycardia: sinus node dysfunction, atrioventricular 
conduction system disease, implanted device malfunction or drug-
induced; Tachycardia: supraventricular or ventricular. 
b. Structural heart disease: structural heart diseases can cause syncope 
when circulatory demands outweigh the impaired ability of the heart to 
increase output. However, in some cases syncope may not solely be 
the result of restricted cardiac output, but be in part due to an 
inappropriate reflex. However, when a structural heart disease was the 
primary cause or contributed most to syncope, it was classified as 
cardiovascular syncope. 
c. Others: pulmonary embolism, acute aortic dissection, pulmonary 
hypertension or any other cause for a cardiovascular syncope. 
7) Reflex (neutrally-mediated) syncope: This syncope is characterized by 
cardiovascular reflexes which are normally useful in controlling circulation but 
become intermittently inappropriate in response to a trigger. The reflex results 
in vasodilation and/or bradycardia which lead to a fall in arterial blood pressure 
and consequently to cerebral hypoperfusion. Identifying a trigger is central 
when diagnosing a reflex syncope. Typically symptoms as lightheadedness, 
nausea, sweating, weakness or visual disturbances precede reflex syncope. 
We distinguished between: 
a. Vasovagal: “common faint”, triggered by emotional distress/ pain or 
mediated by orthostatic stress. 
b. Situational: refers to reflex syncope associated with some specific 
circumstances, e.g. post-micturition, post-prandial, gastrointestinal 
stimulation, cough. 
c. Carotid sinus syncope: triggered by mechanical manipulation of the 
carotid sinus. It can be diagnosed by carotid sinus massage. 
d. Atypical forms: reflex syncope occurring with uncertain or apparently 
absent triggers. 
8) Syncope due to orthostatic hypotension: Orthostatic hypotension is defined as 
an abnormal decrease in systolic blood pressure after changing from supine to 
standing position. Key can be syncope immediately after standing up or a 
pathological Schellong test. We distinguished between: 
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a. Primary autonomic failure: There is an autonomic failure which is 
clearly a primary part of Parkinson syndrome as idiopathic Parkinson 
disease or atypical Parkinson syndrome (multiple system atrophy, 
progressive supranuclear oculomotoric paresis, corticobasal 
degeneration or lewy body dementia). 
b. Secondary autonomic failure: autonomic failure may be due to 
circumstances such as diabetes, uraemia, amyloidosis or spinal cord 
injuries 
c. Drug-induced orthostatic hypotension: orthostatic hypotension is due to 
drugs which can lead to orthostatic hypotension such as diuretics, 
antidepressants, vasodilators, alcohol 
d. Volume depletion: orthostatic hypotension is caused by a hypovolemia 
due to haemorrhage, diarrhoea, vomiting or fever 
e. Others: sometimes the pathophysiology remains unclear. 
9) Others, non-cardiac syncope: Sometimes the underlying pathophysiological 
mechanism of syncope remains unclear, but a cardiac syncope is ruled-out. 
10) Syncope of unknown etiology (cardiac syncope possible): the etiology of 
syncope still remained unknown and a cardiac syncope was considered to be 
a possible cause. 
Evaluation of Guidelines in Syncope Study (EGSYS)[17] diagnostic score 
components 
The point score is found as the sum of the following risk factors:  
- Palpitations: 4  
- Abnormal ECG/Cardiopathy: 3  
- Effort Syncope: 3  
- Syncope in supine position: 2  
- Neurovegetative prodromes: -1  
- Precipitating and predisposive factors: -1  
A score greater than 2 implies an increased risk for cardiac syncope.  
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Osservatorio Epidemiologico sulla Sincope nel Lazio (OESIL)[18] risk score 
components 
The point score is found as the sum of the following risk factors:  
- age >65 years: + 1 
- cardiovascular disease in clinical history +1  
- syncope without prodromes: +1 
- abnormal electrocardiogram  +1 
The primary end point was death from any cause within 12 months of the initial 
evaluation in the ED.  
Patients were considered to have cardiovascular disease in their clinical history in the 
following cases: 
- Previous clinical or laboratory diagnosis of any form of structural heart 
disease, including ischemic heart disease, valvular dysfunction and 
primary myocardial disease, 
- Previous diagnosis or clinical evidence of congestive heart failure, 
- Previous diagnosis or clinical evidence of peripheral arterial disease, 
- Previous diagnosis of stroke or transient ischemic attack. 
 
Electrocardiographic tracings were considered abnormal in the following cases: 
- Rhythm abnormalities (atrial fibrillation or flutter, supraventricular 
tachycardia, multifocal atrial tachycardia, frequent or repetitive premature 
supraventricular or ventricular complexes, sustained or non-sustained 
ventricular tachycardia, paced rhythms), 
- Atrioventricular or intraventricular conduction disorders (complete 
atrioventricular block, Mobitz I or Mobitz II atrioventricular block, bundle 
branch block or intraventricular conduction delay), 
- Left or right ventricular hypertrophy, 
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- Left axis deviation, 
- Old myocardial infarction, 
- ST segment and T wave abnormalities consistent with or possibly related 
to myocardial ischemia. 
Electrocardiographic recordings showing non-specific repolarization abnormalities 
were not considered as abnormal. 
Combination of clinically relevant variables 
The diagnostic accuracy for cardiac syncope of a combination of clinically relevant 
variables was tested against the one of BNP. The combination of clinically relevant 
variables for the diagnosis of syncope were: age, sex, presence or absence of a 
history of cardiovascular disease (myocardial infarction, coronary heart disease, 
stroke or transient ischemic attack, congestive heart failure, atrial fibrillation, and 
intermittent claudication), smoking status, presence or absence of hypertension, 
systolic blood pressure, presence or absence of diabetes, presence of 
hypercholesterolemia, heart rate, and use or nonuse of cardiac medication, including 
antihypertensive medications. These variables were characterized as important 
confounders in the evaluation of syncope in previous research.[51] 
Validation of the ROSE rule 
The ROSE rule is defined as positive if any of the following component is present : 
BNP level ≥ 300pg/mL, bradycardia ≤50 in the ED or pre-hospital, a rectal examination 
showing fecal occult blood (if suspicion of gastrointestinal bleeding), a hemoglobin 
level ≤90g/L, chest pain associated with the syncope, ECG showing Q-wave, oxygen 
saturation ≤94% on room air. The rule was designed to predict a composite outcome 
at 1 month after ED presentation of all-cause death, AMI, life-threatening arrhythmia 
(similarly defined as in our study), decision to implant a pacemaker or ICD, a pulmonary 
embolus, a cerebrovascular accident, an intracranial or subarachnoid hemorrhage, a 
hemorrhage requiring a blood transfusion an acute surgical procedure or endoscopic 
intervention. In the current analysis, we validated the ROSE rule and compared the 
performance of the structured rule to the one of a BNP cut-off of ≥300pg/mL alone for 
this same composite outcome. 
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Predictive accuracy of BNP to predict cardiac syncope: Multivariable model 
Logistic regression was used to assess the predictive accuracy of log-transformed 
BNP concentrations to diagnose cardiac syncope, first in an univariable model and 
second in a multivariable model correcting for pre-defined baseline characteristics as 
recommended in previous literature[94]. The multivariable models were adjusted for 
age, sex, presence or absence of a history of cardiovascular disease (myocardial 
infarction, coronary heart disease, stroke or transient ischemic attack, congestive heart 
failure, atrial fibrillation, and intermittent claudication), smoking status, presence or 
absence of hypertension, systolic blood pressure, presence or absence of diabetes, 
presence of hypercholesterolemia, heart rate, and use or nonuse of cardiac 
medication, including antihypertensive medications.  
Hypertension was a dichotomous variable defined as a systolic blood pressure of at 
least 140 mm Hg, a diastolic blood pressure of at least 90 mm Hg, or current use of 
antihypertensive medication.  
The presence or absence of a history of cardiovascular disease, smoking status, 
presence or absence of diabetes, use or nonuse of cardiac medication and the 
presence of hypercholesterolemia were also included in the model as dichotomous 
variables. Age, systolic blood pressure, and heart rate were included as continuous 
variables. 
The same variables were used to predict the risk of cardiac syncope in all patients, 
risk therefore predicted solely by clinical variables. The performance of these 
variables was then compared to the one of BNP alone.   
Accuracy of BNP to predict adverse outcome: Cox proportional model 
Cox proportional hazard model was used to assess the importance of log-transformed 
BNP concentrations for the prediction of these outcomes in a multivariable model 
accounting for pre-defined important co-variables. We allowed for the correction of one 
variable for every ten events[94]. Accordingly, the prediction of death at 720 days, 
overall MACE and arrhythmic MACE at 30 and 720 days was corrected for age, sex, 
history of cardiovascular disease, smoking status, hypertension, diabetes or 
hypercholesterolemia, systolic blood pressure, heart rate, cardiac medication and the 
adjudicated syncope etiology. The prediction of ischemic MACE at 30 and 720 days 
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was corrected for age, sex, history of cardiovascular disease and the adjudicated 
syncope etiology. The prediction of death at 30 days was corrected for age only. 
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Supplemental table A – BNP cut-offs for specific sensitivities/specificities 
Cut-offs 
for BNP 
Target 
Sensitivity 
Cut-off 
(pg/mL) 
Sensitivity 
(95%-CI) 
Specificity 
(95% CI) 
NPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 48 80.3 (74.8, 84.9) 
58.7 (55.9, 
61.5) 
93.7 (91.7, 
95.2) 
52.2 (49.6, 
54.7) 
85 34.8 85.4 (80.3, 89.3) 
49.6 (46.8, 
52.5) 94.4 (92.3, 96) 
43.8 (41.2, 
46.4) 
90 22.9 90.4 (86, 93.5) 
37.1 (34.4, 
39.9) 
95.1 (92.7, 
96.7) 
32.5 (30.1, 
35) 
95 14.2 95.4 (91.9, 97.4) 
24.1 (21.8, 
26.6) 
96.3 (93.5, 
97.9) 
20.8 (18.8, 
23) 
98 9.9 99.6 (97.7, 99.9) 3.8 (2.8, 5) 
97.8 (88.7, 
99.6) 3.2 (2.4, 4.3) 
Target 
Specificity 
Cut-off 
(pg/mL) 
Specificity 
(95%-CI) 
Sensitivity 
(95% CI) 
PPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 115.6 81.5 (79.2, 83.6) 
58.2 (51.8, 
64.2) 
38.7 (33.8, 
43.9) 
25.1 (22.9, 
27.4) 
85 139.4 85.2 (83.1, 87.1) 52.7 (46.4, 59) 
41.7 (36.3, 
47.4) 
21.1 (19.1, 
23.3) 
90 199.7 90.2 (88.4, 91.7) 
43.5 (37.4, 
49.9) 
47.1 (40.6, 
53.6) 
15.5 (13.7, 
17.4) 
95 308.9 95 (93.7, 96.1) 
30.1 (24.7, 
36.2) 55 (46.4, 63.2) 9.2 (7.8, 10.8) 
98 757.5 98.1 (97.1, 98.7) 10 (6.8, 14.5) 
51.1 (37.2, 
64.7) 3.3 (2.5, 4.4) 
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Supplemental table B – Predictors for a diagnostic of cardiac syncope  
 
Supplemental table 
B Logistic Regression: Predictors for a diagnostic of cardiac syncope 
                  
 Univariable logistic regression    
Multivariable logistic 
regression   
 
OR 95% CI (Lower-Upper) p-val 
 OR 95% CI (Lower-Upper) p-val 
          
BNP concentrations, 
per 10ng/L increase 2,27 2,01 2,59 <0.001  2,059 1,767 2,412 <0.001 
Age, each year 
increase 1,05 1,03 1,06 <0.001 
 1,007 0,992 1,022 0.372 
Sex (Women) 0,76 0,57 1,01 0.061      
Known CV disease 2,61 1,85 3,76 <0.001  1,301 0,661 2,525 0.440 
Smoking status 0,88 0,67 1,17 0.383      
Hypertension 1,8 1,34 2,44 <0.001  0,84 0,511 1,41 0.498 
Hypercholesterolemia 1,53 1,15 2,04 0.003  1,012 0,719 1,424 0.943 
Diabetes 1,76 1,21 2,51 0.002  1,103 0,706 1,697 0.660 
Heart rate, per 5 bpm 
increase 1 0,98 1,02 0.647 
     
Systolic BP, per 
5mmHg increase 1,03 1 1,06 0.044 
 1,017 0,987 1,047 0.279 
Any cardiac 
medication 2,53 1,81 3,6 <0.001 
 0,858 0,487 1,522 0.598 
Abnormal ECG 2,76 2,03 3,8 <0.001  1,645 1,168 2,333 0.005 
 
Bpm = beats per minute, mmHg= milimeter mercury. Variables were used to correct 
the multivariable model only if they were significant in the univariable regression.  
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Supp Table C.A) 
Death 720d Overall MACE 720d Arrhythmic MACE 720d Ischemic MACE 720d 
HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val 
log BNP, per 
10pg/mL increase 
1.61 
[1.36,1.90] <0.001 1.29 [1.15,1.45] <0.001 
1.19 
[1.01,1.39] 0.033 
1.43 
[1.17,1.74] 0.001 
Age 1.04 [1.02,1.06] <0.001 1.00 [0.99,1.02] 0.372 
0.99 
[0.97,1.01] 0.226 
1.00 
[0.98,1.01] 0.668 
Sex 0.68 [0.45,1.02] 0.064 1.16 [0.89,1.51] 0.280 
1.04 
[0.72,1.51] 0.825 
0.80 
[0.51,1.25] 0.330 
Known CV disease 0.88 [0.36,2.17] 0.779 1.28 [0.74,2.20] 0.377 
1.50 
[0.70,3.21] 0.297 
2.26 
[1.10,4.64] 0.026 
Smoking status 1.48 [1.00,2.19] 0.048 1.54 [1.19,1.99] 0.001 
1.27 
[0.90,1.81] 0.176 
 
Hypertension 1.62 [0.89,2.95] 0.112 0.67 [0.48,0.94] 0.022 
0.62 
[0.39,0.98] 0.039 
Hypercholesterolemia 0.65 [0.45,0.95] 0.024 1.22 [0.94,1.57] 0.136 
1.02 
[0.71,1.46] 0.933 
Diabetes 1.44 [0.95,2.19] 0.089 1.25 [0.94,1.67] 0.131 
1.00 
[0.66,1.52] 1.000 
Heart rate, per 5 bpm 
increase 
1.00 
[0.98,1.03] 0.730 0.94 [0.91,0.97] <0.001 
0.91 
[0.87,0.95] <0.001 
Systolic BP, per 
5mmHg increase 
0.94 
[0.91,0.98] 0.001 1.01 [0.99,1.04] 0.233 
1.03 
[1.00,1.07] 0.054 
Any cardiac 
medication 
0.94 
[0.44,1.98] 0.863 1.34 [0.82,2.18] 0.242 
1.27 
[0.65,2.51] 0.483 
Etiology:Reflex 0.42 [0.22,0.79] 0.007 0.06 [0.04,0.08] <0.001 
0.01 
[0.01,0.03] <0.001 
0.22 
[0.12,0.41] <0.001 
Etiology:Orthostatic 1.04 [0.65,1.67] 0.860 0.07 [0.05,0.10] <0.001 
0.04 
[0.02,0.07] <0.001 
0.18 
[0.09,0.35] <0.001 
Etiology:Others 1.14 [0.57,2.29] 0.716 0.07 [0.04,0.13] <0.001 
0.02 
[0.01,0.10] <0.001 
0.22 
[0.08,0.63] 0.005 
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Supplemental table C – Cox proportional Hazards analysis for several short- and long-term outcomes 
 
 
 
Supp Table C.B) 
Death 30d Overall MACE 30d Arrhythmic MACE 30d Ischemic MACE 30d 
HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val 
log BNP, per 
10pg/mL increase 
1.37 
[0.78,2.40] 0.269 1.22 [1.06,1.40] 0.005 
1.25 
[1.05,1.48] 0.011 
1.39 
[1.10,1.74] 0.005 
Age 1.05 [0.99,1.12] 0.131 1.00 [0.99,1.01] 0.869 
0.99 
[0.98,1.01] 0.435 
0.99 
[0.97,1.01] 0.364 
Sex 
 
1.43 [1.04,1.97] 0.027 1.18 [0.80,1.73] 0.414 
0.83 
[0.49,1.41] 0.501 
Known CV disease 1.10 [0.57,2.12] 0.782 1.32 [0.60,2.91] 0.495 
1.98 
[0.88,4.48] 0.100 
Smoking status 1.43 [1.05,1.95] 0.023 1.39 [0.95,2.02] 0.089 
 
Hypertension 0.70 [0.47,1.06] 0.092 0.61 [0.38,1.00] 0.050 
Hypercholesterolemia 1.28 [0.94,1.76] 0.122 0.97 [0.66,1.42] 0.866 
Diabetes 1.07 [0.74,1.53] 0.719 1.07 [0.69,1.66] 0.762 
Heart rate, per 5 bpm 
increase 0.95 [0.92,0.98] 0.004 
0.91 
[0.87,0.95] <0.001 
Systolic BP, per 
5mmHg increase 1.02 [0.99,1.04] 0.245 
1.04 
[1.01,1.08] 0.015 
Etiology:Unknown 1.75 [1.04,2.95] 0.036 0.15 [0.10,0.23] <0.001 
0.17 
[0.10,0.29] <0.001 
0.39 
[0.19,0.79] 0.009 
Abnormal ECG 1.41 [0.94,2.12] 0.094 1.29 [1.15,1.45] <0.001 
1.40 
[0.95,2.06] 0.091 
0.53 
[0.34,0.84] 0.006 
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Any cardiac 
medication 1.26 [0.70,2.27] 0.439 
1.26 
[0.62,2.54] 0.525 
Etiology:Reflex 0.03 [0.02,0.05] <0.001 0.01 [0.00,0.03] <0.001 
0.16 
[0.07,0.34] <0.001 
Etiology:Orthostatic 0.04 [0.02,0.06] <0.001 0.03 [0.01,0.07] <0.001 
0.11 
[0.04,0.26] <0.001 
Etiology:Others 0.05 [0.02,0.12] <0.001 0.01 [0.00,0.10] <0.001 
0.19 
[0.06,0.64] 0.007 
Etiology:Unknown 0.13 [0.08,0.21] <0.001 0.15 [0.09,0.28] <0.001 
0.38 
[0.17,0.83] 0.015 
Abnormal ECG 1.02 [0.74,1.42] 0.888 1.15 [0.77,1.71] 0.498 
0.67 
[0.40,1.14] 0.140 
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Supplemental table D – Prevalence of each component of the ROSE rule in the cohort 
 
Component Number of patients Prevalence 
BNP ≥300pg/mL 147 10.1% 
Positive fecal occult blood 7 0.48% 
Hemoglobin ≤90g/dL 118 8.1% 
Oxygen saturation ≤94% 187 12.8% 
Q waves in the ECG 88 6.0% 
 
Supplemental table E – Performance of the ROSE rule versus a BNP cut-off of 300pg/L 
alone.  
 
 % ruled-
in  
(95%-CI) 
% ruled-
out  
(95%-CI) 
SE  
(95%-CI) 
SP  
(95%-CI) 
NPV  
(95%-CI) 
PPV  
(95%-CI) 
AUC  
(95%-CI) 
BNP cut-
off 
300pg/L 
alone 
9.9  
(8.5, 11.5) 
90.1  
(88.5, 91.5) 
0.3  
(0.24, 
0.37) 
0.93  
(0.91, 
0.94) 
0.91  
(0.89, 
0.93) 
0.35  
(0.27, 0.43) 
0.74  
(0.7, 0.78) 
ROSE 
rule 
32  
(29.8, 
34.4) 
68  
(65.6, 70.2) 
0.51  
(0.44, 
0.59) 
0.7  
(0.68, 
0.73) 
0.92  
(0.9, 0.93) 
0.18  
(0.15, 0.22) 
0.63  
(0.59, 
0.68) 
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Supplemental table F – Optimal cut-offs to rule-out/rule-in events in the 30-day follow-up 
of patients with no obvious syncope cause in the ED.  
 
Cut-offs 
for BNP 
for 30-
day 
death 
Target 
Sensitivity 
Cut-off 
(pg/mL) 
Sensitivity 
(95%-CI) 
Specificity 
(95% CI) 
NPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 56.4 80 (49, 94.3) 55.3 (52.7, 57.8) 
99.7 (99.1, 
99.9) 
55 (52.5, 
57.6) 
85 36 90 (59.6, 98.2) 
42.8 (40.3, 
45.4) 
99.8 (99.1, 
100) 
42.6 (40, 
45.1) 
90 36 90 (59.6, 98.2) 
42.8 (40.3, 
45.4) 
99.8 (99.1, 
100) 
42.6 (40, 
45.1) 
95 33.6 100 (72.2, 100) 
41.1 (38.5, 
43.6) 
100 (99.4, 
100) 
40.8 (38.3, 
43.3) 
98 33.6 100 (72.2, 100) 
41.1 (38.5, 
43.6) 
100 (99.4, 
100) 
40.8 (38.3, 
43.3) 
Target 
Specificity 
Cut-off 
(pg/mL) 
Specificity 
(95%-CI) 
Sensitivity 
(95% CI) 
PPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 171.4 81.6 (79.5, 83.5) 40 (16.8, 68.7) 1.5 (0.6, 3.7) 
18.6 (16.7, 
20.7) 
85 294.3 90.2 (88.6, 91.6) 30 (10.8, 60.3) 2.1 (0.7, 5.9) 9.9 (8.5, 11.6) 
90 294.3 90.2 (88.6, 91.6) 30 (10.8, 60.3) 2.1 (0.7, 5.9) 9.9 (8.5, 11.6) 
95 975.2 98.3 (97.5, 98.8) 20 (5.7, 51) 7.4 (2.1, 23.4) 1.9 (1.3, 2.7) 
98 975.2 98.3 (97.5, 98.8) 20 (5.7, 51) 7.4 (2.1, 23.4) 1.9 (1.3, 2.7) 
 
Cut-offs 
for BNP 
for 30-
day 
MACE 
Target 
Sensitivity 
Cut-off 
(pg/mL) 
Sensitivity 
(95%-CI) 
Specificity 
(95% CI) 
NPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 41 80.5 (73.7, 85.9) 
49.8 (47.1, 
52.5) 
95.4 (93.6, 
96.7) 
46.5 (43.9, 
49.1) 
85 31.1 85.5 (79.2, 90.2) 
41.8 (39.2, 
44.5) 95.9 (94, 97.3) 
38.8 (36.4, 
41.4) 
 96 
90 22.6 90.6 (85, 94.2) 
32.6 (30.1, 
35.2) 
96.6 (94.4, 
97.9) 
30.1 (27.8, 
32.5) 
95 11.8 95.6 (91.2, 97.9) 16.9 (14.9, 19) 
96.9 (93.7, 
98.5) 
15.5 (13.7, 
17.5) 
98 9.9 98.7 (95.5, 99.7) 3 (2.2, 4.1) 
95.1 (83.9, 
98.7) 2.8 (2.1, 3.8) 
Target 
Specificity 
Cut-off 
(pg/mL) 
Specificity 
(95%-CI) 
Sensitivity 
(95% CI) 
PPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 132.8 80.1 (77.9, 82.2) 
54.1 (46.3, 
61.6) 
25.1 (20.8, 
29.9) 
23.6 (21.5, 
25.9) 
85 172.6 85.1 (83, 86.9) 45.3 (37.7, 53) 
27.2 (22.2, 
32.8) 
18.3 (16.4, 
20.3) 
90 254 90.2 (88.4, 91.7) 
35.2 (28.2, 
42.9) 
30.6 (24.4, 
37.6) 
12.6 (11, 
14.4) 
95 409.9 95.1 (93.7, 96.1) 
24.5 (18.5, 
31.8) 
37.9 (29.1, 
47.5) 7.1 (5.9, 8.5) 
98 836.6 98.2 (97.3, 98.8) 
10.1 (6.3, 
15.7) 41 (27.1, 56.6) 2.7 (2, 3.7) 
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Supplemental Figure A : BNP concentrations depending on the subtype of cardiac 
syncope.  
  
Supp. Figure A – A) Boxplots representing the BNP concentrations according to the cardiac 
etiology of the syncope. The boxplots represent the median with the interquartile range (IQR), 
whiskers represent ± 1.5 x the IQR.  P-values are calculated based on a Wilcoxon-rang-sum test. 
B) and C) ROC curves of the performance of BNP for the diagnosis of bradycardia or ventricular 
tachycardia/valvular disease.  
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Supplemental Figure B : Direct comparison of the accuracy of BNP versus MRproANP 
 
Supp Fig. B – Direct comparison of the accuracy of BNP versus MRproANP.   
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Supplemental Figure C : Direct comparison of BNP and MR-proANP for risk-stratification 
  
 
Supp Fig. C – Time-dependent ROC curves for direct comparison of the accuracy of BNP and MR-
proANP for risk-stratification of major adverse cardiac events including death.   
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Abstract 
Background: It is unknown, whether high-sensitivity cardiac troponin I (hs-cTnI) or hs-cTnT 
provide higher accuracy for the diagnosis and risk-stratification of patients with syncope.  
Methods: We directly compared the diagnostic and prognostic accuracy of hs-cTnI and hs-
cTnT in a prospective international multicenter study enrolling patients >40y presenting with 
syncope to the emergency department (ED). Hs-cTnI/T concentrations were measured in a 
blinded fashion using three assays (hs-cTnI-Architect, hs-cTnI-Erenna, hs-cTnT-Elecsys). 
Cardiac syncope, as adjudicated by two physicians using all available information including 
1-year follow-up, was the diagnostic endpoint. Death and major adverse cardiovascular 
events (MACE) at 5, 30 and 720 days were the prognostic endpoints. 
Results: Among 1213 patients, cardiac syncope was the adjudicated diagnosis in 198 
(16.3%). Hs-cTnI (both assays) and hs-cTnT concentrations were higher in patients with 
cardiac syncope compared to patients with other causes (all p<0.01) and remained 
independent predictors of cardiac syncope in multivariable models. Hs-cTnI/T diagnostic 
accuracy for cardiac syncope was moderate-to-good and similar for the three assays, with 
an area under the curve (AUC) of 0.76-0.77 (95%CI, 0.73-0.80, p=ns for all direct 
comparisons). Hs-cTnI/T prognostic accuracy was comparable among the assays and very 
high for imminent (within 5 days) death (AUC 0.93-0.94), and high for 30 and 720-day death 
(AUC 0.74-0.8), as well as MACE (AUC 0.72-0.76). When no obvious etiology is present on 
the ED, hs-cTn could provide guidance for hospitalization. 
Conclusion: Hs-cTnI/T concentrations may have clinical utility in patients presenting with 
syncope as they provide diagnostic as well as prognostic information.  
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Introduction 
Syncope is a transient loss of consciousness associated with an inability to maintain 
postural tone due to global cerebral hypoperfusion[1]. This symptom is common in the 
emergency department (ED), representing 1% to 2% of all ED visits[2]. In contrast to other 
common ED presenting symptoms, e.g., acute chest pain or acute dyspnea,[71,72]  
improvements in the early diagnosis and risk-stratification are limited for patients presenting 
with syncope.[1,51] The risk of an adverse outcome is substantially higher in patients with a 
cardiac cause of syncope as compared to vasovagal or orthostatic causes.[1,51] 
Accordingly, the diagnosis of cardiac syncope and the risk-stratification for short- and long-
time major adverse cardiac events (MACE) are essential, yet challenging tasks in the 
ED.[51] 
In contrast to other common ED presenting symptoms, the clinical utility of high-sensitivity 
cardiac troponin (hs-cTn) in syncope has not been thoroughly evaluated in large multicenter 
diagnostic studies adjudicating the final diagnosis. Cardiomyocyte injury, as quantified by 
hs-cTnT and hs-cTnI concentrations, seems to identify risk in most, if not all, cardiovascular 
disorders.[95–97] Thus, we hypothesized that hs-cTnT and hs-cTnI may provide clinical 
utility in patients with syncope. This hypothesis is supported by pilot data mostly using less 
sensitive cTn assays.[5,98–100] Further, recent research suggests there may be relevant 
pathophysiological differences between hs-cTnT and hs-cTnI. These include a circadian 
rhythm for hs-cTnT, a stronger association with death for hs-cTnT, a slightly earlier 
cardiomyocyte release of hs-cTnI, and a stronger association of hs-cTnT and renal 
dysfunction.[101,102] Therefore, our primary aim was to directly compare hs-cTnT and hs-
cTnI against each other, as well as against a previously derived risk-score1, in the early 
diagnosis and risk-stratification of syncope. As cardiac syncope may be associated with only 
tiny amounts of cardiomyocyte injury, rendering the sensitivity and precision of hs-cTn 
assays in the normal range of possible importance, our secondary aim was to directly 
compare the best validated hs-cTnI assay with an experimental hs-cTnI assay using single-
molecule counting technology and providing even 8-times higher sensitivity (as quantified 
by the limit of detection).[103] 
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Methods 
Study design, setting and selection of participants 
BAsel Syncope EvaLuation Study (BASEL IX) is an ongoing prospective international 
diagnostic multicenter study enrolling patients in fourteen hospitals in nine countries 
(Switzerland, Spain, Germany, Italy, Poland, New Zealand, Australia, the United States of 
America and Argentina). The study is designed to contribute to and improve the 
management of patients presenting with syncope (ClinicalTrials.gov registry, number 
NCT01548352). Patients more than 40 years old, and presenting to the ED with syncope 
within the last twelve hours, were recruited after written informed consent was obtained.  
Patients with the final diagnosis of a non-syncopal loss of consciousness (e.g. epilepsy, fall, 
alcohol intoxication) or in whom at least one hs-cTnT/I measurement was missing were 
excluded for all analyses. Patients in whom the final diagnosis remained unclear, even after 
central adjudication, were excluded for analyses concerning the diagnostic endpoints 
(Figure 1). Patients in whom the final diagnosis remained unclear were still included in all 
survival analyses.  
Patients with no obvious syncope etiology following initial ED evaluation (excluding patients 
presenting with as atrioventricular (AV) block II Type II Mobitz, AV-Block III, heart rate < 
40bpm, life-threatening arrhythmia at presentation, central pulmonary embolism, 
symptomatic orthostatic dysregulation and relevant aortic stenosis) were analyzed as a pre-
defined subgroup to inform the need for hospitalization based on hs-cTn concentrations and 
events in the follow-up. 
The study was carried out according to the principles of the Declaration of Helsinki and 
approved by the local ethics committees. The authors designed the study, gathered, and 
analysed the data according to the STROBE guidelines (Supplemental table 1) for studies 
of diagnostic accuracy, vouched for the data and analysis, wrote the paper, and decided to 
publish. 
Clinical assessment 
All patients underwent clinical assessment that included standardized and detailed 
assessment of predefined details of medical history as listed in the Supplemental. 
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During patient enrolment, most participating sites (8/14) used a conventional less sensitive 
cTn assay clinically. In the remaining centers (6/14), a hs-cTn assay was used.  
As a comparator for diagnostic and prognostic accuracy, the “Evaluation of Guidelines in 
Syncope Study” (EGSYS) risk score was used (Supplemental), as well as a combination of 
several predefined clinically relevant confounders in the evaluation of syncope[51]. 
Follow-up and adjudicated final diagnosis 
Patients were contacted 6, 12 and 24 months after discharge, all information was collected 
as described in the supplemental. To determine the final diagnosis for the index syncope in 
each patient, two independent physicians, blinded to hs-cTn results, reviewed all available 
medical records as detailed in the supplemental. In case of adjudicator disagreement, cases 
were reviewed and adjudicated in conjunction with a third physician. Predefined categories 
for the adjudication included cardiac syncope, reflex syncope, orthostatic syncope, other 
noncardiac syncope, and unknown cause of syncope, as defined by the guidelines[1]. The 
presence of cardiac disease (eg, coronary artery disease) was not, in isolation, sufficient for 
the adjudication of a cardiac cause of syncope. The detailed reconstruction of the syncopal 
event with the study-specific data set and third-party anamnesis, and long-term follow-up on 
cardiovascular events and/or recurrent syncope, were critical pillars of the adjudication.  
Blood sampling and laboratory methods 
Venous blood samples were drawn via a peripheral venous line upon arrival on the ED. 
Blood was then immediately processed and frozen at -80°C until analysis. Details to the 
assays assessed (Hs-cTnI Architect, Hs-cTnI Erenna, Hs-cTnT Elecsys) are available in the 
supplemental.  
The laboratory team who measured hs-cTnI/T concentrations were blinded to all clinical 
information and the adjudicated diagnosis. 
The possible incremental value of serial sampling was evaluated in the subgroup of patients 
that had two consecutive cTn measurements as part of their routine clinical care (study blood 
was ascertained only at a single time point). As the recruiting centers used different cTn 
assays, analyses were standardized to the respective 99th of the respective assay.[71] 
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Outcome measures 
The primary diagnostic endpoint was the diagnostic accuracy for cardiac syncope. The 
primary objective was to compare the diagnostic accuracy of the hs-cTnI versus hs-cTnT 
concentrations for cardiac syncope. The co-primary prognostic endpoints were the accuracy 
of hs-cTnI/T concentrations to predict either death or overall MACE at 5 days, 30 days and 
2 years of follow-up. Secondary endpoints were the comparative prognostic accuracies of 
hs-cTnI/T concentrations for ischemic and arrhythmic MACE at similar time points. Details 
to outcome definition are given in the Supplemental.  
Need for hospitalization in patients with no obvious syncope etiology upon ED evaluation 
In the pre-defined subgroup of patients with no obvious syncope etiology upon ED 
evaluation, hs-cTn concentrations were analyzed depending on whether the patients had 
an adverse event (defined as death or MACE) within 30 days of the ED presentation in 
order to inform the possibility to safely avoid hospitalization in these patients.  
Statistical analysis 
Continuous variables are presented as mean ± standard deviation (SD) or median with 
interquartile ranges (IQR). Categorical variables are expressed as numbers and 
percentages. Mann-Whitney-U test was applied for comparison of continuous variables and 
Pearson Chi-square/Fisher’s exact test for comparison of categorical variables.  
Areas under the receiver operating characteristic curve (AUC) were constructed to quantify 
diagnostic accuracy. Comparisons of AUCs were performed according to DeLong. 
Univariable/Multivariable logistic regression was used to assess the predictive accuracy of 
log-transformed cTn concentrations to diagnose cardiac syncope. Optimized cut-offs for 
given sensitivities/specificities for the diagnosis of cardiac syncope using the three cTn 
assays were derived. Confidence intervals for these measures were computed according to 
Agresti and Coull.  
To address the possible confounding effect of exclusion of patients with unclear diagnosis 
even after final adjudication for the diagnostic analyses, a sensitivity analysis was conducted 
with all syncope patients (Sup.fig.1). 
Time-dependent ROC[88] curves were computed using the “timeROC” package to assess 
the accuracy of the three cTn assays to predict death, MACE, ischemic and rhythmic MACE 
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during the whole follow-up length. For comparison, the prognostic accuracy of a series of 
clinically relevant variables known as relevant confounders in the evaluation of syncope 
were assessed as well.   
Cox proportional hazard (CPH) model was used to assess log-transformed cTn 
concentrations in the prediction of these outcomes when correcting for pre-defined important 
co-variates. Kaplan Meier curves were used to represent survival at 30 days or 1 year, to 
compare stratification with a given hs-cTnT/I cut-off (hs-cTn tertiles or with a given cut-off 
for safe discharge). Differences were assessed through a log-rank test.  
All hypothesis testing was two-tailed, p-values <0.05 were considered statistically significant 
and a Bonferroni correction conducted to control for multiple testing. Statistical analyses 
were performed using the R statistical package (Vienna, Austria).  Details are given in the 
Supplemental.  
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Results 
Characteristics of the patients 
From May 2010 to February 2017, 1894 patients were enrolled (Figure 1), of which 1213 
and 1099 were eligible for the analysis of prognostic and diagnostic endpoints, respectively. 
Mean patient age was 71 years, 39% were women, and about half had a history of 
cardiovascular disease (Table 1). Patients with a final adjudicated cardiac diagnosis (n=198) 
were significantly older, more often had a history of cardiovascular diseases and were more 
often on long-term cardiovascular medications.  
Concentrations of hs-cTnI/T and syncope etiology 
Hs-cTnI/T concentrations were significantly higher in patients adjudicated to have cardiac 
syncope as compared to patients with reflex, orthostatic, or other non-cardiac syncope 
(Figure 2, Bonferroni corrected p<0.001 for each comparison). While intra-assay 
comparisons showed similar differences between cardiac and non-cardiac syncope and the 
correlation among all three hs-cTn assays was high, relevant inter-assay discrepancies 
emerged relative to the approved 99th percentile of each hs-cTnT/I assay (Sup.fig.2). E.g. 
361 patients classified as having elevated hs-cTnT concentrations according to the 
approved 99th-percentile, representing 73.5% of syncope patients with elevated hs-cTnT 
concentrations, would be classified as having normal hs-cTnI (Architect) concentrations 
according to the approved 99th-percentile.  
Diagnostic accuracy of hs-cTnI/T for cardiac syncope 
The diagnostic accuracy of hs-cTnI/T concentrations was moderate-to-good (AUC 0.76-
0.77, 95%-CI 0.73-0.80) and comparable for all three hs-cTnI/T assays (p=ns for direct 
comparisons, Fig.3). Results were consistent in a sensitivity analysis including patients with 
an unknown final diagnosis (Sup.fig.1). Hs-cTnI/T cut-offs achieving a specificity of 95% for 
rule-in of patients with cardiac syncope, identified ~8% of patients. Cut-offs achieving a 
sensitivity of 95% ruled out ~20% (Sup.Table.2). The proportion of patients ruled-in and 
ruled-out were comparable between the three assays. 
The diagnostic accuracy of hs-cTnI/T for cardiac syncope was higher than that of the EGSYS 
score (AUC 0.67, 95%-CI 0.63-0.70, p for comparison with all hs-cTnI/T assays alone 
p<0.001), and significantly higher than the performance of a combination of clinically 
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meaningful variables. Adding one of the three hs-cTn assay to these clinical variables also 
significantly improved their prediction for cardiac syncope (Sup.fig.3, p-value always <0.05).  
Combining hs-cTnI and hs-cTnT concentrations did not lead to any further improvement 
(AUC Abbott-Erenna 0.77, 95%-CI 0.73-0.81, AUC Abbott-Elecsys 0.77, 95%-CI 0.73-0.80, 
AUC Elecsys-Erenna 0.78, 95%-CI 0.74-0.81, p=ns for comparison with all assays alone).  
In the subgroup of patients with serial clinical cTn measurements (368/1099 patients) 
(Sup.Table.3), absolute and relative changes provided incremental value to the first 
measurement, the second measurement had higher accuracy as compared to the first 
measurement, but all clinical cTn measurements had lower accuracy as compared to hs-
cTnT/I (Sup.fig.4). 
Prediction of cardiac syncope 
Logistic regression analysis confirmed hs-cTnI/T concentrations as significant predictors of 
cardiac syncope in both univariable and multivariable analyses (Table 2). 
Prognostic accuracy of hs-cTnI/T concentrations 
The follow-up was completed up to 360 days in 100% and up to 720 days in 85% of patients. 
During the whole follow-up 182 (15.0%) died, 368 (30.3%) suffered MACE, 221 (18.2%) had 
an ischemic MACE and 293 (24.1%) were diagnosed with an arrhythmic MACE 
(Sup.table.4). The prognostic accuracies of hs-cTnI/T concentrations and of the combination 
of several clinically relevant variables for the four endpoints up to 720 days are represented 
using time-dependent ROCs in Figure 4. The performance in predicting death, MACE, 
ischemic MACE and arrhythmic MACE was good and comparable among the three hs-
cTnI/T assays and all three assays performed similarly to the combination of clinical 
variables during the whole follow-up. The prognostic accuracy for imminent death (within 5 
days) was very high (AUC 0.93-0.94, 95%-CI [0.90-0.97]). Hs-cTnI/T identified 100% of all 
deaths within 5 days with 89% specificity (cut-offs: hs-cTnT 38 ng/L, hs-cTnI-Architect 25.6 
ng/L, hs-cTnI-Erenna 13.76 ng/L). Table 3 summarizes the clinical details of all patients 
dying within 5 days. Sup.fig.5 showed a risk-stratification based on hs-cTnT/I tertiles. 
Prediction of death and MACE at 5, 30 and 720 days 
Log-transformed hs-cTnI/T concentrations were significant predictors in the multivariable 
CPH model for death and MACE at all time points (Sup.table.5). 
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Need for hospitalization in patients with no obvious syncope etiology upon ED evaluation 
Among patients with no obvious etiology for their syncope upon ED evaluation, 9 died within 
30 days and 167 suffered from MACE.  
Patients experiencing an event in the follow-up had significantly higher hs-cTnT/I 
concentrations (Sup.fig.6). Figure 5 shows the assay-specific lowest 95%-sensitivity cut-off  
to rule-out both death or MACE up to 30 days, the rule-out allowed by these cut-offs and 
the number of hospitalization days that would have been spared.  
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Discussion 
This large prospective, multicentre study using central diagnostic adjudication and long-term 
follow-up aimed to advance the rapid and accurate diagnosis and risk stratification of 
patients presenting with syncope to the ED by evaluating and comparing the diagnostic and 
prognostic accuracy of three hs-cTnI/T assays.  
We report seven major findings. First, concentrations of hs-cTnI/T were significantly higher 
in patients adjudicated to have cardiac syncope as compared to other syncope etiologies. 
Second, hs-cTnI/T concentrations showed comparable and moderate-to-good accuracy for 
the diagnosis of cardiac syncope, which was higher than that of a currently recommended 
multivariable risk score.[17] Third, if applied as a triage tool, hs-cTnI/T concentrations 
allowed to rule-out and rule-in cardiac syncope with 95% sensitivity and 95% specificity in 
25-30% of patients. Fourth, while intra-assay comparisons showed similar differences 
between cardiac and non-cardiac syncope and high correlation, relevant inter-assay 
discrepancies emerged relative to the approved 99th percentile of each hs-cTnT/I assay. 
Analysing the distribution of high-senstivitiy cardiac troponin I (Architect and Erenna) and 
hs-cTnT (Elecsys) concentrations from the same patients obtained at the same time point 
showed that the currently approved clinical decision values (99th percentiles) are not 
biologically equivalent in this cohort of patients with syncope. This finding extend and 
corroborates prior studies in patients with suspected AMI[104] and population based-
analysis[97], showing that biological equivalent concentrations differ more than 100% from 
the corresponding 99th percentile. The clinical implications of these discrepancies are 
enormous. E.g. 361 patients classified as having elevated hs-cTnT concentrations according 
to the approved 99th-percentile, representing 73.5% of all syncope patients with elevated hs-
cTnT concentrations, would be classified as having normal hs-cTnI (Architect) 
concentrations according to the approved 99th-percentile. Fifth, hs-cTnI/T concentrations 
remained an independent predictor of a cardiac syncope after multivariable adjustments. 
Sixth, hs-cTnI/T concentrations had very high and unprecedented accuracy to predict 
imminent death (AUC 0.93-0.94), as well as high accuracy to predict MACE during long-
term follow-up. Seventh, in the subgroup of patients with no obvious syncope etiology upon 
ED evaluation, hs-cTn could inform the decision for hospitalization by identifying patients 
with a very low risk of death and MACE within 30 days. The respective assay-specific hs-
cTnI/T cut-offs we highlighted would allow to identify about 18% of eligible patients with a 
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mortality risk at 30-days of 0% and therefore spare between 145 and 200 cumulative 
hospitalization days. 
Our findings extend previous diagnostic studies on cTn in patients with 
syncope.[98,99,105,106] Despite relevant emerging pathophysiological differences 
between hs-cTnI and hs-cTnT,[97,107] as well as substantial differences in analytical 
sensitivity among the hs-cTnI/T assays used, this study did not show clinically relevant 
differences in their diagnostic or prognostic accuracy. Given the large number of patients 
enrolled, and their high incidence of cardiac syncope and MACE during follow-up, a type II 
error is unlikely.  
Our findings corroborate previous prognostic single-center studies using less-sensitive cTn 
assays, as well as a recent metaanalysis[13,100,108]. Hs-cTnI/T is a powerful predictor of 
death, however they are less accurate in the prediction of the non-fatal ischemic or 
arrhythmic endpoints captured in the various composite endpoints used. The very high 
accuracy of hs-cTnI/T to predict death within 5 days may have important clinical utility. 
Irrespective of the adjudicated syncope etiology, substantial amounts of cardiomyocyte 
injury, as quantified by hs-cTnI/T, seems to be a universally available and inexpensive 
biochemical signature to rapidly identify syncope patients at very high risk of dying within 
the next 5 days. It is important to highlight that while organ-specific, hs-cTnT/I are not 
disease-specific and may therefore be substantially elevated in several acute cardiovascular 
conditions associated with syncope including AMI, myocarditis, ventricular tachycardia, 
severe aortic stenosis, or central pulmonary embolism. For all of these patients, immediate 
hospitalization in a monitored unit and rapid diagnostic and therapeutic assessment will be 
the direct consequence of this information. In some of these patients (for instance patient 1 
and 3), early pacemaker or defibrillator implantation may have been beneficial. 
Acknowledging the low number of patients dying within the first five days, these results need 
to be further validated and any hypothesis regarding the possible benefit of more precise 
risk assessment proven in an intervention study. 
To the best of our knowledge, this is the first multicenter, centrally adjudicated, long-term 
follow up study performed in syncope. It provides precise and reliable estimates for the 
clinical utility of hs-cTnI/T. Although hs-cTnI/T concentrations remained predictive of cardiac 
syncope in multivariable models, and the AUC was higher as compared to that of a 
commonly used syncope score, it was only moderate-to-good. While AMI may have very 
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atypical symptoms, and syncope may be the sole manifestation of AMI, the diagnostic yield 
in this setting is low.[98,99] Also, some amount of cardiomyocyte injury as quantified by hs-
cTnI/T concentrations seems common also in patients developing orthostatic or other non-
cardiac syncope, and correlates with the extent of atherosclerosis, ventricular hypertrophy 
and vascular stiffness. Accordingly, this biomarker flags patients with a higher burden of 
often subclinical cardiac pathologies, who are at higher risk for long-term cardiac events 
including death.[109] 
Some limitations of the present study merit consideration. First, only patients presenting to 
the ED were recruited. Therefore, it is unknown whether our findings can be extrapolated to 
patients presenting to primary care. Second, we cannot comment on the possible clinical 
utility of hs-cTnI/T in patients presenting >12 hours after their syncope, or patients younger 
than 40 years of age, as these were excluded from our study. Third, hs-cTnI/T 
concentrations were only obtained once at ED presentation and no serial study-specific 
measurements were available. Based on the findings regarding serial measurements of cTn 
performed as part of clinical care available in a selected subgroup of 368 patients in this 
study, it seems unlikely that serial measurements of hs-cTnT/I would provide substantially 
higher diagnostic and prognostic accuracy as compared to that of a single measurement. 
However, further studies seem warranted to evaluate the possible utility of serial hs-cTnI/T 
sampling in unselected syncope patients presenting to the ED. Fourth, despite using one of 
the most stringent methods of final diagnosis adjudication, we cannot exclude the possibility 
that a few patients might have been misclassified by our central adjudication process. This 
could potentially have resulted in an underestimation of the true diagnostic accuracy of hs-
cTnI/T.  
In conclusion, hs-cTnI/T concentrations seem to have some clinical utility in patients 
presenting with syncope as they combine both diagnostic and prognostic information. 
Despite relevant emerging differences between hs-cTnI and hs-cTnT, as well as substantial 
analytical differences among the hs-cTnI/T assays investigated, overall diagnostic and 
prognostic accuracy were comparable.  
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Tables 
Table 1 Baseline characteristics 
 
All patients Cardiac Non cardiac Unknown p 
 
N= 1213 N= 198 N= 901 N= 114 
 
Age-years (median [IQR]) 71.0 [58.0, 80.0] 
76.0 [66.0, 
83.0] 
68.0 [55.0, 
79.0] 
79.0 [70.2, 
85.8] <0.001 
Female - no. (%) 468 (39) 68 (34) 354 (39) 46 (40) 0.398 
Characteristics of the 
syncope - no. (%)      
Nausea or vomiting 338 (28) 36 (19) 287 (32) 15 (13) <0.001 
Sweating 350 (30) 39 (20) 294 (33) 17 (15) <0.001 
Pallor 284 (39) 37 (33) 230 (42) 17 (27) 0.021 
Palpitations 84 (7) 18 (9) 59 (7) 7 (6) 0.423 
Angina 75 (6) 21 (11) 48 (5) 6 (5) 0.022 
Caused injury 163 (14) 26 (14) 118 (13) 19 (17) 0.623 
Position of the syncope - 
no. (%)      
While lying 33 (3) 4 (2) 26 (3) 3 (3) 0.791 
While sitting 453 (38) 64 (32) 344 (39) 45 (39) 0.257 
Orthostatic 149 (12) 14 (7) 125 (14) 10 (9) 0.013 
While standing 563 (47) 115 (58) 393 (44) 55 (49) 0.002 
Exertion 101 (8) 37 (19) 52 (6) 12 (11) <0.001 
Risk factors - no. (%)      
Hypertension 744 (62) 139 (71) 517 (58) 88 (78) <0.001 
Hypercholesterolemia 488 (42) 90 (47) 348 (40) 50 (48) 0.068 
Diabetes 175 (15) 42 (21) 113 (13) 20 (18) 0.004 
Smoking 640 (54) 98 (50) 477 (54) 65 (59) 0.332 
History - no. (%)      
Previous stroke 97 (8) 14 (7) 64 (7) 19 (17) 0.002 
Chronic heart failure  
 (NYHA II-IV) 94 (8) 30 (16) 54 (6) 10 (9) <0.001 
Arrhythmia 269 (23) 78 (40) 162 (18) 29 (26) <0.001 
Pacemaker 63 (5) 18 (9) 44 (5) 1 (1) 0.005 
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Coronary artery disease 257 (22) 67 (35) 160 (18) 30 (27) <0.001 
Previous DVT or PE 89 (7) 13 (7) 60 (7) 16 (14) 0.016 
Previous MI 159 (13) 44 (22) 98 (11) 17 (15) <0.001 
Epilepsy 38 (3) 2 (1) 27 (3) 9 (8) 0.003 
Chronic medication - no. 
(%)      
ACEIs/ARBs 561 (46) 110 (56) 385 (43) 66 (58) <0.001 
Alphablocker 101 (8) 16 (8) 73 (8) 12 (11) 0.671 
Antiarrhythmics Class I 49 (4) 13 (7) 29 (3) 7 (6) 0.047 
Aspirin 356 (29) 71 (36) 243 (27) 42 (37) 0.008 
Beta-blockers 391 (32) 86 (43) 260 (29) 45 (39) <0.001 
Calcium antagonists 208 (17) 37 (19) 142 (16) 29 (25) 0.029 
Digitalis 18 (1) 9 (5) 8 (1) 1 (1) 0.001 
Diuretics 378 (31) 93 (47) 243 (27) 42 (37) <0.001 
IQR = Interquartile Range, DVT=Deep venous thrombosis, PE= Pulmonary embolism, MI= 
Myocardial infarction, ACEI =Angiotensin converting enzyme inhibitors , ARB= Angiotensin 
receptor blockers, NYHA = New York Heart Association. 
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Table 2  Logistic Regression: Predictors for cardiac syncope 
 
         
 
                
 
 Univariable logistic 
regression 
  
 
Multivariable logistic regression 
  
   Hs-cTnI Architect Hs-cTnI Erenna Hs-cTnT Elecsys 
 
 OR 95% CI  
(Lower-
Upper) 
p-val 
 
OR 95% CI  
(Lower-
Upper) 
p-val OR 95% CI  
(Lower-
Upper) 
p-val OR 95% CI  
(Lower-
Upper) 
p-val 
 
 
         
        
cTn 
concentration
s, per 5ng/L 
increase 
Hs-cTnI 
Architect 
2,63 2,22 3,14 <0.001  2,25 1,87 2,73 <0.001         
Hs-cTnI 
Erenna 
3,01 2,44 3,74 <0.001     2,49 1,99 3,14 <0.00
1 
    
Hs-cTnT 
Elecsys 
3,38 2,73 4,22 <0.001         2,88 2,24 3,75 <0.001 
Age, each year increase 1,04 1,03 1,06 <0.001 
 
1,02 1,01 1,04 0.003 1,03 1,01 1,04 0.001 1,01 0,99 1,03 0.255 
Sex (Women) 0,81 0,58 1,11 0.196 
     
        
Known CV disease 2,51 1,71 3,77 <0.001 
 
1,36 0,62 2,90 0.438 1,48 0,69 3,12 0.313 1,46 0,70 3,04 0.311 
Smoking status 0,88 0,64 1,2 0.406 
     
        
Hypertension 1,8 1,29 2,54 0.001 
 
0,72 0,41 1,29 0.255 0,69 0,39 1,22 0.190 0,61 0,35 1,09 0.088 
Hypercholesterolemia 1,36 0,99 1,87 0.054 
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Diabetes 1,88 1,26 2,77 0.002 
 
1,30 0,81 2,06 0.270 1,31 0,82 2,07 0.254 1,16 0,72 1,82 0.541 
Heart rate, per 5 bpm 
increase 
1 0,98 1,03 0.634 
     
        
Systolic BP, per 5mmHg 
increase 
1,04 1,01 1,07 0.022 
 
1,03 1,00 1,07 0.061 1,03 1,00 1,07 0.081 1,04 1,00 1,07 0.031 
Any cardiac medication 2,41 1,67 3,56 <0.001 
 
1,11 0,59 2,12 0.752 1,19 0,64 2,26 0.587 1,13 0,61 2,09 0.705 
Abnormal ECG 3,04 2,14 4,38 <0.001  1,82 1,22 2,75 0.004 1,93 1,30 2,91 0.001 1,88 1,26 2,84 0.002 
Chest pain before the event 2,08 1,19 3,51 0.008  1,87 0,96 3,55 0.060 1,96 1,01 3,70 0.041 1,95 1,00 3,69 0.043 
Bpm = beats per minute, mmHg= millimeter mercury, ECG = electrocardiogram, CV = cardiovascular, BP = blood pressure. 
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Nr Age Sex Syst. BP upon ED arrival 
Diast. BP upon 
ED arrival 
HR upon ED 
arrival Diagnosis 
Syncope 
etiology 
Immediate 
cause of 
death 
Previous AMI 
1 78 man 115 75 125 Supraventr. tachycardia Cardiac  
Asystolie no 
2 84 man 155 83 40 
Drug-induced 
sick-sinus 
syndrom 
Cardiac  
Stroke 
no 
3 82 woman 76 44 74 Sick-sinus syndrome Cardiac  
Asystolie yes 
4 79 man 167 74 87 
Syncope 
etiology 
unknown 
Unknown 
Rapidly 
progressive 
shock (unclear 
etiology) 
no 
 
Nr 
Days of 
hospitalizatio
n 
Hours in ICU Days until death 
hs-cTnI Architect  
(ng/L) 
hs-cTnI Erenna 
(ng/L) 
hs-cTnT 
Elecsys (ng/L) 
Unexpected 
death Preventable death 
1 1 17 1 25,6 13,76 42 yes Likely 
2 3 7 3 35,4 18,54 50 yes No 
3 3 24 3 75,3 42,45 38 yes Likely 
4 3 0 3 78,9 76,97 132 yes Likely 
 
 
Table 3 – Characteristics of the 4 patients dead by the 5th day post-syncope. BP = blood pressure, ICU = intensive care unit.  
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Figures 
 
Figure 1 - Patient flow 
  
Patients enrolled
n=1894
Eligible for prognostic
analyses
n=1213
• Non-syncopal loss of consciousness 
(n=234)
- Stroke/TIA (n=16)
- Epilepsy (n=75)
- Falls (n=34)
- Intoxication (n=5)
- Pre-syncope (n=73)
- Functional (n=12)
- Metabolic disorders (n=12)
- Other (n=7)
• One cTn measurement missing 
(n=447)
• Final diagnosis of
syncope adjudicated as
unknown (n=114)
Eligible for diagnostic
analyses
n=1099
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Figure 2 – Boxplots representing the high-sensitivity cardiac troponin I/T (hs-cTnI/T) 
concentrations according to the syncope etiology. The boxplots represent the median with 
the interquartile range (IQR), whiskers represent ± 1.5 x the IQR.  P-values are calculated 
based on a Wilcoxon-rang-sum test and corrected for multiple testing according to 
Bonferroni. The red lines indicate the respective 99th percentile (99th p.) for each assay, as 
provided by the manufacturer.  
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Figure 3 – Accuracy of the three cTn assays, separately, and as comparison of the EGSYS 
score and of a set of clinically relevant variables (Supplemental) for the diagnosis of cardiac 
syncope.  
  
0.0
0.2
0.4
0.6
0.8
1.0
0.00.20.40.60.81.0
Specificity
Se
ns
itiv
ity
hs-cTnI Architect, AUC 0.76, CI 0.73-0.8
hs-cTnI Erenna, AUC 0.77, CI 0.73-0.8
hs-cTnT Elecsys, AUC 0.76, CI 0.73-0.8
EGSYS Score, AUC 0.67, CI 0.63-0.7
Combination of Clinical variables, AUC 0.72, CI 0.68-0.76
 124 
 
Figure 4 – Time-dependent ROC curves for the accuracy of the three cTn assays and of a 
set of clinically relevant variables (Supplemental) for the prognosis of death, all MACE, 
ischemic MACE and arrhythmic MACE.  
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Figure 5 – Hospitalization and potential rule-out pattern and survival curves for death and MACE using the lowest 95%-sensitivity 
cut-off  to rule-out both outcomes up to 30 days for each assay. 
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Supplemental material 
Supplemental methods 
Clinical assessment 
All patients underwent clinical assessment that included standardized and detailed 
assessment of predefined details of medical history including previous syncope events 
and circumstances of current syncope, vital signs, physical examination, routine 
laboratory tests, radiologic testing, and a 12-lead ECG. Additional tests and treatment 
of patients were left to discretion of the attending physician. Additional tests included 
24-hour ECG, external or implantable loop device, cardiac exercise test, Schellong 
test, tilt table testing, coronary angiography, continuous rhythm monitoring, pulse 
oximetry, echocardiography, interrogation of implanted devices (e.g. pacemaker) or 
electrophysiological examinations, and recording of findings of further investigations 
during recurrent hospitalization or ambulant treatment.  
Follow-up and Adjudication of the final syncope diagnosis 
Patients were contacted 6, 12 and 24 months after discharge by telephone or in 
written form. Information regarding recurrent syncope, hospitalization and cardiac 
events during follow up was obtained from the patient’s hospital notes, the family 
physician’s records and national mortality registries, where available. 
To determine the final diagnosis for the index syncope in each patient, two 
independent physicians, blinded to hs-cTn results, reviewed all available medical 
records from clinical and study-specific datasets. Clinical data included information 
from the clinical assessment, while study-specific data included standardized forms 
uniformly collecting predefined details of patient history, the circumstances of 
syncope, and physical examination, as well as at least 12 months follow-up. 
According to guidelines,[1] cardiac causes of syncope were defined as 
supraventricular or ventricular arrhythmias, severe structural heart diseases (eg, 
hypertrophic cardiomyopathy or valvular diseases), pericardial tamponade, 
congenital myocardial or valvular anomalies, aortic dissection, or acute pulmonary 
hypertension (eg, attributable to pulmonary embolism), leading to a transient loss of 
consciousness. 
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The first step in the adjudication process was to decide whether there was syncope 
or not. If the criteria for a true syncope were not fulfilled, a distinction between the 
following non-syncopal disorders was made: pre-syncope; falls; stroke/TIA; epilepsy; 
metabolic disorders: e.g. hypoglycaemia, hypoxia, hyperventilation; intoxication: e.g. 
alcohol, benzodiazepines, opiates; functional (psychogenic pseudosyncope); others. 
The classification of syncope is based on pathophysiological considerations. The 
following predefined differential diagnoses were used: 
11) Cardiac syncope: We distinguished between: 
a. Arrhythmia as primary cause: Arrhythmias are the most common cause 
of syncope; Bradycardia: sinus node dysfunction, atrioventricular 
conduction system disease, implanted device malfunction or drug-
induced; Tachycardia: supraventricular or ventricular. 
b. Structural heart disease: structural heart diseases can cause syncope 
when circulatory demands outweigh the impaired ability of the heart to 
increase output. However, in some cases syncope may not solely be 
the result of restricted cardiac output, but be in part due to an 
inappropriate reflex. However, when a structural heart disease was the 
primary cause or contributed most to syncope, it was classified as 
cardiovascular syncope. 
c. Others: pulmonary embolism, acute aortic dissection, pulmonary 
hypertension or any other cause for a cardiovascular syncope. 
12) Reflex (neutrally-mediated) syncope: This syncope is characterized by 
cardiovascular reflexes which are normally useful in controlling circulation but 
become intermittently inappropriate in response to a trigger. The reflex results 
in vasodilation and/or bradycardia which lead to a fall in arterial blood pressure 
and consequently to cerebral hypoperfusion. Identifying a trigger is central 
when diagnosing a reflex syncope. Typically symptoms as lightheadedness, 
nausea, sweating, weakness or visual disturbances precede reflex syncope. 
We distinguished between: 
a. Vasovagal: “common faint”, triggered by emotional distress/ pain or 
mediated by orthostatic stress. 
 128 
b. Situational: refers to reflex syncope associated with some specific 
circumstances, e.g. post-micturition, post-prandial, gastrointestinal 
stimulation, cough. 
c. Carotid sinus syncope: triggered by mechanical manipulation of the 
carotid sinus. It can be diagnosed by carotid sinus massage. 
d. Atypical forms: reflex syncope occurring with uncertain or apparently 
absent triggers. 
13) Syncope due to orthostatic hypotension: Orthostatic hypotension is defined as 
an abnormal decrease in systolic blood pressure after changing from supine to 
standing position. Key can be syncope immediately after standing up or a 
pathological Schellong test. We distinguished between: 
a. Primary autonomic failure: There is an autonomic failure which is 
clearly a primary part of Parkinson syndrome as idiopathic Parkinson 
disease or atypical Parkinson syndrome (multiple system atrophy, 
progressive supranuclear oculomotoric paresis, corticobasal 
degeneration or lewy body dementia). 
b. Secondary autonomic failure: autonomic failure may be due to 
circumstances such as diabetes, uraemia, amyloidosis or spinal cord 
injuries 
c. Drug-induced orthostatic hypotension: orthostatic hypotension is due to 
drugs which can lead to orthostatic hypotension such as diuretics, 
antidepressants, vasodilators, alcohol 
d. Volume depletion: orthostatic hypotension is caused by a hypovolemia 
due to haemorrhage, diarrhoea, vomiting or fever 
e. Others: sometimes the pathophysiology remains unclear. 
14) Others, non-cardiac syncope: Sometimes the underlying pathophysiological 
mechanism of syncope remains unclear, but a cardiac syncope is ruled-out. 
15) Syncope of unknown etiology (cardiac syncope possible): the etiology of 
syncope still remained unknown and a cardiac syncope was considered to be 
a possible cause. 
Evaluation of Guidelines in Syncope Study (EGSYS)[17] diagnostic score 
components 
The point score is found as the sum of the following risk factors:  
 129 
- Palpitations: 4  
- Abnormal ECG/Cardiopathy: 3  
- Effort Syncope: 3  
- Syncope in supine position: 2  
- Neurovegetative prodromes: -1  
- Precipitating and predisposive factors: -1  
A score greater than 2 implies an increased risk for cardiac syncope.  
Blood sampling and laboratory methods 
Hs-cTnI Architect measurements were performed at the University Hospital of Basel 
using the ARCHITECT High Sensitive STAT Troponin I assay (Abbott Laboratories, 
Abbott Park, IL). This assay has a 99th percentile concentration of 26.2 ng/L with a 
corresponding CV of <5% and an LoD of 1.9 ng/L[110]. Hs-cTnI Erenna measurements 
were performed at Singulex, Inc. (Alameda, CA, USA) using the experimental Erenna 
system, a single-molecule counting technology. The Erenna Immunoassay System 
reports an LOD of 0.2 ng/L, a 10% CV between 0.78 and 1.6 ng/L, and a 99th percentile 
of 9 ng/L[111].  
Hs-cTnT measurements were performed at the University Hospital of Basel on the 
Elecsys 2010 (Roche Diagnostics). The limit of blank and LOD have been determined 
to be 3 ng/L and 5 ng/L. An imprecision corresponding to 10% CV was reported at 13 
ng/L and the 99th-percentile of a healthy reference population at 14 ng/L.[112]  
 
Outcome definition 
Arrhythmic MACE were defined as a composite of death, resuscitation, life-threatening 
arrhythmia, implantation of a pacemaker or implantable cardioverter defibrillator (ICD). 
Ischemic MACE were defined as a composite of death or acute myocardial infarction. 
Overall MACE included all of the above as well as pulmonary embolism, 
stroke/transient ischemic attack (TIA), intracranial bleeding and valvular surgery. Life-
threatening arrhythmia was defined as ventricular fibrillation, sustained ventricular 
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tachycardia [>120 beats/min], ventricular pause [>3 s], ventricular standstill, or 
asystole, consistent with the definition given in previous syncope research[5]. Acute 
myocardial infarction was defined according to the Fourth Universal Definition.  
Statistical analysis 
Predictive accuracy of Troponin to predict cardiac syncope: Multivariable model and 
diagnostic ROC curve incorporating important co-variables. 
We assessed the predictive accuracy of log-transformed hs-cTnI concentrations to 
diagnose cardiac syncope first in an univariable model and second in a multivariable 
model correcting for pre-defined baseline characteristics (age, sex, history of 
cardiovascular disease, smoking status, hypertension, diabetes or 
hypercholesterolemia, systolic blood pressure, heart rate, and cardiac medication, as 
recommended in previous literature[51]).  
When assessing the diagnostic accuracy of hs-cTnI for the diagnosis of cardiac 
syncope, multivariable models were adjusted for age, sex, presence or absence of a 
history of cardiovascular disease (myocardial infarction, coronary heart disease, 
stroke or transient ischemic attack, congestive heart failure, atrial fibrillation, and 
intermittent claudication), smoking status, presence or absence of hypertension, 
systolic blood pressure, presence or absence of diabetes, presence of 
hypercholesterolemia, heart rate, and use or nonuse of cardiac medication, including 
antihypertensive medications.  
Hypertension was a dichotomous variable defined as a systolic blood pressure of at 
least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or current use of 
antihypertensive medication.  
The presence or absence of a history of cardiovascular disease, smoking status, 
presence or absence of diabetes, use or nonuse of cardiac medication and the 
presence of hypercholesterolemia were also included in the model as dichotomous 
variables. Age, systolic blood pressure, and heart rate were included as continuous 
variables. 
 131 
The same variables were used to predict the risk of cardiac syncope in all patients, 
risk therefore predicted solely by clinical variables. The performance of these 
variables was then compared to the one of cardiac troponins alone.  
Cox proportional hazard model:  
We allowed for the correction of one variable for every ten events[94].  
Accordingly:  
- Overall MACE at 720 days and arrhythmic MACE at 720 days were 
corrected for age, sex, history of cardiovascular disease, smoking status, 
hypertension, diabetes or hypercholesterolemia, systolic blood pressure, 
heart rate, cardiac medication, the adjudicated syncope etiology, an 
abnormal ECG and the presence of chest pain before the event.  
- Death at 720 days, ischemic MACE at 720 days, overall MACE at 30d, 
arrhythmic MACE at 30d, overall MACE at 5d were corrected for age, sex, 
history of cardiovascular disease, smoking status, hypertension, diabetes, 
cardiac medication, the adjudicated syncope etiology, and an abnormal 
ECG.  
- Ischemic MACE at 30d and ischemic MACE at 5d were corrected for age, 
sex, history of cardiovascular disease and the adjudicated syncope 
etiology. 
- Death at 30d and arrhythmic MACE at 5d were corrected for age.  
- Death at 5d was not corrected 
Time dependent ROC curves:  
To compare the performance of cardiac troponins with the predictive accuracy of a 
combination of clinically relevant variables, known as potential confounders in the 
evaluation of syncope[51], we computed a time-dependent ROC curve incorporating 
following variables : age, sex, presence or absence of a history of cardiovascular 
disease (myocardial infarction, coronary heart disease, stroke or transient ischemic 
attack, congestive heart failure, atrial fibrillation, and intermittent claudication), 
smoking status, presence or absence of hypertension, systolic blood pressure, 
presence or absence of diabetes, presence of hypercholesterolemia, heart rate, and 
use or nonuse of cardiac medication, including antihypertensive medications. 
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Supplemental information to the figures:  
The set of clinically relevant variables for the diagnosis of syncope were: age, sex, 
presence or absence of a history of cardiovascular disease (myocardial infarction, 
coronary heart disease, stroke or transient ischemic attack, congestive heart failure, 
atrial fibrillation, and intermittent claudication), smoking status, presence or absence 
of hypertension, systolic blood pressure, presence or absence of diabetes, presence 
of hypercholesterolemia, heart rate, and use or nonuse of cardiac medication, 
including antihypertensive medications. 
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Supplemental table 1 – STROBE Statement 
STROBE Statement—checklist of items that should be included in reports of 
observational studies 
 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term 
in the title or the abstract (page 2 and title) 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found (page 2) 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported (page 3-4) 
Objectives 3 State specific objectives, including any prespecified 
hypotheses (page 3-4) 
Methods 
Study design 4 Present key elements of study design early in the paper 
(page 5) 
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, and 
data collection (page 6-7) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. 
Describe methods of follow-up (page 6-7) 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
(b) Cohort study—For matched studies, give matching 
criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable (page 5-8) 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and 
details of methods of assessment (measurement). 
Describe comparability of assessment methods if there is 
more than one group (page 5-10) 
Bias 9 Describe any efforts to address potential sources of bias 
(page 5-10) 
Study size 10 Explain how the study size was arrived at (page 5-10) 
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why (page 6-10) 
Statistical methods 12 (a) Describe all statistical methods, including those used 
to control for confounding (page 9-10) 
(b) Describe any methods used to examine subgroups 
and interactions (page 6-10) 
(c) Explain how missing data were addressed  
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(d) Cohort study—If applicable, explain how loss to follow-
up was addressed 
Case-control study—If applicable, explain how matching 
of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
(e) Describe any sensitivity analyses (page 5) 
 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
(page 11) 
(b) Give reasons for non-participation at each stage (page 11, 
Figure 1) 
(c) Consider use of a flow diagram (Figure 1) 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders (page 11, Table 1) 
(b) Indicate number of participants with missing data for each 
variable of interest (Table 1) 
(c) Cohort study—Summarise follow-up time (eg, average and total 
amount) (page 12) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary 
measures over time (page 12) 
Case-control study—Report numbers in each exposure category, 
or summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or 
summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and why 
they were included (page 11-13) 
(b) Report category boundaries when continuous variables were 
categorized (page 11-13) 
(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period (page 11-13) 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses (page 11-13) 
Discussion 
Key results 18 Summarise key results with reference to study objectives (page 
14) 
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Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and magnitude 
of any potential bias (page 16) 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence (page 15-16) 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
(page 14-16) 
Other information 
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which the 
present article is based (Page 17) 
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Supplemental table 2 – hs-cTnI/T cut-offs for specific sensitivities/specificities 
1A) hs-cTnI Architect 
Target 
Sensitivity 
Cut-off 
(ng/L) 
Sensitivity 
(95%-CI) 
Specificity 
(95% CI) 
NPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 5.6 80.3 (74.1, 85.3) 64.1 (60.9, 67.2) 93.8 (91.6, 95.4) 56.2 (53.2, 59.1) 
85 3.9 86 (80.4, 90.2) 51.4 (48.1, 54.7) 94.4 (92, 96.1) 44.7 (41.8, 47.7) 
90 2.7 91.7 (87, 94.8) 33.9 (30.9, 37.1) 95 (92, 96.9) 29.3 (26.7, 32.1) 
95 2.2 95.9 (92, 97.9) 21.9 (19.3, 24.7) 96.1 (92.4, 98) 18.7 (16.5, 21.2) 
98 1.6 98.4 (95.5, 99.5) 9.9 (8.1, 12) 96.7 (90.8, 98.9) 8.4 (6.9, 10.2) 
Target 
Specificity 
Cut-off 
(ng/L) 
Specificity 
(95%-CI) 
Sensitivity 
(95% CI) 
PPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 10.9 80.5 (77.7, 82.9) 53.9 (46.8, 60.8) 37.4 (31.9, 43.2) 25.6 (23.1, 28.3) 
85 14.1 85.9 (83.4, 88) 44.6 (37.7, 51.6) 40.6 (34.2, 47.3) 19.6 (17.3, 22) 
90 19.5 90.5 (88.4, 92.2) 36.3 (29.8, 43.3) 45.2 (37.5, 53) 14.3 (12.3, 16.5) 
95 34.2 95.1 (93.4, 96.3) 24.9 (19.3, 31.4) 52.2 (42.1, 62.1) 8.5 (7, 10.3) 
98 73.9 98.3 (97.2, 99) 15 (10.7, 20.7) 65.9 (51.1, 78.1) 4.1 (3, 5.4) 
 
Supp 1B) hs-cTnI Erenna 
Target 
Sensitivity 
Cut-off 
(ng/L) 
Sensitivity 
(95%-CI) 
Specificity 
(95% CI) 
NPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 2.46 80.3 (74.1, 85.3) 59.9 (56.7, 63.1) 93.4 (91, 95.1) 52.8 (49.8, 55.7) 
85 1.92 85.5 (79.8, 89.8) 51.4 (48.1, 54.7) 94.2 (91.8, 96) 44.8 (41.9, 47.8) 
90 1.46 90.2 (85.1, 93.6) 41.8 (38.6, 45) 95.1 (92.5, 96.9) 36.1 (33.3, 39) 
95 0.78 95.3 (91.4, 97.5) 25.8 (23, 28.8) 96.2 (93, 98) 22 (19.7, 24.6) 
98 0.59 98.4 (95.5, 99.5) 18.2 (15.8, 20.8) 98.2 (94.8, 99.4) 15.2 (13.2, 17.5) 
Target 
Specificity 
Cut-off 
(ng/L) 
Specificity 
(95%-CI) 
Sensitivity 
(95% CI) 
PPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 5.47 80.2 (77.5, 82.7) 54.9 (47.9, 61.8) 37.6 (32.1, 43.4) 26 (23.5, 28.7) 
85 7.16 85.2 (82.7, 87.4) 49.7 (42.8, 56.7) 42.1 (35.9, 48.6) 21 (18.7, 23.6) 
90 10.21 90 (87.9, 91.8) 36.8 (30.3, 43.8) 44.4 (36.9, 52.1) 14.8 (12.8, 17) 
95 18.54 95.3 (93.7, 96.5) 24.4 (18.8, 30.9) 52.8 (42.5, 62.8) 8.2 (6.7, 10) 
98 30.73 98.3 (97.2, 99) 18.1 (13.3, 24.2) 70 (56.2, 80.9) 4.6 (3.5, 6) 
 
Supp 1C) hs-cTnT Elecsys 
Target 
Sensitivity 
Cut-off 
(ng/L) 
Sensitivity 
(95%-CI) 
Specificity 
(95% CI) 
NPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
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80 10 83.4 (77.5, 88) 54.4 (51.2, 57.7) 93.8 (91.4, 95.6) 47.7 (44.7, 50.7) 
85 9 87 (81.6, 91.1) 50.7 (47.5, 54) 94.8 (92.4, 96.4) 44 (41.1, 47) 
90 8 90.2 (85.1, 93.6) 45.1 (41.9, 48.4) 95.5 (93.1, 97.1) 38.8 (36, 41.8) 
95 5 96.9 (93.4, 98.6) 22.3 (19.7, 25.2) 97.1 (93.8, 98.7) 18.9 (16.7, 21.4) 
98 4 99 (96.3, 99.7) 15.3 (13.1, 17.8) 98.6 (94.9, 99.6) 12.7 (10.9, 14.9) 
Target 
Specificity 
Cut-off 
(ng/L) 
Specificity 
(95%-CI) 
Sensitivity 
(95% CI) 
PPV 
(95%-CI) 
Incidence of 
criteria % 
(95%-CI) 
80 20 81.1 (78.4, 83.6) 51.8 (44.8, 58.8) 37.3 (31.7, 43.2) 24.7 (22.2, 27.4) 
85 23 86.1 (83.7, 88.2) 48.2 (41.2, 55.2) 42.9 (36.5, 49.5) 20 (17.7, 22.5) 
90 29 90.2 (88.1, 92) 38.3 (31.8, 45.4) 46 (38.4, 53.7) 14.9 (12.9, 17.1) 
95 44 95.1 (93.4, 96.3) 24.4 (18.8, 30.9) 51.6 (41.5, 61.6) 8.4 (6.9, 10.2) 
98 62 98.5 (97.5, 99.1) 14.5 (10.2, 20.2) 68.3 (53, 80.4) 3.8 (2.8, 5.1) 
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Supplemental table 3 – Baseline characteristics and adjudicated diagnosis of the patients 
for whom serial troponin measurements were or were not clinically ordered.  
 
 No serial measurements ordered 
Serial measurements 
ordered  P value 
Number of patients 731 368  
Age-years (median [IQR]) 69.0 [56.0, 79.0] 73.0 [58.8, 81.0] 0.002 
Female - no. (%) 329 (45) 93 (25) <0.001 
Characteristics of the syncope - no. (%)    
Nausea or vomiting 233 (32) 90 (25) 0.016 
Sweating 227 (32) 106 (29) 0.483 
Pallor 162 (38) 105 (44) 0.135 
Palpitations 47 (7) 30 (8) 0.369 
Angina 30 (4) 39 (11) <0.001 
Caused injury 107 (15) 37 (10) 0.036 
Position of the syncope - no. (%)    
While lying 19 (3) 11 (3) 0.873 
While sitting 257 (36) 151 (41) 0.085 
Orthostatic 107 (15) 32 (9) 0.005 
While standing 339 (47) 169 (46) 0.796 
Exertion 54 (8) 35 (10) 0.286 
Risk factors - no. (%)    
Hypertension 406 (56) 250 (68) <0.001 
Hypercholesterolemia 261 (37) 177 (50) <0.001 
Diabetes 80 (11) 75 (20) <0.001 
Smoking 360 (50) 215 (59) 0.009 
History - no. (%)    
Previous stroke 47 (7) 31 (8) 0.303 
Chronic heart failure  
 (NYHA II-IV) 42 (6) 42 (12) 0.001 
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 No serial measurements ordered 
Serial measurements 
ordered  P value 
Arrhythmia 145 (20) 95 (26) 0.028 
Pacemaker 34 (5) 28 (8) 0.065 
Coronary artery disease 118 (17) 109 (30) <0.001 
Previous DVT or PE 47 (6) 26 (7) 0.786 
Previous MI 66 (9) 76 (21) <0.001 
Epilepsy 19 (3) 10 (3) 1.000 
Chronic medication - no. (%)    
ACEIs/ARBs 295 (40) 200 (54) <0.001 
Alphablocker 56 (8) 33 (9) 0.527 
Antiarrhythmics Class I 26 (4) 16 (4) 0.632 
Aspirin 185 (25) 129 (35) 0.001 
Beta-blockers 211 (29) 135 (37) 0.010 
Calcium antagonists 106 (15) 73 (20) 0.030 
Digitalis 9 (1) 8 (2) 0.349 
Diuretics 198 (27) 138 (38) 0.001 
Syncope etiology as by adjudicated diagnosis - 
no. (%)    
Reflex syncope 325 (44) 135 (37) 0.016 
Orthostatic syncope 220 (30) 110 (30) 1.000 
Cardiac syncope 101 (14) 97 (26) <0.001 
Cardiac syncope: Arrhythmia 84 (11) 54 (15) 0.160 
Cardiac syncope: Structural disease 10 (1) 31 (8) <0.001 
Cardiac syncope: Structural disease - AMI 4 (1) 19 (5) <0.001 
IQR = Interquartile Range, DVT=Deep venous thrombosis, PE= Pulmonary embolism, MI= 
Myocardial infarction, ACEI =Angiotensin converting enzyme inhibitors , ARB= Angiotensin 
receptor blockers, NYHA = New York Heart Association. 
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Supplemental table 4 – Number of events in each of the composite endpoints   
 
Outcome : Overall MACE (first 
event) Number with event (%) 
Death 125 (10.3 %) 
Non-fatal Life-threatening 
arrhythmia 48 (4.0 %) 
Pacemaker implantation 69 (5.7 %) 
Survived cardiac arrest 7 (0.6 %) 
ICD implantation 9 (0.7 %) 
Valvular surgery 11 (0.9 %) 
Non-fatal ACS 51 (4.2 %) 
Non-fatal Stroke or TIA 21 (1.7 %) 
Non-fatal pulmonary embolism 21 (1.7 %) 
Non-fatal intracranial bleeding 6 (0.5 %) 
 
Outcome : Arrhythmic MACE 
(first event) 
Number with event (%) 
Death 151 (12.4 %) 
Non-fatal life-threatening arrhythmia 51 (4.2 %) 
Pacemaker implantation 73 (6.0 %) 
Survived cardiac arrest 9 (0.7 %) 
ICD implantation 9 (0.7 %) 
 
Outcome : Ischemic MACE 
(first event) 
Number with event (%) 
Death 164 (13.5 %) 
Non-fatal ACS 57 (4.7 %) 
 
Supplemental table 4 – Number of events within the three composite outcomes. Listed are 
the numbers and percentages of patients who experienced the outcomes as their first event 
during follow-up. ICD = Implantable Cardioverter Defibrillator , ACS = Acute coronary 
syndrome, TIA = transient ischemic attack.   
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Supplemental table 5 – Cox proportional Hazards analysis for several short- and long-term outcomes 
  
HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnI, per 5ng/L 
increase 1.58 [1.32,1.90] <0.001 1.32 [1.17,1.48] <0.001 1.12 [0.98,1.29] 0.094 1.46 [1.25,1.71] <0.001
Age 1.05 [1.03,1.07] <0.001 1.02 [1.01,1.03] <0.001 1.01 [1.00,1.03] 0.032 1.04 [1.03,1.06] <0.001
Sex 0.57 [0.36,0.92] 0.022 1.07 [0.81,1.42] 0.609 0.91 [0.66,1.25] 0.562 0.78 [0.53,1.14] 0.201
Known CV disease 1.08 [0.38,3.08] 0.879 1.24 [0.69,2.23] 0.471 1.39 [0.69,2.83] 0.361 1.57 [0.67,3.68] 0.298
Smoking status 1.35 [0.88,2.07] 0.175 1.35 [1.04,1.76] 0.025 1.24 [0.92,1.68] 0.160 1.76 [1.22,2.55] 0.003
Hypertension 1.13 [0.60,2.13] 0.714 0.72 [0.50,1.04] 0.083 0.77 [0.50,1.18] 0.223 1.13 [0.66,1.95] 0.652
Hypercholesterolemia 0.95 [0.73,1.23] 0.680 0.81 [0.60,1.09] 0.164
Diabetes 1.40 [0.89,2.20] 0.142 1.38 [1.02,1.87] 0.036 1.21 [0.85,1.73] 0.293 1.61 [1.11,2.33] 0.012
Heart rate, per 5 bpm 
increase 0.96 [0.93,0.99] 0.005 0.93 [0.90,0.97] <0.001
Systolic BP, per 
5mmHg increase 0.99 [0.97,1.02] 0.466 0.99 [0.96,1.02] 0.540
Any cardiac 
medication 1.22 [0.51,2.91] 0.659 1.67 [0.99,2.81] 0.056 2.25 [1.19,4.28] 0.013 0.84 [0.43,1.64] 0.612
Etiology:Reflex 0.50 [0.26,0.97] 0.042 0.06 [0.04,0.09] <0.001 0.05 [0.03,0.09] <0.001 0.35 [0.20,0.59] <0.001
Etiology:Orthostatic 1.04 [0.62,1.75] 0.868 0.10 [0.07,0.15] <0.001 0.12 [0.08,0.18] <0.001 0.55 [0.35,0.85] 0.008
Etiology:Others 0.94 [0.44,2.00] 0.873 0.09 [0.05,0.16] <0.001 0.10 [0.05,0.19] <0.001 0.60 [0.32,1.15] 0.126
Etiology:Unknown 1.38 [0.76,2.50] 0.294 0.21 [0.14,0.31] <0.001 0.28 [0.18,0.44] <0.001 0.78 [0.47,1.30] 0.340
Abnormal ECG 1.23 [0.77,1.95] 0.384 0.89 [0.67,1.19] 0.434 1.42 [1.00,2.00] 0.047 0.78 [0.54,1.13] 0.192
Chest pain before the 
event 1.40 [0.90,2.17] 0.136 0.69 [0.38,1.23] 0.205
Supp Table 2A1) 
hs-cTnI Architect
Death 720d Overall MACE 720d Arrhythmic MACE 720d Ischemic MACE 720d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnI, per 5ng/L 
increase 2.13 [1.41,3.21] <0.001 1.18 [1.03,1.35] 0.020 0.92 [0.77,1.09] 0.338 1.31 [1.03,1.66] 0.027
Age 1.04 [0.99,1.10] 0.114 1.01 [1.00,1.02] 0.137 1.00 [0.99,1.02] 0.522 1.01 [0.98,1.03] 0.559
Sex 1.42 [1.03,1.98] 0.034 1.31 [0.89,1.93] 0.173
Known CV disease 1.53 [0.75,3.10] 0.242 1.74 [0.74,4.10] 0.207 2.26 [0.92,5.58] 0.075
Smoking status 1.42 [1.02,1.97] 0.035 1.21 [0.82,1.77] 0.333
Hypertension 0.59 [0.39,0.91] 0.017 0.54 [0.33,0.88] 0.013
Hypercholesterolemia
Diabetes 1.36 [0.95,1.96] 0.097 1.27 [0.83,1.96] 0.274
Heart rate, per 5 bpm 
increase
Systolic BP, per 
5mmHg increase
Any cardiac medication 1.63 [0.84,3.13] 0.146 2.58 [1.13,5.89] 0.024
Etiology:Reflex 0.03 [0.02,0.06] <0.001 0.01 [0.01,0.04] <0.001 0.22 [0.10,0.49] <0.001
Etiology:Orthostatic 0.04 [0.02,0.07] <0.001 0.04 [0.02,0.08] <0.001 0.14 [0.06,0.36] <0.001
Etiology:Others 0.04 [0.01,0.10] <0.001 0.01 [0.00,0.10] <0.001 0.23 [0.07,0.78] 0.018
Etiology:Unknown 0.13 [0.08,0.22] <0.001 0.15 [0.08,0.28] <0.001 0.43 [0.19,1.00] 0.051
Abnormal ECG 0.81 [0.56,1.16] 0.239 1.26 [0.81,1.97] 0.297
Chest pain before the 
event
Supp Table 2A1) hs-
cTnI Architect
Death 30d Overall MACE 30d Arrhythmic MACE 30d Ischemic MACE 30d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnI, per 5ng/L 
increase 2.65 [1.49,4.72] 0.001 1.24 [1.05,1.46] 0.011 1.75 [1.47,2.08] <0.001 1.33 [1.04,1.70] 0.025
Age 1.01 [0.99,1.03] 0.277 1.03 [1.01,1.05] <0.001 1.00 [0.98,1.03] 0.756
Sex 1.35 [0.90,2.03] 0.147
Known CV disease 1.84 [0.73,4.63] 0.193 2.42 [0.90,6.47] 0.079
Smoking status 1.46 [0.97,2.19] 0.069
Hypertension 0.73 [0.42,1.24] 0.240
Hypercholesterolemia
Diabetes 1.41 [0.92,2.17] 0.120
Heart rate, per 5 bpm 
increase
Systolic BP, per 
5mmHg increase
Any cardiac 
medication 1.23 [0.55,2.76] 0.623
Etiology:Reflex 0.02 [0.01,0.05] <0.001 0.20 [0.09,0.46] <0.001
Etiology:Orthostatic 0.03 [0.01,0.07] <0.001 0.07 [0.02,0.24] <0.001
Etiology:Others 0.02 [0.00,0.12] <0.001 0.16 [0.04,0.67] 0.012
Etiology:Unknown 0.11 [0.05,0.22] <0.001 0.25 [0.09,0.73] 0.011
Abnormal ECG 0.70 [0.45,1.10] 0.124
Chest pain before the 
event
Supp Table 2A1) 
hs-cTnI Architect
Death 5d Overall MACE 5d Arrhythmic MACE 5d Ischemic MACE 5d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnI, per 5ng/L 
increase 1.52 [1.23,1.88] <0.001 1.30 [1.13,1.50] <0.001 1.06 [0.90,1.24] 0.488 1.36 [1.13,1.63] 0.001
Age 1.05 [1.03,1.07] <0.001 1.02 [1.01,1.03] <0.001 1.02 [1.00,1.03] 0.024 1.05 [1.03,1.07] <0.001
Sex 0.53 [0.33,0.86] 0.010 1.07 [0.81,1.41] 0.641 0.90 [0.65,1.25] 0.545 0.74 [0.50,1.09] 0.127
Known CV disease 1.18 [0.42,3.30] 0.747 1.27 [0.71,2.27] 0.416 1.40 [0.69,2.84] 0.348 1.68 [0.72,3.88] 0.228
Smoking status 1.34 [0.87,2.06] 0.180 1.34 [1.03,1.75] 0.029 1.24 [0.92,1.69] 0.160 1.76 [1.22,2.55] 0.003
Hypertension 1.05 [0.56,1.98] 0.877 0.71 [0.49,1.03] 0.069 0.77 [0.50,1.17] 0.221 1.07 [0.62,1.83] 0.814
Hypercholesterolemia 0.94 [0.72,1.23] 0.668 0.80 [0.59,1.08] 0.148
Diabetes 1.37 [0.87,2.16] 0.176 1.42 [1.05,1.92] 0.025 1.24 [0.87,1.78] 0.237 1.61 [1.11,2.35] 0.012
Heart rate, per 5 bpm 
increase 0.96 [0.93,0.99] 0.006 0.94 [0.90,0.97] <0.001
Systolic BP, per 
5mmHg increase 0.99 [0.97,1.02] 0.493 0.99 [0.96,1.02] 0.491
Any cardiac 
medication 1.21 [0.51,2.86] 0.664 1.70 [1.01,2.86] 0.045 2.25 [1.19,4.24] 0.012 0.86 [0.44,1.66] 0.644
Etiology:Reflex 0.47 [0.24,0.92] 0.026 0.06 [0.04,0.09] <0.001 0.05 [0.03,0.08] <0.001 0.32 [0.19,0.54] <0.001
Etiology:Orthostatic 1.03 [0.61,1.75] 0.897 0.10 [0.07,0.14] <0.001 0.12 [0.08,0.18] <0.001 0.53 [0.34,0.83] 0.005
Etiology:Others 0.94 [0.44,2.02] 0.877 0.09 [0.05,0.16] <0.001 0.09 [0.05,0.19] <0.001 0.59 [0.31,1.12] 0.107
Etiology:Unknown 1.32 [0.73,2.40] 0.356 0.20 [0.14,0.30] <0.001 0.28 [0.18,0.43] <0.001 0.74 [0.44,1.23] 0.240
Abnormal ECG 1.28 [0.81,2.04] 0.291 0.94 [0.70,1.24] 0.641 1.46 [1.04,2.06] 0.029 0.82 [0.57,1.19] 0.299
Chest pain before 
the event 1.48 [0.95,2.30] 0.080 0.71 [0.40,1.28] 0.255
Supp Table 2A2) 
hs-cTnI Erenna
Death 720d Overall MACE 720d Arrhythmic MACE 720d Ischemic MACE 720d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnI, per 5ng/L 
increase 1.98 [1.15,3.42] 0.014 1.18 [1.01,1.38] 0.035 0.89 [0.73,1.09] 0.259 1.16 [0.87,1.55] 0.302
Age 1.06 [1.00,1.12] 0.059 1.01 [1.00,1.02] 0.122 1.01 [0.99,1.02] 0.509 1.01 [0.99,1.03] 0.398
Sex 1.40 [1.01,1.94] 0.046 1.29 [0.87,1.91] 0.200
Known CV disease 1.55 [0.77,3.15] 0.220 1.72 [0.73,4.05] 0.215 2.25 [0.92,5.55] 0.077
Smoking status 1.40 [1.01,1.95] 0.044 1.19 [0.81,1.75] 0.372
Hypertension 0.58 [0.38,0.89] 0.012 0.54 [0.33,0.89] 0.014
Hypercholesterolemia
Diabetes 1.37 [0.95,1.97] 0.095 1.25 [0.81,1.93] 0.310
Heart rate, per 5 bpm 
increase
Systolic BP, per 
5mmHg increase
Any cardiac 
medication 1.66 [0.86,3.18] 0.130 2.56 [1.12,5.83] 0.026
Etiology:Reflex 0.03 [0.02,0.06] <0.001 0.01 [0.01,0.04] <0.001 0.20 [0.09,0.43] <0.001
Etiology:Orthostatic 0.04 [0.02,0.07] <0.001 0.04 [0.02,0.08] <0.001 0.14 [0.06,0.34] <0.001
Etiology:Others 0.04 [0.01,0.10] <0.001 0.01 [0.00,0.10] <0.001 0.21 [0.06,0.72] 0.013
Etiology:Unknown 0.13 [0.08,0.22] <0.001 0.15 [0.08,0.28] <0.001 0.41 [0.17,0.94] 0.036
Abnormal ECG 0.83 [0.58,1.19] 0.308 1.24 [0.80,1.91] 0.341
Chest pain before the 
event
Supp Table 2A2) 
hs-cTnI Erenna
Death 30d Overall MACE 30d Arrhythmic MACE 30d Ischemic MACE 30d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnI, per 5ng/L 
increase 3.36 [1.68,6.75] 0.001 1.22 [1.01,1.47] 0.035 1.79 [1.44,2.22] <0.001 1.17 [0.86,1.57] 0.318
Age 1.01 [0.99,1.03] 0.252 1.04 [1.02,1.06] <0.001 1.01 [0.98,1.03] 0.570
Sex 1.33 [0.88,2.01] 0.170
Known CV disease 1.91 [0.76,4.75] 0.167 2.38 [0.89,6.38] 0.084
Smoking status 1.43 [0.95,2.15] 0.083
Hypertension 0.70 [0.41,1.19] 0.186
Hypercholesterolemia
Diabetes 1.42 [0.92,2.20] 0.110
Heart rate, per 5 bpm 
increase
Systolic BP, per 
5mmHg increase
Any cardiac 
medication 1.25 [0.56,2.80] 0.586
Etiology:Reflex 0.02 [0.01,0.05] <0.001 0.18 [0.08,0.40] <0.001
Etiology:Orthostatic 0.03 [0.01,0.07] <0.001 0.07 [0.02,0.23] <0.001
Etiology:Others 0.02 [0.00,0.11] <0.001 0.14 [0.03,0.61] 0.009
Etiology:Unknown 0.10 [0.05,0.22] <0.001 0.23 [0.08,0.67] 0.007
Abnormal ECG 0.74 [0.47,1.14] 0.174
Chest pain before the 
event
Supp Table 2A2) 
hs-cTnI Erenna
Death 5d Overall MACE 5d Arrhythmic MACE 5d Ischemic MACE 5d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnT, per 5ng/L 
increase 2.21 [1.72,2.83] <0.001 1.57 [1.32,1.87] <0.001 1.16 [0.96,1.40] 0.112 1.91 [1.54,2.36] <0.001
Age 1.04 [1.02,1.06] <0.001 1.02 [1.00,1.03] 0.008 1.01 [1.00,1.03] 0.071 1.03 [1.02,1.05] <0.001
Sex 0.64 [0.40,1.03] 0.065 1.15 [0.87,1.51] 0.316 0.92 [0.66,1.27] 0.592 0.85 [0.58,1.25] 0.408
Known CV disease 1.13 [0.41,3.12] 0.813 1.18 [0.66,2.09] 0.583 1.39 [0.69,2.82] 0.359 1.57 [0.68,3.63] 0.287
Smoking status 1.38 [0.90,2.12] 0.146 1.32 [1.01,1.72] 0.039 1.25 [0.93,1.70] 0.145 1.79 [1.24,2.59] 0.002
Hypertension 0.98 [0.52,1.85] 0.952 0.70 [0.49,1.01] 0.060 0.75 [0.49,1.15] 0.191 1.00 [0.58,1.72] 0.993
Hypercholesterolemia 0.99 [0.76,1.29] 0.951 0.79 [0.59,1.07] 0.132
Diabetes 1.30 [0.83,2.05] 0.248 1.28 [0.94,1.74] 0.112 1.21 [0.85,1.74] 0.290 1.50 [1.03,2.18] 0.032
Heart rate, per 5 bpm 
increase 0.96 [0.93,0.99] 0.007 0.93 [0.90,0.97] <0.001
Systolic BP, per 
5mmHg increase 1.00 [0.97,1.02] 0.772 0.99 [0.96,1.02] 0.664
Any cardiac 
medication 1.27 [0.54,2.96] 0.585 1.73 [1.04,2.88] 0.034 2.27 [1.20,4.29] 0.011 0.91 [0.47,1.75] 0.775
Etiology:Reflex 0.56 [0.29,1.08] 0.083 0.06 [0.04,0.10] <0.001 0.05 [0.03,0.09] <0.001 0.37 [0.22,0.63] <0.001
Etiology:Orthostatic 1.08 [0.65,1.80] 0.776 0.10 [0.07,0.15] <0.001 0.12 [0.08,0.18] <0.001 0.55 [0.35,0.85] 0.008
Etiology:Others 1.03 [0.48,2.22] 0.931 0.10 [0.06,0.17] <0.001 0.10 [0.05,0.19] <0.001 0.64 [0.34,1.22] 0.177
Etiology:Unknown 1.38 [0.76,2.51] 0.285 0.20 [0.13,0.29] <0.001 0.28 [0.18,0.43] <0.001 0.76 [0.46,1.27] 0.295
Abnormal ECG 1.20 [0.76,1.91] 0.433 0.88 [0.66,1.17] 0.393 1.42 [1.00,2.00] 0.047 0.77 [0.53,1.11] 0.161
Chest pain before the 
event 1.41 [0.91,2.18] 0.122 0.62 [0.34,1.11] 0.108
Supp Table 2A3) 
hs-cTnT Elecsys
Death 720d Overall MACE 720d Arrhythmic MACE 720d Ischemic MACE 720d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnT, per 5ng/L 
increase 3.02 [1.70,5.34] <0.001 1.45 [1.19,1.78] <0.001 0.89 [0.70,1.13] 0.325 1.62 [1.18,2.22] 0.003
Age 1.03 [0.97,1.08] 0.332 1.01 [0.99,1.02] 0.281 1.01 [0.99,1.02] 0.482 1.00 [0.98,1.02] 0.986
Sex 1.52 [1.10,2.10] 0.011 1.26 [0.85,1.85] 0.244
Known CV disease 1.46 [0.72,2.94] 0.296 1.76 [0.74,4.18] 0.200 2.18 [0.89,5.38] 0.089
Smoking status 1.40 [1.01,1.94] 0.044 1.22 [0.83,1.79] 0.306
Hypertension 0.57 [0.37,0.87] 0.009 0.55 [0.34,0.89] 0.014
Hypercholesterolemia
Diabetes 1.25 [0.86,1.80] 0.244 1.30 [0.84,2.01] 0.237
Heart rate, per 5 bpm 
increase
Systolic BP, per 5mmHg 
increase
Any cardiac medication 1.75 [0.92,3.34] 0.090 2.54 [1.11,5.84] 0.028
Etiology:Reflex 0.04 [0.02,0.07] <0.001 0.01 [0.01,0.04] <0.001 0.25 [0.11,0.54] 0.001
Etiology:Orthostatic 0.04 [0.02,0.07] <0.001 0.04 [0.02,0.08] <0.001 0.15 [0.06,0.37] <0.001
Etiology:Others 0.04 [0.01,0.11] <0.001 0.01 [0.00,0.10] <0.001 0.25 [0.07,0.84] 0.026
Etiology:Unknown 0.13 [0.07,0.22] <0.001 0.15 [0.08,0.29] <0.001 0.44 [0.19,1.01] 0.054
Abnormal ECG 0.79 [0.55,1.13] 0.191 1.25 [0.81,1.94] 0.320
Chest pain before the 
event
Supp Table 2A3) hs-
cTnT Elecsys
Death 30d Overall MACE 30d Arrhythmic MACE 30d Ischemic MACE 30d
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HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val HR [95%CI] p-val
log hs-TnT, per 5ng/L 
increase 4.35 [1.91,9.88] <0.001 1.51 [1.19,1.91] 0.001 2.00 [1.55,2.58] <0.001 1.62 [1.16,2.26] 0.005
Age 1.01 [0.99,1.02] 0.448 1.02 [1.00,1.04] 0.017 1.00 [0.97,1.02] 0.855
Sex 1.44 [0.96,2.16] 0.075
Known CV disease 1.73 [0.69,4.30] 0.242 2.33 [0.87,6.23] 0.093
Smoking status 1.42 [0.95,2.14] 0.088
Hypertension 0.69 [0.41,1.17] 0.168
Hypercholesterolemia
Diabetes 1.29 [0.84,2.00] 0.246
Heart rate, per 5 bpm 
increase
Systolic BP, per 
5mmHg increase
Any cardiac 
medication 1.37 [0.61,3.05] 0.443
Etiology:Reflex 0.02 [0.01,0.06] <0.001 0.22 [0.10,0.51] <0.001
Etiology:Orthostatic 0.03 [0.01,0.07] <0.001 0.08 [0.02,0.25] <0.001
Etiology:Others 0.02 [0.00,0.12] <0.001 0.17 [0.04,0.72] 0.016
Etiology:Unknown 0.10 [0.05,0.21] <0.001 0.25 [0.09,0.73] 0.011
Abnormal ECG 0.70 [0.45,1.09] 0.112
Chest pain before the 
event
Supp Table 2A3) 
hs-cTnT Elecsys
Death 5d Overall MACE 5d Arrhythmic MACE 5d Ischemic MACE 5d
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Supplemental figure 1  
Supplemental Figure 1 – Sensitivity analysis for the diagnostic accuracy of the three cardiac troponin assays to detect cardiac syncope when A) 
all syncope adjudicated as unknown are classified as being of non-cardiac origin or B) when all syncope adjudicated as unknown are classified 
as being of cardiac origin.   
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Supplemental figure 2 
 
 
Supplemental figure 2 – Pearson correlations between the three logged troponin assays and the bioequivalent value of the 99th percentile 
(dotted blue line) for each assay, as predicted by the 99th percentile of one of the two other assays (red line). 
For instance, 7.5ng/L as given by the Architect hs-cTnI assay would be bioequivalent to 14ng/L for the Elecsys hs-cTnT assay  (99th percentile for 
this assay) and 26.2ng/L of the Architect hs-cTnI assay (99th percentile for this assay) would be bioequivalent to 26.6ng/L of the Elecsys hs-cTnI 
assay.  
  
r=0.941, p=<0.0019
26.2
12.6
15.6
10
100
1000
10
-1
10
0
10
1
10
2
10
3
log10(hs-cTnI Abbott+1) in ng/L
log
10
(h
s-
cT
nI
 E
re
nn
a+
1)
 in
 n
g/
L
r=0.787, p=<0.00114
9
21.3
3.2
10
100
10
-1
10
0
10
1
10
2
log10(hs-cTnI Erenna+1) in ng/L
log
10
(h
s-
cT
nT
 E
lec
sy
s+
1)
 in
 n
g/
L
r=0.812, p=<0.00114
26.2
28.6
7.5
10
100
10
-1
10
0
10
1
10
2
10
3
log10(hs-cTnI Abbott+1) in ng/L
log
10
(h
s-
cT
nT
 E
lec
sy
s+
1)
 in
 n
g/
L
 152 
 
Supplemental figure 3 
 
 
Supplemental Figure 3 – Diagnostic accuracy of the three hs-cTn assays in combination with a set of clinical variables  to detect cardiac 
syncope.  The clinical variables added to the model were : age, sex, presence or absence of a history of cardiovascular disease (myocardial 
infarction, coronary heart disease, stroke or transient ischemic attack, congestive heart failure, atrial fibrillation, and intermittent claudication), 
smoking status, presence or absence of hypertension, systolic blood pressure, presence or absence of diabetes, presence of 
hypercholesterolemia, heart rate, and use or nonuse of cardiac medication, including antihypertensive medications. 
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Supplemental figure 4 
 
Supplemental figure 4 – Accuracy of the first and second clinical series of measurement of cTn, of the delta between the first and second series 
of measurement (Delta between the 1st and 2nd measurements) and of the delta over time for the diagnosis of cardiac syncope. Serial clinical cTn 
measurements were available in 368/1099 patients. As comparison, the accuracy of the Elecsys hs-cTnT assay in these patients is represented 
as well.  
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 Supplemental figure 5 
 
Supplemental figure 5 – Kaplan Meier representing the survival of patients for death and MACE according to Architect hs-cTnI tertiles (assay 
chosen as example).  
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Supplemental figure 6 
 
 
Supplemental  figure 6 – Boxplots representing the hs-cTn concentrations for each assay at 30-days depending on whether or not patients died 
or experienced MACE. 
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Discussion and outlook 
The aim of this PhD Thesis was to contribute to the improvement of the diagnosis and risk-stratification of 
patients presenting to the ED following a syncopal event by assessing and validating important components 
of the initial ED evaluation in a large cohort study.  
For more than ten years, several scores have been derived[5,17–22] to improve the evaluation of syncope 
on the ED but our cohort is the first one to assess the validity of all these scores in comparison.  
Similarly, several small studies assessed the usefulness of BNP[5,79–81] or cardiac troponins[34,98,99] in 
syncope patients in the ED. Thanks to our stringent methodology, large sample size and the use of the most 
modern assays, we are able to contribute important novel insights to this topic. 
Novel insights in the diagnosis of cardiac syncope in the emergency department. 
Syncope Guidelines[1,4] emphasize the need for a detailed clinical history taking, a physical examination 
and the conduction of an ECG during initial patient evaluation. These components have been the 
cornerstones for the derivation of the several scores currently available for the diagnosis and risk stratification 
of syncope patients in the ED, which attempted to link important variables in their respective cohort to a 
diagnosis of cardiac syncope or an adverse outcome[5,17–22]. In our validation, most of these scores did 
not perform with the same accuracy than the one reached during original derivation and  some non syncope-
specific, readily calculable markers of morbidity (the CHADS2 or CHA2DS2VASc Scores) performed 
equivalently for the prediction of death or MACE. 
The poor performance of these scores in our cohort probably is explained by several issues. First, the 
monocentric character and lack of internationality of most of the original cohorts seems to be detrimental to 
the external validity of the derived scores. Indeed, assessment procedures but also patients’ understanding 
of symptoms[113,114] are likely to be hospital and country-specific and do not seem to translate well across 
borders. Second, the small size of these cohorts and the possibly resulting lack of power could have led to 
incorrect inferences regarding the respective importance of the selected score components. Third, despite 
targeting similar important variables (such as past medical history or electrocardiographic abnormalities), the 
exact definition of these components was heterogenous between scores[58], which contributed to their 
varying diagnostic and prognostic accuracy. Further research on each specific step of the patient evaluation 
seems warranted to accurately define when these components have to be considered “abnormal”.  
Some of the underlying complexity associated with syncope evaluation is also linked with the partly subjective 
components assessed by the ED physician, the strong overlap of these components between syncope 
etiologies and the hospitals’ specific assessment procedures. For instance, the patients’ description and 
clinicians’ understanding of prodromi strongly varies between individuals[113,114], hospitals and countries 
and moreover, their presence or absence is not pathognomonic for either cardiac or reflex syncope[115]. 
Similarly, physician education greatly varies between hospital and departments and leads to different 
diagnostic strategies.[8]  
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However, as highlighted in an Editorial[116] on the first manuscript of this thesis, all these scores targeted 
important and available variables: A thorough history of the syncopal event, the underlying comorbidities and 
a good physical examination undoubtedly provide valuable information about the underlying etiology and 
prognosis of syncope.  
All available syncope-specific scores were based on an attempt to accurately model and then efficiently 
simplify the clinical evaluation for the emergency physician and to provide a structured and homogenous 
initial evaluation of syncope patients, a currently clearly unmet clinical need[1,4]. Despite the appeal of using 
a simple score to assess patients and the success of such an approach for other diseases in the ED (such 
as triage algorithms for myocardial infarctions[68]), reducing the complex evaluation of syncope patients to 
a sum of points appears to be an invalid oversimplification and current scores fail at providing important clues 
to the initial patient evaluation[116].  
More developed statistical techniques and larger sample size seem to be required to accurately model an 
optimal assessment strategy for syncope in the ED. American guidelines already recognized the importance 
of emerging technologies, which imperatively need to be integrated in diagnostic and prognostic strategies.[4] 
Machine learning procedures for instance, were tentatively introduced in the diagnostic evaluation of syncope 
in the ED.[66] Despite the complexity of such models, they could easily be integrated in computer- or phone-
based applications to efficiently function in an ED setting.  
In order to rely on assessor-, structure- and patient-independent measures, more objective parameters such 
as biomarkers could play an essential role in the early evaluation of syncope patients on the ED. Indeed, 
cardiac biomarkers such as several cardiac troponin or BNP assays are currently readily available on many 
EDs and reflect important components of the patient’s cardiac health, providing precious hints for diagnosis. 
Moreover, as observed in several other cardiac diseases or population-wide studies[74–76,109,117], blood 
concentrations of these biomarkers seem to be linked with short- and long-time prognosis in syncope 
patients.[5,13,34,79,80] The promising potential of these biomarkers in syncope has already been largely 
acknowledged[8,116] but whether these biomarkers should be used as screening tools or as guidance in 
specific patient populations has to be further investigated.  Nevertheless, a definitive clinical utility of cardiac 
troponin and BNP is present in patients with no obvious syncope etiology following initial ED evaluation, 
where assay-specific cut-offs could inform the decision to admit patients and have a large impact on 
hospitalization reductions and cost savings.[8]  
However, biomarkers still present some important drawbacks which need to be taken into account. First, as 
biomarkers gained in importance during the last years, pharmaceutical companies developed several 
different assays to measure the same molecule, with an increasing sensitivity coming along with each new 
assay. In an attempt to simplify diagnosis and care delivery, a binary notion of “normal” and “abnormal” was 
introduced for each of these assays. For cardiac troponins for instance, a 99th percentile cut-off, reflecting 
the upper reference limit of a normal, healthy reference population as well as the decision level for the 
diagnosis of myocardial infarction, was defined for each of the assay currently available. Debates have 
emerged on how this cut-off was defined, as lack of attention to this question might result in misleading 
medical decisions.[104,118] We effectively observed large differences in patients’ classification when this 
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99th percentile was applied to our cohort, emphasizing the need for more homogenous definitions of 
abnormality. Second, false-positive cases could again lead to unnecessary diagnostic measures and the 
several non-cardiac diseases potentially leading to increased cardiac troponin concentrations[119] (such as 
chronic obstructive pulmonary diseases, endogenous antibodies, chronic muscle disorders or chronic renal 
failure) need to be taken into account and integrated in physicians’ education.  
Directions for future research  
Both American[4] and European[1] Guidelines as well as previous expert consensus[58,120] emphasize the 
need for structured and accurate evaluation tools in the ED, thriving for the improvement of the diagnostic 
accuracy for cardiac syncope, correct prognostic prediction and reduction of unnecessary hospitalization.  
The BASEL IX Syncope study displays several unique strengths: First, the adjudication used to determine 
the final diagnosis is extremely stringent and allows to reduce the rate of unknown syncope to a much lower 
rate than the one observed in other observational studies.[51] Second, the study design includes a follow-up 
up to five years, which will allow for important long-term inferences regarding prognosis. Third, all included 
patients underwent venous puncture and frozen blood samples are available for the measurements of 
potentially promising future biomarkers. Finally, this study displays an impressive international character, 
bolstering its external validity.  
Syncope is a complex and heterogenous symptom and its successful evaluation can most likely only be 
achieved by models of equal complexity. The development of currently available diagnostic and risk-
stratification tools has been subject to many flaws[8] (overfitting, mono-centric studies with lack of external 
validity, too small sample size, wrong modelling assumptions), which need to be addressed in future 
research. The idea of summarizing the most important data and variables to structure, simplify and accelerate 
the diagnostic process (and its prognostic implications) in the ED has been shown very efficient for other 
cardiovascular diseases[68] and stay an attractive and efficient option to achieve accurate and rapid care. 
Despite the recognized importance of patients history, results from the physical examination and 
electrocardiographic data, these components do not seem to have been modelled with sufficient precision 
for the correct assessment of syncope patients. Similarly, both biomarkers assessed in this thesis do not, on 
their own, have the accuracy to reliably rule-in or rule-out cardiac syncope or accurately predict prognosis. 
Moreover, summarizing continuous data in binary responses (such as “normal” or “abnormal” for biomarkers) 
might be an unreasonable simplification, which needs to be addressed by developing continuous estimates 
based on a large number of syncope patients. Therefore, new approaches based on more flexible models 
need to be developed and eventually integrated into readily-available technologies.  
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Contributions by the PhD student  
I had the chance to be part of the BASEL IX Syncope Team for the whole time of my MD-PhD and contributed 
to data collection, patient recruitment, international study management, synchronisation of the adjudication 
of final diagnoses, ethics amendments, grants submissions, data management, database updates, 
computation of masterfiles and data analysis.  
I benefited from the large infrastructure of the Cardiovascular Research Institute Basel (CRIB) and its 
incredible manpower, which both contributed to the large number of patients included in the database.  
At the beginning of my PhD, I first learned about the project by recruiting patients in the ED, entering these 
data in the dedicated database and conducting follow-up. This very practical hands-on experience allowed 
me to later manage the team working for the study. Indeed, to insure a constant and excellent data quality, I 
could then efficiently train several team member in these tasks. 
The multi-centric character of the study required a great amount of coordination work: Not only in Switzerland 
but also in our participating centers distributed over nine countries, several patients  were enrolled each 
week. This led to several shipments of patient data and blood samples, asking for a collaborative 
synchronisation effort from our whole team.  
All recruited patients received at least two (and sometimes three) adjudications of their final diagnosis by a 
seasoned team of physicians in our external centers and in the department of internal medicine and 
cardiology at the University Hospital of Basel, for which I ensured a timely coordination.  
We quickly noticed that one of the main strength of the BASEL IX study could be emphasized by prolonging 
the follow-up. Such a modification in the protocol and in patients consent required me to submit an 
amendment not only to the respective Swiss ethics boards, but also internationally and separately for each 
external center.  
I wrote and submitted several grants to participate in the financing of the Syncope Study during my time, 
such as grants for the PPHS and the Swiss Heart Foundation. I also participated to the submission of a large 
and approved SNF-grant. Writing grants provided me with supplementary skills in study planning, budgeting 
and project development.  
Data management and database updates also represented an important part of my work at the CRIB. 
External centers use similar databases, and require regular synchronisation with the main database in Basel. 
For the purpose of specific projects or data cleaning, variables had to be updated and reprogrammed 
regularly. To allow for analyses, data needed to be cleaned and extracted from the main database to create 
a Masterfile. I developed an exhaustive computing code to allow for automatic and rapid generation of these 
files.  
Last but not least, I learned essential components of data analysis: Writing a data-analysis plan, conducting 
and computing statistical analyses, presenting results in tables and graphics, summarizing and discussing 
them. Thanks to the precious help and patience of several collaborators inside (Patrick Badertscher, Christian 
Puelacher, Ivo Strebel, Joan Walter, Tobias Zimmermann) and outside of the CRIB (Michael Coslovsky, 
Clara Sailer), my computing and statistical abilities rapidly improved and allowed for the timely redaction of 
the three manuscript submitted in this work.  
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Teaching is an important component of our everyday life at the CRIB. I could particularly benefit from teaching 
by other PhD students and post-docs upon my arrival and have later transmitted my knowledge to subsequent 
colleagues, post-docs, doctoral and master students.  
A second important project marked my time at the CRIB : I designed, with the help of Professor Müller and 
collaborators of the department of Neurology and Rheumatology, a prospective study assessing cardiac 
troponin levels in patients with musculoskeletal diseases, which is currently enrolling patients. Starting a 
study from the very beginning brought me further valuable and essential insights in study design, database 
development, team leading and the importance of interdisciplinary projects.  
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Conclusion and closing remarks  
This MD-PhD Thesis represents a part of the large effort of our group to improve the diagnosis of syncope 
on the ED, a currently recognized unmet clinical need. In our large cohort, we could observe that the 
diagnosis and risk-stratification of these patients is challenging and is hardly well modelled by comprehensive 
summaries of clinical variables. With growing utilization of biomarkers in the ED, a better assessment using 
BNP or cardiac troponins could be reached in patients with no obvious syncope etiology upon ED admission. 
Future research needs to investigate new assessment strategies englobing more variables and making best 
use of new technologies for their practical implementation. 
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